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How do patient and carer-held beliefs about medication administration in domiciliary care 
affect initiation and use of Multicompartment Compliance Aids? 
 
Abstract 
 
Aim 
To find out how Multicompartment Compliance Aids (MCAs) are initiated and used in practice. 
 
Introduction 
Evidence in the area of MCA use is scarce, and knowledge is largely anecdotal, yet they are 
used in health and social care as an aid for self or carer-led administration of medication. 
There is a lack of clarity regarding patient suitability for MCA use, in particular how initial 
assessment and ongoing monitoring take place for patients using MCAs. The evidence base 
regarding the use of MCAs in practice will be strengthened by exploring the experiences of 
patients who use MCAs, carers who use them to administer medicines, community health 
services staff and the community pharmacists who dispense MCAs. 
 
Methods 
A sequential mixed-methods study was performed; a quantitative scoping exercise where 
community pharmacists were surveyed was conducted and used to inform the topic guide for 
the next stages of qualitative enquiry. The survey contained a section for narrative response 
that was also themed and analysed. The qualitative stages began with a collective case study 
of MCA users with data analysed using framework analysis. Community Health Services (CHS) 
nurses and CHS pharmacists were then interviewed and data analysed using a thematic 
analytical model. In addition, medication policies were reviewed and analysed using codes 
based on predetermined medication themes. 
 
Results 
Community pharmacy involvement in MCA supply was mainly dispensing and delivery, which 
was inadequately resourced; there was little scope for assessing patient suitability under 
current arrangements. In the case studies, it was found that the value of the MCA was limited, 
that informed decision making encouraged medication adherence and patients were not 
involved in the decision to start a MCA. CHS nurses saw cases where care provided by agencies 
was deficient and unrelated to care agency medication policy and had little confidence in the 
iii 
 
social care system. CHS health care professionals (HCPs) thought that carers using MCAs may 
be safest and easiest only in the fragmented health and social care system they worked in. 
 
Conclusion 
There is an urgent need for guidance for pharmacists and other HCPs involved in the provision 
of MCAs to determine the suitability of MCAs for individual patients and their inclusion in the 
decision making process, appropriate remuneration sources, and monitoring patient success 
when using them. The message that MCAs are not a panacea needs to be re-iterated to 
healthcare professionals and the social care sector. 
 
Keywords: Homebound person, homecare services, medication systems, medication 
organisation, medication error, muliticompartment compliance aid, blister pack, community 
health services. 
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How do patient and carer-held beliefs about medication administration in domiciliary care 
affect initiation and use of Multicompartment Compliance Aids? 
 
Chapter 1 Introduction 
 
1.1 Multicompartment Compliance Aids (MCAs) 
 
Compliance aids are devices designed to enable self-administration of medication, thereby 
compliance
1
. They include Multicompartment Compliance Aids (MCAs), often referred to as 
blister packs, dose calendars, timers and self-administration devices for inhalers and eye 
drops. Figure 1.1 shows a typical MCA blister pack. The pharmacist heat-seals medicines in the 
pack instead of dispensing it in original packaging; the intention is that the patient finds it 
easier to take each “blister” full of medication at the indicated time of day. 
 
 
Figure 1.1 – A blister pack 
 
MCAs are provided by the NHS for patients who meet requirements under the Equalities Act 
(EA) 2010, as a reasonable adjustment for the dispensing pharmacist to make to enable a 
person to self-medicate; MCA use in this scenario is not based on any published research
2
. The 
2 
 
NHS is not required to provide MCAs outside of the EA, yet they are used widely in the 
community and social care to assist carers administering medication
1
. 
 
There are established problems with MCAs; the stability of certain medicines (e.g. nifedipine) 
is compromised or unknown once removed from manufacturers packaging
3, 4
. There is sparse 
evidence that MCAs are effective at aiding self-administration
5
. From the author’s practice as a 
medication trainer for social carers, care agency medication policies commonly state carers 
cannot administer medication unless it is packaged in an MCA;  false perception exists that if 
the medication is being given from an MCA, carers do not need medication training
6
. When 
required (PRN) medication, medicines in liquid, cream or other forms, and short courses of 
antibiotics, cannot be included in the MCA and are potentially omitted. 
 
Though anecdotal, there are widely held views in pharmacy practice that MCAs cause more 
harm than they seek to cure
7
, and research is needed into their use. The intention of the 
research presented in this thesis is to enhance this evidence base. The rest of this chapter 
discusses the key features of MCA use in clinical settings. 
 
1.2 Paucity of evidence for MCA benefit 
 
Medication adherence is defined as the extent to which medication is taken in accordance 
with the agreed recommendations of a health care provider
8
. An older term, compliance, does 
not emphasise the agreement reached between the prescriber and a patient and is now used 
less commonly. The National Institute for Health and Care Excellence (NICE) has released 
guidelines for adherence that include the involvement of patients in discussions about their 
medicines, strategies for improving adherence, reviewing medication and communication 
between healthcare professionals
9
. There is a paucity of research evidence demonstrating the 
efficacy of MCAs in improving adherence, and other, non-MCA approaches to increase 
adherence under-utilised. 
 
In 2013 the Royal Pharmaceutical Society (RPS) released guidance on the use of MCAs to 
improve adherence and therefore outcomes patient outcome
10
. The essence of this report was 
the lack of evidence for improved adherence with MCAs. The RPS still recommends that, 
unless a specific need for an MCA to improve adherence has been demonstrated, medicines 
should be issued in original packaging
10
. 
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1.3 Pharmacists and medication review of frail patients 
 
NICE uses the term frailty to describe when a person is at a higher risk of sudden deterioration 
in their physical and mental health. Frailty is associated with long term conditions (LTCs), 
dementia, falls, polypharmacy, disability and mortality
11
. 
 
Initiatives where pharmacists have conducted medication reviews in the homes of frail elderly 
people have been shown to reduce admissions to acute care and save public funds. The Exeter 
Cluster Pharmacy (ECP) Team is part of the integrated community health and social care 
service in Exeter that serves a population of 145 thousand people. The ECP team 
demonstrated in 2014 that 109 fewer hospital admissions per year could be attributed this 
service that was established in 2006, equivalent to a £100K saving in the local healthcare 
economy for 2.8 whole time equivalent (WTE) pharmacy staff
12
. The Proactive Care service in 
West Sussex has made £600K savings in one year by investing in pharmacist medication 
reviews of complex frail housebound patients
13
. Pharmacists were embedded in 13 
multidisciplinary teams (MDTs) that included GPs and nurses. In the first year, 1178 medication 
reviews were performed; 96% of these led to a reduction in patient harm and 20% contributed 
to a reduction in hospital admissions. A similar scheme runs in the London borough of 
Lewisham, where MDT review included the community pharmacist; the increased use of MCAs 
was one of the drivers behind setting up the service
14
. 
 
Community pharmacists have been shown to positively influence patient outcomes by 
conducting Medicines Use Reviews (MURs) as part of their contract. There is emerging 
evidence to support MURs in improving non-intentional non-adherence
15, 16
.  
 
1.4 Current NHS and social care climate 
 
MCA use may be viewed against a difficult economic background.  The NHS must meet a target 
of £22 billion in efficiency savings by 2020-21, made possible only by significantly reconfiguring 
services. In community pharmacy, the government cut funding by 4% for 2016-17, and 3.4% in 
2017-18. These cuts made way for a new quality scheme in April 2017, where the global 
budget was top-sliced and contractors incentivised to increase revenue through meeting 
various quality criteria
17
.  
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Chapter 2 Overarching study design 
 
2.1 Literature review aims 
 
The overarching aim of the literature review was to explore the evidence base for MCA use in 
the domiciliary social care setting by carers and patients. The following questions were 
explored: 
 
 What is the impetus for MCA initiation? 
 How do the beliefs of carers and patients affect the process of MCA initiation? 
 What are the perceived advantages and disadvantages of MCAs in terms of efficient 
and safe administration of medicines? 
 What is the pharmacist’s role in MCA initiation and provision? 
 
Performing the literature review addressed the areas of interest highlighted by the author, 
provided a picture of what research has already been conducted and identified gaps in the 
existing evidence base. 
 
2.2 Literature review methodology 
 
2.2.1 Systematic reviews 
 
Systematic reviews (SRs) are the most robust form of evidence, where results of all studies in 
an area are considered together
18
. The Cochrane Library
19
 was searched using the strategy in 
Table 2.1
20
. The Boolean operator “OR” was used within each concept to include all possible 
synonyms. “AND” was used to filter down results. Wildcards and MeSH headings were used as 
indicated in the Table. A screenshot of this database search is shown in Appendix 1. 
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Table 2.1 – Search strategy for Cochrane reviews 
 
Search 
one 
Concept one – the carer / care agency 
(“Carer*” OR “Caregiver*” OR “Care giver*” OR “Domiciliary care*” OR 
“Home care*” OR “Adult social care*” OR “Social services” OR 
“Homebound person” OR “Homecare services”) 
9622 
results 
346 SRs 
Search 
two 
Concept two – the blister pack 
(“Blister pack*” OR “blister pak” OR “compliance aid*” OR “monitored 
dos* system*” OR “measured dos* system*” OR “multidose system*” 
OR “multi dos* system*” OR “multicompartment compliance aid*” OR 
“multi compartment compliance aid*” OR “reminder packag*” OR 
“dosette*” OR “dosett*” OR “pill organiser” OR “pill organizer” OR 
“medication aid*” OR “medication systems” OR “medication 
organisation”) 
2061 
results 
89 SRs 
Search 
three 
1 AND 2 
33 
results 
4 SRs 
Search 
four 
Concept three - administration 
(“Medication administration” OR “Medicines administration” OR “Drug 
administration” OR “Medication assist*” OR “Medicines assist*” OR 
“Assisting with medicines” OR “Assisting with medication*” OR 
“Administration of medicines” OR “Administration of medication” OR 
“Administration of drugs” OR “Giving medicines” OR “Giving 
medication” OR “Prompt* medicines” OR “Prompt* medication*) 
86916 
results 
209 SRs 
Search 
five 
Concept four – medication error 
(medication error” OR “medicine* error” OR “medication mistake” or 
“drug error” OR “drug mistake”) 
394 
results 
5 SRs 
Red terms are mesh headings / subheadings / thesaurus terms 
Combination searches of search three (concept one AND concept two) with concepts three 
and then concept four were not included as few enough papers found to be hand-searched 
in searches two, four and five. 
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The first search – concept one – produced 346 SRs. A search for concept two produced 89 SRs. 
Combining searches one and two produced only four SRs; one was an overview of other 
reviews looking at interventions to improve medicines use by patients. The full article included 
reviews that stated MCAs and other organisers may have positive effects on adherence, but 
not consistently so. The other three papers were irrelevant; one was about email alerts in 
public health initiatives, another about diagnosing acute respiratory illness in paediatric 
emergency departments and the third was about the co-bedding of twins in neonatal units, 
where the term “multi-compartment” was used to describe sleeping compartments. 
 
The five SRs pertaining to concept four – medication error – included only irrelevant papers; 
combining concepts four with three therefore was deemed futile. 
 
The next step was to see if a meta-synthesis of qualitative studies had been carried out that 
related to the areas highlighted above. A meta-synthesis is an interpretive process, designed to 
deepen understanding of the area of interest
21
. It is analogous to a meta-analysis of 
quantitative studies in that the results of similar studies are amalgamated. Meta-analyses of 
quantitative studies increase the certainty of the results, but do not attempt to deepen 
understanding or explanation of findings
18
. The Campbell Library is a sibling to the Cochrane 
Library but focussed on research into social rather than health care interventions; a search 
produced no relevant meta-syntheses
22
. 
 
2.2.2 Inclusion and exclusion criteria for the primary source review 
 
In the absence of a SR or meta-synthesis, the next step was to search for original studies. 
Quantitative and qualitative papers that met the following criteria were searched for: 
 
 Published in English 
 Adult subjects 
 Primary research in the domiciliary (home care) or community setting 
 
Studies not published in English, those with children as subjects and those carried out in the 
care home setting where medicines administration was carried out by staff were excluded. 
 
2.2.3 The search strategy 
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Table 2.2 shows the primary source search strategy as conducted on electronic databases. 
AMED, BNI, EMBASE, HMIC, MEDLINE PsychINFO, CINAHL, HEALTH BUSINESS ELITE were 
searched via the NHS Evidence portal, accessed via Athens membership. Nursing and medical 
databases were chosen as they would allow access to relevant peer-reviewed articles. The 
search strategy screenshot is shown in Appendix 2. 
 
Randomised controlled trials (RCTs) are the gold standard quantitative clinical study as bias is 
minimised by the randomisation process
18
. It is not always possible or appropriate to conduct 
an RCT however. Title and abstracts only rather than whole papers were searched as shown in 
Table 2.2; blister packs are used in lots of drug trials as a way of packaging medication or 
placebo for participants and would therefore appear in the method sections of irrelevant 
papers. Nineteen of the 20 papers found in the quantitative search were not relevant as they 
were set in other countries, focussed on general compliance aids in the context of medication 
review or looked at specific areas where MCAs were used but without critique of MCA use. 
One was not primary research, one had children as subjects and in another the authors took 
the term “blister pack” as meaning the foil strips that the manufacturer packages doses into 
and so was irrelevant. 
 
Qualitative studies are difficult to find compared with quantitative studies. This is largely 
because of varied use of the term “qualitative”
23
. Around half of all qualitative studies are 
sourced by snowballing, a quarter from direct contact with the author and around 30% are 
identified from databases and hand searches
24
. Table 2.2 shows how databases were used in 
this search strategy as an accessible starting point. Titles and abstracts were searched as often 
in qualitative research, the title does not indicate what the study is really about
25
. 
 
Three hundred and fifty four studies were found that included terms pertaining to the concept 
of “the blister pack” and typical terminology used in qualitative studies (belief, attitude, 
qualitative research) once date restriction was administered (2010-2016) and duplicates 
removed. Narrowing the search down further than this could have caused elimination of some 
of the relevant papers, as with these qualitative studies concept one – “the carer / care 
agency” may be so fundamental to the nature of the study that it is not mentioned until the 
methodology stages. Many papers found were based in adult social care and would not state 
as much in an obvious way in either the title or the abstract. A larger number of qualitative 
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study titles and abstracts (354) than those of the quantitative studies found (20) were 
therefore checked individually for relevance. Qualitative papers were eliminated according to 
inclusion and exclusion criteria in Section 2.2.2. Papers where MCAs were not the focus of the 
study and where the term “MCA” was used as an abbreviation for the Mental Capacity Act 
were eliminated. Three relevant qualitative papers were found. 
 
Using the same NHS portal, the search was saved and an alert set up that meant the search 
was re-run automatically every two weeks and results sent by email to the author. Two further 
relevant papers were found after the original search was performed and are included in this 
review. 
 
The Pharmaceutical Journal was searched by hand as the author subscribes to this periodical 
and, though the content is not peer reviewed, articles covering the relevant areas could 
contain references that were primary sources. No original research had been published 
concerning the use of MCAs since 2005, though there were many reviews and anecdotal 
viewpoints, letters and other opinion pieces published. An online search of the archived (pre-
2005) content of the Pharmaceutical Journal was performed as this journal’s audience were 
likely to be the most interested in the review subject. A review paper was found that, though 
excluded itself as not an original article, provided two further hand searched references from 
2001 that are included in this review. 
 
The eight papers identified as being suitable for inclusion in this review are shown in Table 2.3. 
Four were qualitative, each involving interviews of patients and/or health care professionals 
(HCPs); one used a grounded theory approach, one phenomenological, one case study and 
another did not specify a paradigm though used a thematic framework analysis method. Of the 
four quantitative studies, one was an audit of demographic data versus appropriateness of 
individual drugs dispensed in MCAs and the rest were questionnaire based. 
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Table 2.2 – Search Strategy for primary sources 
Search 
one 
Concept one – the carer / care agency 
(“Carer*” OR “Caregiver*” OR “Care giver*” OR “Domiciliary care*” OR 
“Home care*” OR “Adult social care*” OR “Social services” OR 
“Homebound person” OR “Homecare services”) 
299,081 
papers 
Search 
two 
Concept two – the blister pack 
(“Blister pack*” OR “blister pak” OR “compliance aid*” OR “monitored 
dos* system*” OR “measured dos* system*” OR “multidose system*” 
OR “multi dos* system*” OR “multicompartment compliance aid*” OR 
“multi compartment compliance aid*” OR “MDS” OR “MCA” OR “MCS” 
OR “reminder packag*” OR “dosette*” OR “dosett*” OR “pill 
organiser” OR “pill organizer” OR “medication aid*” OR “medication 
systems” OR “medication organisation”) 
94,446 
papers 
Search 
three 
Search two within Concept two: NOT “middle cerebral artery” 78,269 
papers 
Quantitative papers 
Search 
four 
Concept one AND Concept two (search three) 951 
papers 
Search 
five 
Search four: limited to papers from 2010-16 35 papers 
Search 
six 
Duplicates removed from search four 35 
papers* 
Qualitative papers 
Search 
seven 
(Belief* OR attitude* OR “qualitative research”) 761,944 
papers 
Search 
eight 
Search three AND Search seven 756 
papers 
Search 
nine 
Search eight: limited to papers from 2010-16 414 
papers 
Search 
ten 
Duplicates removed from search nine 353 
papers 
Italic terms are mesh headings / subheadings 
*a further fifteen of these papers were duplicates on examination leaving 20 papers 
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Table 2.3 – Summary of papers included in the literature review 
Author Title Method and sample 
(Nunney & Raynor, 
2001a)
1 
How are multi-compartment 
compliance aids used in primary 
care? 
Self-completion questionnaire of 
123 pharmacies. 
(Nunney & Raynor, 
2001b)
26 
Mind the gap: how compliance 
aids increase the distance 
between patients and their 
medicines. 
Structured questionnaire of 10 
randomly selected community 
pharmacists and all their non care 
home based MCA patients. 
(Brown, Hafeez, & 
Abdelhafiz, 2010)
27 
Use of multicompartment 
compliance aids for elderly 
patients: patient viewpoints and 
hospital length of stay. 
Prospective cross-sectional survey 
of hospital patients admitted to 
the elderly care ward that were 
already using an MCA (51 in total). 
(Nunney, Raynor, 
Knapp, & Closs, 
2011)
28 
How do the attitudes and beliefs 
of older people and healthcare 
professionals impact on the use 
of multi-compartment 
compliance aids? A qualitative 
study using grounded theory. 
Qualitative study using grounded 
theory. Interviews of 15 older 
people (72-92) living 
independently in the community 
and 17 healthcare professionals 
from primary, secondary and 
intermediate care. 
(Rivers, Kavia, & 
Seedat, 2011)
29 
The perceived value and 
effectiveness of Monitored 
Dosage Systems (MDS) dispensed 
for domiciliary use by hospital 
and community pharmacists. 
Qualitative (phenomenological); 
11 structured interviews – 4 
pharmacists, 3 technicians, 1 
hospital discharge nurse, 2 
patients, 1 carer. 
(Lecouturier, 
Cunningham & 
Campbell, 2011)
30 
Medication compliance aids: a 
qualitative study of users’ views. 
Qualitative: 19 in-depth interviews 
using topic guides of patients aged 
20s to late 80s, four with 
accompanying informal carers. 
(MacLure, 
MacLeod, Forbes-
McKay et al, 
2016)
31  
A case study investigation into 
the use of multi-compartment 
compliance aids in older people 
resident in very sheltered 
housing. 
Qualitative: Case study using 
semi-structured interviews with 
20 patients and 34 members of 
their care team based on the 
Theoretical Domains Framework. 
(Counter, Stewart, 
MacLeod et al, 
2016)
32 
Multicompartment compliance 
aids in the community: the 
prevalence of potentially 
inappropriate medications 
Audit of MCAs dispensed by 48 
pharmacies over four months for 
prevalence of potentially 
inappropriate medicines and 
association with demographic 
data of patients. 
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2.3 Results of the literature review 
 
2.3.1 The impetus for MCA initiation 
 
General practitioners (GPs) requested the majority of MCAs (51%) in one study and patient 
survey results showed that 35% would not want the aid if asked
27
. In another that used a self-
completion questionnaire of pharmacies, pharmacists named the GP as the person most likely 
to request use of an MCA, along with hospital staff, and saw themselves as the least likely to 
initiate them
1
. The authors speculated that this was because the pharmacist had a better 
appreciation MCA disadvantages. 
 
A qualitative study showed MCAs were often issued without discussion with the patient; GPs 
and other healthcare professionals cited polypharmacy, physical disability, memory problems 
and requests from relatives and social care staff as reasons for starting them
28
. 
 
A more recent qualitative study of MCA users found that one of the drivers for starting an MCA 
was the difficulty of the treatment regimen experienced by the patient or an informal carer 
(family member) responsible for managing the medication. Most patients interviewed had 
purchased the MCA, or their family member had. In three of 19 patients, a healthcare 
professional (HCP) had suggested it may help in the medication management process
30
. 
 
A case study showed that one goal of MCA use was medicines adherence in the patient cohort, 
where polypharmacy and multi-morbidity where apparent. Carers cited safety as a reason for 
MCA use and a few interviewees said they helped the patient remain independent. Patients 
were less aware of these goals than the care team. The authors concluded that there was 
uncertainty with respect to who should be involved in the decision to start a MCA and often 
the commencement process could not be determined as the process was undocumented
31
. 
 
2.3.2 The beliefs of carers and patients and how this affects the process of MCA 
initiation 
 
There was evidence from one paper that the common misconception that MCAs were 
mandatory for social carers to administer medication triggered initiation
28
. In the case study
31
 
the carers cited safety as one of the goals of MCA use, but it was not clear what impact this 
12 
 
carer-held belief had on the process of initiation and the data from carers was amalgamated 
with that of HCPs so it was difficult to isolate. The influence of carer and patient beliefs and 
how this affected MCA initiation was not addressed in any of the other papers. 
 
2.3.3 The perceived advantages and disadvantages of MCAs in terms of efficient and 
safe administration of medicines 
 
The perceived advantages and disadvantages varied, with those involved in the dispensing 
process seeing more disadvantages and other healthcare professionals, patients and carers 
seeing more advantages. 
 
One qualitative study found that pharmacy staff were sceptical about the advantages of MCAs, 
particularly where non-adherence was intentional. Dispensing them was also deemed labour 
intensive, potentially drawing disproportionately higher staff resource than the other patient 
services they offered
29
. A study performed in secondary care went as far as to state that the 
provision of MCAs was so labour intensive it delayed discharge from hospital by 1.3 days
27
. 
One study found that patients could sometimes not use the aid properly, and HCPs agreed 
they did not really help with memory-impaired patients
28
. 
 
Association between MCA use and a significant incidence of potentially inappropriate 
medicines, particularly in those patients under the age of 80 living in deprived areas was 
demonstrated in a quantitative study
32
. A total of 1977 potentially inappropriate medicines 
were identified affecting 57.8% of patients issued MCAs from 48 pharmacies over a 5-month 
period. 
 
Some advantages were that patients and carers were relieved that they did not need to 
organise complex regimens and saw the time saving aspects of the MCA as advantageous, 
though the study where this was found did not address the fact that time saving on behalf of 
the carer is not the intended purpose of the MCA
29
. There was some suggestion from another 
study, however, that using MCAs distanced patients from their medication; older people 
wanted to remain independent and in control
28
. Some patients saw the aids as facilitating their 
independence and others felt that they cast doubt over their ability to handle their own 
medication. A questionnaire showed that MCAs produced a lack of patient autonomy, and 35% 
of patients would not have wanted the aid, had they been asked
27
. In another previous patient 
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survey, 90% of patients said they preferred the MCA to separate bottles, even though over 
67% could not name any of their medicines
26
. The survey did not address the possibility that 
patients may not want to know anything about their medicines. 
 
Lecouturier et al
30
 found that the use of the MCA brought order to chaos for some patients 
with treatment regimens that caused them and their family members anxiety
30
. The MCAs 
helped when the patients had forgotten what they had already taken, and when taking 
medications directly from the original packs was time consuming, physically difficult or 
impractical to do outside of the home. Some patients felt that the use of the MCA had 
introduced some “normality” back to their lives by reducing dependency on others, along with 
reducing the visibility of the medication and thereby the stigma of illness. This study was in 
patients who were well motivated to adhere to their medicines where all but two participants 
loaded the MCA themselves; they found the loading of the MCA on the whole to be a laborious 
task but worth it. Advantages and disadvantages of using the MCA in this population are likely 
to differ greatly from those of frail elderly users with formal carers and pharmacy-filled MCAs. 
 
In a study of vulnerable patients in sheltered housing, HCPs and carers interviewed believed 
that MCAs enhanced adherence, safety, patient independence and freed up staff time for 
patient-centred care
31
. The beliefs about the impact on patient independence in this study 
were at odds with findings from other studies discussed above
27, 28
. Negative consequences 
were decreased awareness of the indications of medicines taken and difficulties dealing with 
regimen changes once MCAs had been prepared. 
 
2.3.4 The pharmacist’s role in MCA initiation and provision 
 
All of the papers in this review proposed that assessment of suitability for MCAs should be 
carried out before initiation. Pharmacists themselves were cynical about the benefits of MCAs 
but were supplying them, often unjustifiably. One survey showed that 77% of pharmacists 
dispensed into MCAs, but less than 1% had a written protocol for this process
1
. No paper 
reviewed here really assessed why pharmacists supplied MCAs at all, when the only obligation 
according to the national pharmacy contract would have been after an assessment under the 
Disability Discrimination Act (DDA) 2005 (replaced by the EA in 2010) as a reasonable 
adjustment to enable adherence in self-medicating patients. MCAs were often issued without 
14 
 
any patient involvement
28, 30, 31
and in one study DDA assessment only occurred in 3% of 
cases
27
. 
 
Dispensing and delivery of MCAs was addressed in two papers. In one study, 86% of MCA 
patients had a delivery from the pharmacy and nearly half of these were by unqualified staff
26
. 
In another quantitative study, only 14% of MCA users collected their medicines from the 
pharmacy in person
32
. These findings show there is little opportunity for assessment of 
continued need, adherence and problems experienced by the patient by a qualified healthcare 
professional in the most vulnerable, housebound patients. In the case study
31
 dispensing 
pharmacists were concerned about capacity and workload, expressing their dissatisfaction 
with inadequate remuneration for MCA supply. 
 
2.3.5 Summary and discussion of evidence base 
 
The literature review aimed to explore the evidence base for the use of MCAs in the 
domiciliary social care setting by carers and patients. Results showed there was little 
involvement from the patient in the decision to start a MCA, with initiating HCPs citing desire 
to address adherence, safety, patient independence, memory problems, physical disability, 
polypharmacy and the influence of relatives and social care as initiation reasons. MCAs were 
generally not initiated in response to any documented medication review, and it is still unclear 
what HCPs based their decision making on when initiating MCAs in patients. 
 
GPs, carers and HCPs other than pharmacists were identified as the main requesters for MCAs, 
though it was not firmly established as to why this was the case. There was some reference to 
social care staff requiring MCAs to administer medication to patients. The perceived 
advantages and disadvantages varied, with those involved in the dispensing process seeing 
more disadvantages and other HCPs, patients and carers seeing more advantages. The 
variation in patient willingness to understand and take ownership of their medication regimens 
was not addressed in any of the studies. All of the papers in this review proposed that 
assessment of suitability for MCAs should be carried out before initiation in order to justify the 
supply. Pharmacists rarely assessed patient suitability despite being the most sceptical about 
the advantages of the aids. 
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In the remainder of this chapter, a theoretical basis for the research study is defined and the 
nature of that research determined. 
 
2.4 The research questions 
 
The overarching design of this study was a sequential mixed methods design. The first phase 
was a quantitative scoping exercise aimed at establishing the extent of MCA use and origins of 
requests. This was achieved by surveying community pharmacists in Lambeth and Southwark. 
The second phase used a qualitative approach to explore the attitudes and beliefs that MCA 
users held about medicines administration and how this affected MCA initiation and use. The 
chosen strategy in the qualitative phase was collective case study. 
 
2.4.1 Qualitative question formulation 
 
The qualitative research question is: How does what patients and carers believe about MCAs 
affect how they are initiated and used? This question is a psycho-social question, which aims 
to explore the relationships between beliefs of MCA users and practical aspects of how they 
are supplied and used. Table 2.4 shows how this question was formulated using the qualitative 
People, Issue, Context-setting and Outcome (PICO) question formulation format
18
. 
 
Table 2.4 - People, Issue, Context-setting and Outcome Question Formulation 
P Adult MCA users (including patients themselves and carers who use MCAs to administer 
medication to the patient) and HCPs involved in the care of frail elderly patients 
I Administering medication from MCAs 
C People living in their own homes who are receiving care (informally from relatives or as 
social care commissioned packages) 
O The value of MCAs in supporting adherence and providing good quality, patient focussed 
care 
Question: “How does the administration of medicine from MCAs to frail elderly patients living 
in their own homes support adherence and provide good quality patient care according to 
MCAs users, carers and HCPs”. 
 
2.5 Aims 
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i. To investigate how MCAs are initiated and used, and their value in supporting 
adherence and quality of care. 
ii. To clarify the place of MCAs in medicines administration and use for those involved in 
initiation, supply and use. 
 
2.6 Objectives 
 
i. Using a survey of community pharmacists, establish the extent of MCA use and 
investigate the impetus for MCA initiation in Lambeth and Southwark. 
ii. Using a collective case study methodology, explore the attitudes that MCA users 
(patients and employed carers) hold about administering medication, and how this 
affects MCA initiation and use. 
iii. Use an opt-in strategy to recruit suitable individual patients and patient and carer pairs 
into the qualitative phase of the study. 
iv. Collect data to answer the qualitative research question by conducting semi-structured 
interviews of patients and carers and collecting qualitative data from other relevant 
sources within each case. 
v. Collect data to answer the qualitative research question by conducting focus groups 
with domiciliary carers and focus groups with community nurses. Conduct interviews 
with community health services pharmacists to further understand the issue of MCA 
use. 
vi. Use framework analysis to analyse qualitative data from multiple sources, including 
patient and carer interview transcripts, interviews with specialist community health 
services pharmacists and focus groups with healthcare professionals and carers. 
 
2.7 Philosophical assumption 
 
The philosophical assumption underpinning this study is pragmatism. The pragmatic view is 
that qualitative and quantitative research methods should not be seen as opposed approaches 
to research, but instead as complementary strategies that can be employed freely depending 
on the question being asked
33
; the main area of interest is with the practicality of carrying out 
the research and problem-solving, choosing from an array of methods, data collection 
techniques and analysis procedures that are best able to address the research question(s). 
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Pragmatism applies to mixed methods research, the overarching design of this research 
project. 
 
2.8 Research design justification 
 
The choice of design is not only informed by the philosophical assumption, but also by the 
nature of the research problem being addressed and the researcher’s personal experience
34
. 
There are three broad types of study design considered in this chapter: quantitative, 
qualitative and mixed methods. 
 
Quantitative research is concerned with testing theories deductively by examining 
relationships between measurable variables. Numbered data are produced which can be 
analysed using statistical methods
35
.  Qualitative research is concerned with understanding the 
meaning that people attribute to social or human issues
36
. Findings are arrived at without 
statistical or other quantitative procedures
37
. The approach is inductive; theory is derived from 
the data rather than data being generated for the purpose of testing a preconceived theory as 
in quantitative research
38
. A qualitative approach is desirable when the aim of the research is 
to explore situations or lived experiences of people (individuals or groups), to describe the 
world around us or to explain how or why an outcome has occurred
35, 38
. The question in this 
research study aims to explore attitudes and beliefs, so a qualitative approach is very suitable. 
In mixed methods research, both quantitative and qualitative forms of research are employed 
and merged so that results are used to reinforce one another (concurrent), or methods 
conducted sequentially so that the findings of the second method expand on the first
33
. 
 
The overarching design of this study is a sequential mixed methods design. The author chose a 
mixed methods design because she felt that neither the quantitative nor the qualitative 
approach alone was sufficient to best understand the research problem, which was complex in 
nature and scarcely explored to date. In terms of the author’s personal experiences and 
approach to research, she would capitalise on the flexibility of qualitative enquiry whilst 
feeling more comfortable with the structure provided by quantitative research. 
 
The quantitative part of the study and the qualitative parts are discussed below in Chapters 4-
6. The quantitative enquiry is presented first in Chapter 3. 
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2.9 Ethical considerations and approval process 
 
Ethical approval was obtained before the research project began 
34, 35
. Research Ethics 
Committees (RECs) review proposed research to ensure that the law, policy, researcher and 
university reputation and the care and protection of researchers and participants is given due 
consideration
39
. Because the study application demonstrated minimal risk or burden for the 
participants, proportionate review was applied for in the first instance
40
; a provisional opinion 
was awarded by HSC REC A in November 2013 which became a favourable opinion that same 
month upon the sub-committee receiving minor clarification. HSC REC A, based in Northern 
Ireland, was the group responsible for reviewing all proportionate reviews based in the NHS. 
The relevant ethics approval letter can be seen in Appendix 3. 
 
A minor amendment was made in May 2014 when the author changed workplace. An 
honorary contract was retained with the host organisation to continue the project. 
 
As the study progressed, recruitment difficulties were experienced because the patients who 
had carers that used MCAs tended to be those with dementia. Including patients with 
dementia in this research was not desirable ethically. To remedy this, the protocol was 
changed in February 2015 to include the following: 
 
1) The option of patients without dementia who use MCAs to enter into the research without 
their carer, alongside focus groups of carers to capture their perspectives without reference to 
a particular patient (i.e. recruited in patient-carer pairs no longer a necessity, though still an 
option). 
 
2) Focus groups of community nurses employed by Guy’s and St Thomas’ NHS Foundation 
Trust. These nurses work very closely with carers and were often asked to initiate MCAs by 
care agencies. This was to allow another perspective on why MCAs are used for proxy 
medicines administration instead of self-administration for which they are intended. 
 
3) Semi-structured interviews with pharmacists who carry out medication reviews in patients’ 
homes, employed by Guy’s and St Thomas’ NHS Foundation Trust or other NHS organisations. 
These pharmacists were specialists in optimising medicines in the domiciliary care setting and 
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it was considered valuable to obtain their professional opinion on what the barriers to good 
practice in medicines administration were. 
 
A substantial amendment was submitted to the same sub-committee to in February 2015. 
Further items were requested regarding focus group topic guides, identification, consent and 
recruitment of new participant groups before approval, which was provided to the sub-
committee in March 2015. A favourable opinion was finally issued in April 2015 (Appendix 3). 
 
Governance procedures of the host organisation (Guy’s and St. Thomas’ NHS Foundation Trust) 
were followed. A protocol was completed in the trust template and registered with the 
Research and Development Department, and a Site Specific Information (SSI) form completed 
and approved by the host organisation (Appendix 5). A declaration of ethical research (form 
UPR16) is shown in Appendix 4. 
 
2.10 Maintaining researcher objectivity and neutrality 
 
The research in this thesis is presented as part of a Professional Doctorate in Pharmacy. 
Practitioner research is central to the philosophy of a professional doctorate
41
, and the key 
processes and outcomes presented related to research knowledge and skill generated from 
the practice setting by the author as a practitioner. The author had worked in different 
commissioning, CHS and acute provider roles throughout this study. The following steps were 
taken to mitigate the potential of the author’s experiences as a pharmacist unduly influencing 
the study results and conclusions drawn from them: 
 
 Piloting the community pharmacy questionnaire. 
 Producing topic guides based on the community pharmacy questionnaire findings 
instead of author opinions. 
 Using topic guides consistently with each interview. 
 Using open, non-leading questioning techniques and taking care not to divulge 
personal opinion during data collection. 
 Third party assistance with recruitment. 
 Third party assistance with interview transcription. 
 Overall monitoring by supervisors, including listening to interview samples and 
checking a sample of open coding before analysis). 
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Chapter 3 The community pharmacist questionnaire 
 
3.1 Methodology 
 
A survey of community pharmacists was conducted to establish the extent of MCA use and 
investigate the impetus for MCA initiation in Lambeth and Southwark. The survey was 
intended to find out whether there was a pattern with regard to who requested MCAs, why 
they were requested and whether the pharmacist felt involved in the decision to supply MCAs 
outside of NHS provision. 
 
The boroughs of Lambeth and Southwark sit within South London, and were chosen as the 
corresponding Clinical Commissioning Groups (CCGs) in these boroughs are the main local 
commissioners of services provided by the trust that hosted this research, Guy’s and St. 
Thomas’ NHS Foundation Trust. Lambeth and Southwark are urban, inner-city, densely 
populated areas of London (both over twice as densely populated as the rest of London) with 
populations of approximately 320,000 and 310,000 respectively. The populations of each 
borough are similar demographically: the proportion of young people is above national 
average and the populations are also both socially and ethnically diverse. Though both areas 
are ranked highly in terms of deprivation when compared with other London boroughs 
(Lambeth 8
th
 most deprived and Southwark 12
th
 most deprived of 33 London boroughs) and 
nationally (Lambeth 22
nd
 most deprived ward out of 326 in England; Southwark 41
st
), 
geographic areas of affluence (e.g. South bank, the London Eye, East Dulwich) sit side by side 
with areas of high deprivation
42, 43
. 
 
3.1.1  Questionnaire design 
 
No piloted questionnaires were available that could have been used or adapted for use, and so 
the author designed the questionnaire specifically for use in this study
44, 45
. A copy of the 
questionnaire can be seen in Appendix 6. The questionnaire had 13 questions, some with 
multiple tick-box answers. The first two questions were designed to obtain some idea of the 
scale of MCA provision in the pharmacy. There were no questions about the size of the 
pharmacy or the number of items dispensed per month. Neither of these enquiries were 
relevant – large pharmacies may have few MCA patients and small pharmacies may have 
many. Also, enquiring about number of items is commercially sensitive and may feel intrusive 
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from the perspective of the respondent
46
. Questions one and two required the pharmacist to 
enter a number, for question one this was a number of patients who the pharmacist regularly 
dispensed MCAs for, and question two asked how many of those lived in their own homes, 
which the pharmacist was anticipated to know as there should be so few patients on MCAs 
and usually they were delivered to the patient in the author’s experience. 
 
The next two questions asked about what the intention of the MCA was for those MCA 
patients quantified in question two, making a differentiation between those started for the 
patient to self-administer (question three) and those started for the carer to administer 
(question four). The option of “unknown” was included as a response, as it was likely that the 
pharmacist did not know the answer to this question; this response was anticipated to be a 
research finding in itself indicating MCA supply without thorough investigation. The responses 
for questions three and four were tick-box rather than requiring a written number, as 
estimations were enough
45
. 
 
In question five, the pharmacist was asked under what circumstances they would supply a 
MCA and could tick as many scenarios as apply. The options of “never” and “other (please 
specify)” were included to ensure that the question was answerable by pharmacists who had 
not had a patient who needed one and to capture scenarios not anticipated by the author 
respectively. The same set of responses were emulated for question six, which asked under 
which circumstances they would assess a patients suitability for an MCA before supplying one; 
answering “never” for question six indicated supply without assessment
47
. 
 
Questions seven and eight were designed to uncover whether compiling MCAs was 
disproportionately time-consuming compared to standard dispensing. Questions seven asked 
pharmacists to decide what proportion of all of their patients were MCA users living in their 
own homes and questions eight then followed up with what proportion of time these patients 
demand including dispensing, liaising with GPs and other HCPs and answering queries. In order 
to draw comparison between these two questions, the same options were given to “circle” by 
the completing pharmacist: <1%, 1-5%, 6-15%, 16-25% or >25%. There was no option for 
“unknown” as there would be temptation to instinctively circle this response rather than 
spend time working out the true answer
47
. 
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Question nine focussed on the frequency of scenarios under which an MCA may have been 
supplied, with the pharmacist asked if this happened very frequently, often, sometimes, rarely 
or never
45
. The scenarios given were in order for a social carer to administer the medication, 
when a GP believes there are issues with the patient’s ability to manage their medicines, 
requested by a district nurse or community matron, requested by a specialist nurse in the 
community, at the request of the patient themselves, or in response to full medication 
assessment performed by another pharmacist. These were included as they were considered 
by the author to be the main reasons MCAs are initiated. Again the option of “other” was 
included in order to capture scenarios that were previously unknown to the author. 
 
The next question, number 10, asked the pharmacist whether they asked for 7-day scripts 
from the GP to cover expenses when dispensing into MCAs, with the option to tick just one 
box only out of “yes – always”, “yes – most of the time”, “sometimes”, “only when I know the 
patient does not really need it”, “only if the prescription is very complicated” and finally “no”. 
The author placed this question carefully in the questionnaire as it would be too blunt to put 
this at the beginning of the question set and there was a risk of alienating the completer. As it 
was placed near the end, the pharmacist would have already completed most of the 
questionnaire so would be unlikely to stop and abandon the process by this point
46
. 
 
In question 11, the pharmacist is asked if they do not always assess a patient for the suitability 
of using an MCA before supplying one, to indicate why and tick all reasons that apply. There 
were 15 specific reason choices and three further choices that required the respondent to 
“specify” details. The choices were focussed on sources of pressure to supply (e.g. from GP or 
relatives), the pharmacists’ anxiety about the patient’s situation, the pharmacists resources 
and capacity and their approach to risk
45
. 
 
In question 12, the extent to which pharmacists agreed or disagreed with a list of statements 
was assessed, with “agree strongly”, “agree”, “neither agree nor disagree”, “disagree” and 
“disagree strongly” being a single option for each statement. The statements included value of 
the MCA in non-compliance, and a separate statement for intentional and non-intentional 
non-compliance. Perceived value in forgetful patients was also assessed. Some statements 
were about the pharmacists’ beliefs – e.g. “the stability of some medicines in MCAs is severely 
compromised” or “MCAs reduce the likelihood of medication administration errors” – some 
focussed on their behaviour e.g. “I always check whether a medicine is going to be stable 
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before dispensing it into an MCA”. Some statements asked the pharmacist to make a 
judgement about the patients’ perspective e.g. “patients feel less involved in their treatment 
when an MCA is used” and “some patients find MCAs too difficult to use”
48
. 
 
The final question was a free-text question for the pharmacist to give their views and opinions 
about MCAs, for example any errors they have experienced, improvements to patient 
wellbeing or other perceptions they had of MCA use. In this sense, the questionnaire had a 
qualitative as well as quantitative element
49
. The pharmacist was informed at the beginning of 
this question that if they were happy for the author to use a quote from this verbatim which 
would be anonymised, to tick a box indicating this. 
 
3.1.2  Recruitment 
 
The questionnaire and letter explaining the study (Appendix 6) were piloted and sent out to all 
registered pharmacy premises in Lambeth and Southwark (69 and 62 respectively) along with a 
stamped addressed envelope, for the attention of the managing pharmacist. Before being sent 
out the letter and the questionnaire were reviewed by a community pharmacy contractor who 
did not work in a Lambeth or Southwark community pharmacy in order to assess readability 
and ease of completion; no changes were made. 
 
A pilot was performed on ten pharmacies to assess the design of the questionnaire and 
whether it needed to be changed in order to capture the data required; five from each 
borough were selected randomly by choosing every eleventh pharmacy from an alphabetical 
list of premises. No changes to the questionnaire were required after the pilot, the other 
pharmacies were surveyed and data from the pilot combined with the rest of the survey data. 
The questionnaire was numbered so that responses from individual pharmacies were tracked, 
and an initial response date set of 30 days from the date of the letter. After this time non-
respondents were contacted using the NHS.net feature fax system where a bulk reminder was 
sent out to pharmacists to return the original documentation. Non-respondents after this bulk 
reminder using feature fax were also contacted by phone to remind them to complete the 
questionnaire and send it back within the following week. Some completed the questionnaire 
over the phone at the time of the call and some declined to take part. 
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When the feature fax was sent out, there were 23 delivery failure notices received into the 
author’s nhs.net inbox. Reasons for failure were that the number was not in service or some 
other type of communication failure. The fax number list that the author had was the same as 
that used to alert community pharmacy contractors of important and urgent safety alerts e.g. 
drug recalls. The pharmacy advisor at NHS England was alerted to these failed communication 
attempts in order to mitigate against future failure to urgently contact these 23 premises. 
These 23 pharmacies were called; some completed the questionnaire over the phone or were 
reminded to return the original paperwork. Some numbers were not in service; again these 
were reported back to the pharmacy contracting team at NHS England. 
 
3.1.3  Data analysis 
 
Survey results were collated and analysed. Quantitative data were analysed using descriptive 
statistics and volunteered comments from the free-text question was subject to thematic 
analysis. All data were anonymised. 
 
Survey results were also used to help develop the list of areas to cover in patient and carer 
interviews (called the “topic guide”) for the qualitative phase of the study; this is discussed in 
Section 3.4 below and Chapters 4-6. 
 
3.2 Results 
 
The questionnaire can be seen in Appendix 6. 
 
3.2.1 Quantitative results 
 
There was a low response rate to the questionnaire: 18 in total (13.7%), of which five were 
returned after the first mail-out, five after the reminder fax was sent and eight conducted over 
the phone at the reminder call stage. 
 
The ratio of respondents from Lambeth versus Southwark was 12:6 (Lambeth 17.4%, 
Southwark 9.7%). The number of MCA patients each pharmacy had ranged from 5-180 (mean 
64) with the majority in every pharmacy being dispensed for patients who lived in their own 
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homes. Eleven respondents said that all of the MCAs they dispensed were for patients who 
lived in their own homes. 
 
3.2.1.1 Intended purpose (Questions one and two in Appendix 6) 
 
Seven of the 18 community pharmacy respondents said that they did not know what 
proportion of patients was started on an MCA with the specific intention of enabling self-
administration. Nine of the 18 community pharmacy respondents said they did not know how 
many of the MCAs were initiated specifically to enable carer administration; these nine 
included the seven who were unaware if patient self-administration was enabled, and also 
included the two pharmacies that issued the highest number of MCAs to patients who lived in 
their own homes (180 and 150). 
 
Of the nine respondents who were able to indicate the intended nature of use of the MCAs 
they dispensed, one response was voided as the respondent answered that all of the MCAs 
were supplied for self-administration and that all of the MCAs were supplied for carer-
administration, which both cannot be the case as these statements were mutually exclusive. 
Two respondents said that some of the MCAs that they dispensed were for self-administration 
and some were for carer-administration but they did not give numbers. These two pharmacies 
dispensed less than the average number of MCAs at 35 and 37. Only one said that all were for 
patient self-administration and none were for carer administration. This pharmacy dispensed 
less than the average number of total dispensed MCAs (40). Of the five remaining pharmacies, 
ratios of carer use versus self-administration ranged from 2:53 to 43:23 but on average 
approximately a third were reported to be for carer use (25:50, 8:20, 19:36). Four of these five 
pharmacy respondents reported that the majority was for self-administration. 
 
3.2.1.2 Impact on work pattern (Questions three, four, seven, eight and ten in 
Appendix 6) 
 
Ten pharmacy respondents reported that supply activity for MCA patients living in their own 
home, including dispensing, took up over 25% of the time that was spent in the pharmacy on 
all activities. Only six of these ten respondents reported that over 25% of their regular patients 
were MCA users living in their own homes; the other four had less than 25%. 
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Only three pharmacy respondents reported that less than 1% of their regular patients were 
MCA users who lived in their own home. In all three pharmacies, dispensing these and other 
activities related to supplying the MCA took up over 1% of the time that the pharmacy spent 
on all activities (one at 1-5%, two at 6-15%). 
 
Overall in eight of the 18 pharmacies, activities relating to supply for regular patients who 
were MCA users living in their own homes took up a disproportionately large time when 
compared to that of the non-MCA patients (Questions seven and eight). In three pharmacies, 
the activities relating to supply for regular patients who were MCA users living in their own 
home took up disproportionately small time when compared to that of the non-MCA patients. 
In the remaining seven pharmacies, the activities relating to supply for regular patients who 
were MCA users living in their own home were reported as being the same when compared to 
that of the non-MCA patients. In six of these, this same percentage was reported to be over 
25%. The question did not allow specific numbers or any estimation above 25%, and so it is not 
known what the actual percentage time spent on supply activities was. 
 
All of the 18 pharmacy respondents said that they asked for 7-day scripts to cover expenses 
(question ten); 17 did this all of the time and one most of the time. One pharmacy respondent 
commented that if the GP refused to issue 7-day scripts, they would still dispense MCAs. This 
was an unprompted comment added to the questionnaire by the completer – it is not known 
how many other pharmacists had this same approach. 
 
3.2.1.3 MCA provision and assessment (question 5 in Appendix 6) 
 
Figure 3.1 shows the frequency that community pharmacies reported that they supplied an 
MCA for a given list of circumstances. The most frequently reported circumstance was “every 
time an MCA is requested by a HCP” with 15 out of 18 positive responses. None of the 
pharmacy respondents said they never supplied a MCA. 
 
12 of the 18 pharmacy respondents provided MCAs for patients who lived in their own homes 
and received help with their medicines from a carer, if the MCA was requested by a GP or care 
agency. Eight supplied a MCA in the same circumstance even when not specifically requested 
by a GP or care agency. Half supplied a MCA every time it was requested by a social care 
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professional; half did so every time a relative requested one and this was more than the 
number (eight) who supplied one at the request of the patient themselves. 
 
Five of the 18 pharmacy respondents said they only supplied a MCA once they had assessed 
the patient’s ability to use it. The least frequently reported reasons for MCA supply were only 
when a GP requested one and post MUR assessment, with two positive responses for each. 
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Figure 3.1 – The frequency of community pharmacy MCA supply for given circumstance 
(n=18) 
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Figure 3.2 shows the frequency of circumstances in which pharmacy respondents reported 
assessing patients before MCA supply. 
 
Figure 3.2 – Frequency of circumstances in which pharmacy respondents reported assessing 
patients before MCA supply (n=18) 
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before issuing an MCA were before signposting to a GP, because the patient seemed confused 
and post-MUR. 
 
Sixteen respondents did not perform an assessment every time a blister pack was issued, but 
of these only thirteen indicated why this was.  Figure 3.3 shows the reasons community 
pharmacy respondents gave for not assessing the patient before supplying a MCA. 
 
The most frequent reason given for not performing an assessment before supplying a MCA 
was that the pharmacist was unable to assess housebound patients, with eleven out of 
thirteen positive responses. The next most frequent reason with nine positive responses was 
that the pharmacist believed that the MCA would be of benefit - more respondents thought 
this than thought that the MCA would simply not introduce further harm; only four pharmacy 
respondents reported this. The majority of the 13 respondents to this question (seven) 
assumed that the requestor had already made an assessment. 
 
The next most frequent reasons given for not assessing before supplying a MCA was carer 
involvement in the process, more specifically a fear that either a paid (six respondents) or 
unpaid (six respondents) carer relied on the blister pack instead of the patient. 
 
Pressure from the GP was highlighted by five respondents as being a reason to not assess 
patients before issuing a MCA. Pressure from other HCPs, GP practice staff, other primary care 
staff, patient, relatives, secondary care or social care were less frequently referred to as a 
reason preventing MCA assessments, with none of these being reported by more than two 
pharmacy respondents. 
 
Five respondents said that not having guidelines or a tool to perform the assessment was a 
barrier to assessments being completed, though fewer respondents (three) felt uncertain as to 
how to carry out an assessment. 
 
Three respondents each reported that assessments were not performed because they were a 
time consuming process and because it was less hassle to just do the MCA than it was to raise 
a query with the requestor. 
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Figure 3.3 – Frequency of reasons community pharmacy respondents gave for not carrying 
out an assessment before an MCA was supplied (n=18) 
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3.2.1.4 Reasons for MCA supply to patients who live in their own homes 
(Question nine in Appendix 6) 
 
Figure 3.4 shows the frequency that respondents reported supplying an MCA to patients who 
live in their own homes for the purpose of enabling a social carer to administer medication. 
Frequency of supply in order for a social carer to administer medication was spread fairly 
evenly across respondents, with the majority reporting that they did this, half of them supplied 
in this circumstance either sometimes or often. 
 
Figure 3.4 - The frequency that respondents supplied an MCA to patients who live in their 
own homes for the purpose of enabling a social carer to administer medication (n=18). 
 
 
Figure 3.5 shows the frequency that respondents reported supplying an MCA to patients who 
live in their own homes because the GP believed that there were issues with the patient’s 
ability to manage their medicines but without full assessment. Only one respondent of the 18 
said they did not supply in this circumstance. Nearly half reported GP belief of medicines 
management issues with the patient as a very frequent reason for supplying MCAs to patients 
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Figure 3.5 - The frequency that respondents supplied an MCA to patients who live in their 
own homes because the GP believed that there were issues with the patient’s ability to 
manage their medicines but without full assessment (n=18). 
 
 
Figure 3.6 shows the frequency that respondents reported supplying an MCA to patients who 
lived in their own homes because the district nurse or community matron requested it. Nearly 
half of respondents reported that they supplied MCAs in this circumstance sometimes; two 
supplied in this circumstance frequently and three never did so. 
 
Figure 3.6 - The frequency that respondents reported supplying an MCA to patients who live 
in their own homes because the district nurse or community matron requested it (n=18). 
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Figure 3.7 shows the frequency that respondents reported supplying an MCA to patients who 
live in their own homes because a specialist nurse had requested one for a patient. This reason 
for supplying an MCA was not very popular, with nearly a quarter of respondents never having 
supplied in this circumstance and only one doing so frequently. 
 
Figure 3.7 - The frequency that respondents supplied an MCA to patients who live in their 
own homes because a specialist nurse had requested one for a patient (n=18). 
 
 
Figure 3.8 shows the frequency that respondents reported supplying an MCA to patients who 
live in their own homes because the patient requested it. None of the respondents supplied in 
this circumstance frequently, and nearly a quarter never supplied an MCA in this circumstance. 
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Figure 3.8 – The frequency that respondents reported supplying an MCA to patients who live 
in their own homes because the patient requested it (n=18). 
 
 
Figure 3.9 shows the frequency that respondents reported supplying an MCA to patients who 
live in their own homes because another pharmacist (e.g. from the hospital) had carried out a 
medication assessment. This reason was the one that had the highest frequency of 
respondents answering “never”. There were, however, two respondents who reported very 
frequently supplying an MCA in this circumstance. 
 
Figure 3.9 - The frequency that respondents supplied an MCA to patients who live in their 
own homes because another pharmacist had carried out a medication assessment (n=18). 
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3.2.1.5 Opinion about which patients MCAs are suitable for (Question 12 of 
Appendix 6) 
 
Figure 3.10 shows the extent to which respondents agreed with the statement “MCAs are 
valuable in cases where patients are unintentionally non-compliant”. None of the 18 
pharmacists disagreed with this statement, with half of them agreeing strongly. 
 
Figure 3.10 - The extent to which respondents agreed with the statement “MCAs are 
valuable in cases where patients are unintentionally non-compliant” (n=18) 
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Figure 3.11 - The extent to which respondents agreed with the statement “MCAs are 
valuable in cases where patients are intentionally non-compliant” (n=18) 
 
 
Figure 3.12 shows the extent to which respondents agreed with the statement “MCAs are 
valuable in patients who forget to take their medicines”. The vast majority of respondents 
agreed with this statement, half of the 18 respondents agreeing strongly. Only one respondent 
disagreed, and no respondents disagreed strongly. 
 
Figure 3.12 - The extent to which respondents agreed with the statement “MCAs are 
valuable in patients who forget to take their medicines” (n=18) 
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Figure 3.13 shows the extent to which respondents agreed with the statement “Some patients 
find MCAs too difficult to use”. The majority of respondents disagreed with this statement 
(13/18) with one of these respondents disagreeing strongly. Only four respondents agreed 
with the statement, and none strongly agreed. 
 
Figure 3.13 - The extent to which respondents agreed with the statement “Some patients find 
MCAs too difficult to use” (n=18) 
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3.2.1.6 Views on MCA use by patients and carers for complex regimens 
(Question 12 in Appendix 6) 
 
Figure 3.14 shows the extent to which respondents agreed with the statement “MCAs should 
be used when patients are on a complex regimen in order to help them take their own 
medicines”. The majority of the respondents (14/18) agreed with this statement, most of these 
(8) strongly so. Only two respondents disagreed, one of these strongly so. 
 
Figure 3.14 - The extent to which respondents agreed with the statement “MCAs should be 
used when patients are on a complex regimen in order to help them take their own 
medicines” (n=18) 
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medicines”. The vast majority of respondents agreed with this statement (17/18); only 1 
disagreed and there was no strong disagreement. The results of these two questions show that 
there is even stronger support from community pharmacists for carer use of MCAs than there 
is for self-administration from MCAs. 
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Figure 3.15 - The extent to which respondents agreed with the statement “MCAs should be 
used when patients are on a complex regimen in order to help carers give them their 
medicines” (n=18) 
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3.2.1.7 Involvement of social care (Question 12 in Appendix three) 
 
Figure 3.16 shows the extent to which respondents agreed with the statement “Most social 
care agencies do not allow their carers to administer medicine in any way other than from an 
MCA”. The majority of respondents held this belief, only one disagreeing and two neither 
agreeing nor disagreeing. 
 
Figure 3.16 - The extent to which respondents agreed with the statement “Most social care 
agencies do not allow their carers to administer medicine in any way other than from an 
MCA” (n=18) 
 
 
Figure 3.17 shows the extent to which respondents agreed with the statement “MCAs reduce 
the likelihood of medication administration errors”. Just two respondents disagreed with this 
statement, the majority agreeing. 
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Figure 3.17 - The extent to which respondents agreed with the statement “MCAs reduce the 
likelihood of medication administration errors” (n=18) 
 
 
Figure 3.18 shows the extent to which respondents agreed with the statement “It is legitimate 
to use MCAs as a time saving device for carers”. Only a third of respondents agreed with this 
statement, and half disagreed. 
 
Figure 3.18 - The extent to which respondents agreed with the statement “It is legitimate to 
use MCAs as a time saving device for carers” (n-18) 
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Figure 3.19 shows the extent to which respondents agreed with the statement “I worry that 
carers will not be able to administer medicines unless they are dispensed into an MCA and I 
will be at fault”. Only a third of respondents agreed with this statement, and half disagreed. 
 
Figure 3.19 - The extent to which respondents agreed with the statement “I worry that carers 
will not be able to administer medicines unless they are dispensed into an MCA and I will be 
at fault” (n=18) 
 
 
  
5
1
3
6
3
I worry that carers will not be able to administer medicines 
unless they are dispensed in an MCA and I will be at fault 
(n=18)
Agree strongly
Agree
Neither
Disagree
Disagree strongly
44 
 
3.2.1.8 Pharmacy processes around MCA supply (Question 12 in Appendix 6) 
 
Figure 3.20 shows the extent to which respondents agreed with the statement “The stability of 
some medicines in MCAs is severely compromised”. None of the respondents disagreed 
strongly here, but over half of respondents either disagreed or neither agreed nor disagreed.  
 
Figure 3.20 - The extent to which respondents agreed with the statement “The stability of 
some medicines in MCAs is severely compromised” (n=18) 
 
 
Figure 3.21 shows the extent to which respondents agreed with the statement “I always check 
whether a medicine is going to be stable before dispensing it into an MCA”. Only one 
respondent disagreed with this statement. 
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Figure 3.21 - The extent to which respondents agreed with the statement “I always check 
whether a medicine is going to be stable before dispensing it into an MCA” (n=18) 
 
 
Figure 3.22 shows the extent to which respondents agreed with the statement “Dispensing 
into an MCA increases the likelihood of dispensing errors occurring”. Only three of the 18 
respondents agreed with this statement, with the majority disagreeing and over a third neither 
agreeing nor disagreeing. 
 
Figure 3.22 – The extent to which respondents agreed with the statement “Dispensing into 
an MCA increases the likelihood of dispensing errors occurring” (n=18) 
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Figure 3.23 shows over a third of respondents neither agreed nor disagreed with the 
statement “The community pharmacist is the person best able to assess patient need for an 
MCA (even if this is not facilitated locally)”. Nobody strongly disagreed; more agreed than 
disagreed. 
 
Figure 3.23 - The extent to which respondents agreed with the statement “The community 
pharmacist is the person best able to assess patient need for an MCA (even if this is not 
facilitated locally)” (n=18) 
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The community pharmacist is the person best able to assess 
patient need for an MCA (even if not facilitated locally) 
(n=18)
Agree strongly
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Disagree
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3.2.1.9 Attitudes towards key pre-conceived disadvantages of MCAs (Question 
12 in Appendix 6) 
 
In Question 12 of the questionnaire (Appendix 6), there were two statements where anecdotal 
disadvantages about MCAs were addressed. Figure 3.24 shows the extent to which 
respondents agreed with the statement “Patients feel less involved in their treatment when an 
MCA is used (e.g. if started without telling them or if no Patient Information Leaflets (PILs) are 
supplied)”. The most frequently reported response to this statement was disagreement (8/18), 
with only a third of respondents agreeing with this. 
 
Figure 3.24 - The extent to which respondents agreed with the statement “Patients feel less 
involved in their treatment when an MCA is used (e.g. if started without telling them or if no 
PILs are supplied)” (n=18) 
 
 
 
Figure 3.25 shows the extent to which respondents agreed with the statement “Not being able 
to include PRN, topical or temporary medicines is a significant disadvantage of MCAs”. A third 
of respondents disagreed with this statement, one strongly so, and equal numbers (4) agreed, 
agreed strongly and neither agreed nor disagreed. 
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Figure 3.25 - The extent to which respondents agreed with the statement “Not being able to 
include PRN, topical or temporary medicines is a significant disadvantage of MCAs” (n=18) 
 
 
 
3.2.2 Qualitative results (Question 13) 
 
The answers from the free-text question (Q13) at the end of the questionnaire were collated 
and analysed using a simple thematic analysis. Table 3.1 shows a list of the codes identified 
from the complete coding of the original dataset. Table 3.2 shows initial sub-themes taken 
from these codes after review, arranged as three main themes, under which results are 
reported (with numbers of community pharmacists who contributed to each theme in 
parentheses).  
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Table 3.1 – Codes from the qualitative component of the questionnaire 
Examples of MCA use – positive and negative 
Literacy 
Positive views on patient use of MCAs 
Carer administration from MCAs 
Medication errors: taking own medicines, dispensing, administration 
Practical issues in the pharmacy 
Memory issues 
The NHS and funding 
HCP assessment and requests 
Future community pharmacy developments 
Problems identified with MCAs 
 
 
Table 3.2 – Themes developed from coding of the qualitative data 
(number of contributing community pharmacists) 
1. Experience of patient use 
Examples of use – positive and negative (2) 
Literacy (2) 
Positive experience (10) 
Problems identified* (3) 
2. Carer administration 
Carer administration and training (6) 
Error prevention* (1) 
3. Practicalities of supply 
Initiation of MCA (3) 
Pharmacy processes (5) 
Dispensing errors – unlikely* (1) 
The NHS and funding (6) 
Proposed future models (1) 
*each of these sub-themes combined showed that community 
pharmacists generally thought MCAs had a positive effect on safety 
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3.2.2.1 Experience of patient use 
 
The pharmacists reported some instances of positive use of MCAs: 
 
Pharmacist 2: “Patient was confused about the blood pressure tablet which looked 
similar to a cholesterol tablet and had literacy issues. Would be taking blood pressure 
medication twice daily resulting in hyperkalaemia and eventually leading to a fall when 
she was assessed for an MCA.” 
 
Mostly though, positive use was expressed by the respondent as a general feeling, or 
expression of general experience, regarding safety and ease of use of MCAs: 
 
Pharmacist 6: “MCAs are a valuable way to help our patients who are not able to safely 
administer their medication themselves” 
 
Pharmacist 8: “I feel most of my MCA patients find it very helpful and find it very easy 
to understand” 
 
Pharmacist 9: “They generally are of benefit to the patient or carer” 
 
Pharmacist 11: “Generally they help lots of carers and patients” 
 
Pharmacist 15: “MCAs are easier for patients” 
 
Some positive expressions were made around the issue of memory: 
 
Pharmacist 10: “It gives them freedom and independence to administer their own 
medication. It's also largely beneficial to those with difficulty remembering to take all 
their medication” 
 
Pharmacist 13: “They help even if the patient forgets to take their medicine” 
 
51 
 
There were also some responses that indicated that caution was required when MCAs were 
used, and some that showed a belief that MCAs were not always the answer to medication 
taking problems: 
 
Pharmacist 17: “There are a wide range on the market. Issues with patient moving, 
different brands, it "throws" patients. They have been known to take medicines in the 
wrong order / layout. Uniformity is important” 
 
Pharmacist 18: “If appropriate questioning is used, MCAs shown to be not so useful. 
With intentional compliance, if packaged in the original pack or in the blister pack it 
doesn't matter, there is no change in compliance, though it is easier for the patient in a 
blister, they do work. MCAs are not always the answer - there are a range of ways to 
aid compliance and GPs are not aware of them all” 
 
Pharmacist 14: “Dosette boxes are not the answer, it is proper explanation to relatives 
and carers that is the answer” 
 
3.2.2.2 Carer administration 
 
Comments from respondents regarding carer administration focussed on the perceived lack of 
training they receive regarding medicines, and introduced the notion that it is safer to use 
MCAs in these scenarios for this reason: 
 
Pharmacist 13: “Carers don't know any other way to give medication, they are not 
trained and it is safer to use a blister pack. They don't know what the patient is taking 
or when they should take it” 
 
Pharmacist 11: “I would show the patient how to use it the first time, not with their 
carer. I expect for carers to know how to use them, though don't think they are trained 
well enough” 
 
Pharmacist 14: “There are problems in the Social care system. Training carers has to be 
paid for so agencies don't do it” 
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Comments were made regarding MCAs increasing the time available for carers to spend caring 
for the patient by speeding up or simplifying the medicines administration process: 
 
Pharmacist 11: “Care agency should be spending more time with clients, not less” 
 
Pharmacist 16: “I can understand why care agencies want blister packs as we do all the 
tablet popping for them” 
 
3.2.2.3 Practicalities of supply 
 
The respondents reported GPs or other prescribers as being the HCPs they thought should be 
the decision makers regarding MCA initiation: 
 
Pharmacist 10: “Usually if we notice a patient having difficulty with a complex regime 
rather than dispense into an MCA straight away we contact the prescriber who then is 
able to validate via an assessment process if the patient would benefit from an MCA” 
 
Pharmacist 13: “Not sure about the pharmacist checking intended use - we should 
leave that to the GP, it is their decision not the pharmacist's / up to them” 
 
Pharmacist 18: “GPs carry out the assessment for a blister pack or refer to the 
community pharmacist to do it” 
 
The issue of stability was explained by two pharmacists who do not see it as an issue as tablets 
are in MCAs for such a short amount of time: 
 
Pharmacist 9: “As regards to stability this is minimised as only one week is given at a 
time - this might be a problem if 4/52 is supplied. Most of our patients are given 1/52 
at a time and most are delivered to their home” 
 
Pharmacist 11: “I am not worried about stability as they are not in the blister pack for 
long (7-day scripts)” 
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In terms of processes in the pharmacy, concerns were raised by respondents regarding the 
time spent on MCAs, and the cost of supplying and delivering them. Some other pharmacy 
procedures – such as writing out what the tablets look like, dealing with secondary care, 
wastage and prescription changes, dispensing errors and asking for 7-day scripts – were also 
mentioned: 
 
Pharmacist 9: “They are very time consuming and require many checks to ensure 
accuracy… If GP uses repeat dispensing then the re-ordering is simple except when 
meds are changed. It is easier to check meds when a patient is discharged from 
secondary care especially if there is a copy of the TTO sent to the pharmacy” 
 
Pharmacist 10: “My pharmacy is more concerned about the cost and time associated 
with MCA's” 
 
Pharmacist 11: “I always write what tablets look like on the box” 
 
Pharmacist 12: “It is a very costly exercise, and delivery also. It is done out of the 
goodness of our hearts” 
 
Pharmacist 13: “I would do the blister packs anyway, even without the prescriptions, 
but do always ask” 
 
Pharmacist 15: “MCAs are easier for patients but harder for us! Don't get that much 
payment for it, very time consuming. Short notice changes e.g. if the patient is 
hospitalised are difficult to manage and co-ordinate FP10 supply. All the time, I need to 
allocate 1.5 people to do it (mix of tech, pharmacist) which occurs in a dedicated room 
and nobody can disturb them. For these patients their prescriptions are kept on an 
excel sheet with date of receipt, date dispensed, changes, notes etc. 1 sheet per 
patient…Some patients want particular colours and makes - we can't keep track of that 
(160 patients). Six checks are performed per box - there have been no errors in 7 years” 
 
There were many comments regarding the role of the NHS in MCA provision, either current 
lack of funding or future proposed models where the NHS takes a greater role: 
 
54 
 
Pharmacist 11: “They (MCAs) probably save the NHS a fortune” 
 
Pharmacist 12: “The NHS does not fund this service” 
 
Pharmacist 14: “The NHS should get more involved, outsourcing hospital staff to help 
with medicines management and explanation to carers…MURs could be targeted to 
housebound patients.” 
 
Pharmacist 15: “The NHS is asking for community pharmacy (CP) services - it is really 
hard to get on but pharmacy is still patient orientated” 
 
Pharmacist 16: “Provision of blister packs should be properly funded by the NHS” 
 
3.3 Discussion and future areas for research 
 
 3.3.1 Limitations of the study 
 
There was a low rate of return for the community pharmacy questionnaire of 13.7%, which 
could be for a number of reasons. It may have been that time constraints in the community 
pharmacy meant that completing the questionnaire was not feasible, or that the community 
pharmacist did not want to reveal detailed information about the pharmacy and the MCA 
dispensing process despite the assurances of confidentiality. There may have been reluctance 
from managers of branches of large corporate pharmacy chains to participate as they may not 
have the same level of autonomy as small chain or independent pharmacy managers. The low 
response rate may mean that the range and depth of phenomena presented are limited. 
 
One of the limitations of the questionnaire was that the questions aimed at finding out what 
proportions of regular patients were MCA users living in their own homes, and what 
proportion of time dispensing activities relating to these patients of all pharmacy activities, 
were both limited to a maximum answer of “over 25%”. It may be that the true answer 
exceeded 25% by a long way, and this could not be captured from either question. The limit 
being set too low at “over 25%” did not become apparent in piloting, nor when the review of 
the questionnaire by a non-Lambeth or Southwark community pharmacy contractor took 
place. It is still a pertinent finding that in many pharmacies, over a quarter of the time spent on 
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activities related to MCA provision for patients who lived in their own homes, and that in some 
pharmacies patients who used MCAs made up over a quarter of all patients. The question 
would have been improved if the answer options had been extended, perhaps by adding the 
options 26-40%, 41-55%, 56-70% then over 70%. This wider range of options would have 
enabled a better understanding of whether the work activities for MCA patients was in 
proportion to the number of regular MCA patients. 
 
There was stronger support from community pharmacists for carer use of MCAs than patient 
use. This finding is in conflict with the intended purpose of MCAs as enabling self-
administration. The two questions regarding use in complex drug regimens were presented in 
the questionnaire in the order they are presented in the results, with the question pertaining 
to patients first, immediately followed by the carer question (Question 12, 3.2.1.6; Figures 3.14 
and 3.15). It is possible that when considering the cohort of patients for the first question, the 
respondent had already “ruled out” this same cohort in their minds as being able to self-
administer when answering the next question about carer use. 
 
3.3.2 Result summary and suggestions for future research 
 
  3.3.2.1 Intended purpose 
 
The lack of awareness that community pharmacists had about the intended use of the MCAs 
they provided raises some questions. There is an expectation that as NHS contractors, 
community pharmacists supplying MCAs for NHS patients have done so in line with the EA 
2010, and have demonstrated that the MCA is a reasonable adjustment for the community 
pharmacist to make in order to enable a patient to take their own medicine. If there is not an 
awareness of the intended use of the MCA, it follows that the community pharmacist cannot 
be assured that they are supplying the MCA in line with NHS policy. The finding that the two 
pharmacies that reported the highest numbers of MCAs dispensed were not aware of the 
intended use of the MCAs they supplied suggests that with such a high volume of MCAs 
supplied and workload pressures, they are unable to keep track of this information. 
 
There is an argument that because most of the time, MCAs are requested by a health or social 
care professional, the community pharmacist can assume they are issuing the MCA in line with 
NHS policy; if there was no adjustment necessary, the request would not have been made. 
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More research is needed to find out if this is the case, and to establish the expectation of 
community pharmacy contractors regarding their involvement in the decision to initiate a 
MCA. Three community pharmacists said they never assessed a patient for an MCA before 
issuing one: making enquiries before supplying a MCA could be viewed as duplicating work, 
unnecessarily intrusive or even extra unfunded activity on the part of the community 
pharmacist. Exploring this further is a worthwhile topic for future research; one suggestion is a 
qualitative approach, focussed on the direct interaction between social services (social 
workers and care managers) and community pharmacists, as well as indirect interaction via 
GPs. In-depth interviews with social care professionals and community pharmacists using a 
topic guide to explore the process, reasoning and decision making before an MCA is issued 
could be used to explore the pre-dispensing process in depth
38
. 
 
3.3.2.2 Impact on work pattern 
 
There is scope to explore the work patterns of community pharmacies further in future 
research; there was a wide variation in proportions of time spent on MCAs between the 
pharmacies, even when the proportion of patients was taken into consideration. This indicates 
that either work is organised very differently between contractors or that the conditions to 
optimise and streamline MCA supply are more readily met in some pharmacies than others; 
either way, there is no standard approach. One way this could be addressed is by conducting a 
time and motion study
50
 in a systematic sample of community pharmacies where staff are 
observed and timed carrying out the processes associated with MCA supply. Other pharmacy 
processes have been assessed and timed using this technique
51
. It would be possible then to 
understand and map out what an efficient MCA supply process looks like as a template for 
other community pharmacies. 
 
All pharmacists asked for 7-day scripts to cover their expenses for dispensing MCAs (confirmed 
in the qualitative responses); this increases the income of the community pharmacist as each 
item attracts a dispensing fee. By splitting up monthly or three-monthly scripts into smaller 
scripts for 7-days at a time, dispensing the items attracts four fees for every 28 days supplied 
per item on the script. The dispensing fee already includes an element for dispensing MCAs 
and other compliance aids as reasonable adjustments to make to enable a person to take their 
own medicines. It is probable that community pharmacists feel that the nominal value 
included in the dispensing fee for enabling reasonable adjustments under the EA 2010 is not 
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enough; certainly some respondents felt they were inadequately funded and others felt they 
were saving the NHS money by doing MCAs at all (confirmed in the qualitative responses). 
Future research in this area could concentrate on this widespread practice of requesting 
weekly prescriptions, particularly how often this is honoured by the patient’s GP practice and 
what happens if the GP practice refuses. GPs are not obligated to provide 7-day scripts to 
bolster the income of the community pharmacist, and the community pharmacist has no legal 
grounds to refuse to dispense into MCAs if they are not furnished with weekly scripts. Whether 
GPs are aware that they do not need to do this, and the impact of having to write and sign four 
scripts for every month of medication for all of their MCA patients on the workload of GP 
practices, are valid areas for future enquiry. Quantitative investigation using a survey
45
 of GP 
practice managers could address the understanding of practice staff with regard to the EA 
requirements, honouring requests for weekly scripts and what they experience if they refuse 
to issue weekly scripts to community pharmacists.  Any future research in this area should 
include the possibility that community pharmacies actively promote an MCA service in order to 
increase revenue, a possibility than cannot be deduced from the results here. 
 
3.3.2.3 MCA provision and assessment 
 
The relatively fewer numbers of MCAs requested by the patients themselves suggests that 
most MCAs are for people who have health and social care representatives. In the majority of 
cases, MCAs were supplied on the recommendation of somebody else rather than the 
community pharmacist. Two pharmacists supplied MCAs after performing a MUR and five said 
they would assess the patient’s ability to use it before supplying; many more pharmacists said 
they would supply the MCA on the recommendation of a GP, social care professional, or other 
HCP. The low number of patients started on a MCA post-MUR, indicates that perhaps the 
patient cohort who have MCAs are not able to access the pharmacy-based MUR scheme 
offered in their pharmacy due to being housebound, or possibly community pharmacists do 
not perform MURs in such complex patients. The link or absence of a link, between MURs and 
MCA provision is worthy of future research, which could be achieved by gathering and plotting 
MCA vs. MUR activity data
52
. Housebound patients who need to use a MCA are prime 
candidates for MURs; community pharmacists performing MURs away from the pharmacy 
premises is not usually funded for locally and as long as there is a flat fee per MUR that does 
not take complexity into consideration as is the case now, there is no financial incentive for 
community pharmacists to perform MURs in complex housebound patients. 
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Assessment was more likely to occur in patients who had requested the MCA themselves or 
who had relatives who had done so. This may be because community pharmacists had 
assumed that the health or social care requestor would have performed an assessment. The 
results show that community pharmacists were unsure of when an assessment should occur, 
whether they should be the ones to do this assessment and what the assessment should 
entail; there was no standard approach apparent from the results, and the qualitative question 
revealed trepidation from the pharmacists about performing them. 
 
3.3.2.4 Reasons for MCA supply to patients who live in their own homes 
 
Community pharmacists supplied MCAs for patients living in their own homes more frequently 
at the request of social care and GPs than at the request of the patient themselves and other 
pharmacists. This may be due to the type of patients that MCAs are viewed as being useful for 
in the opinion of the GPs and social care professionals, e.g. patients with dementia (who do 
not form a part of this study). Another reason may be that GPs and social carers see such a 
high volume of patients for whom MCAs are used. There are not very many community health 
services pharmacists in post and these pharmacists are far more likely to have carried out a full 
medication review and assessment of the suitability of a MCA than a GP; secondary care 
pharmacists are under pressure to discharge patients quickly and so review of what happens 
when the patient gets home is not usually a part of their remit. It is fair to say that the 
patient’s view is not being taken into consideration at this initiation stage routinely, and this 
finding warrants future research, some of which is addressed in Chapters 4-6 of this thesis. 
Community pharmacists did not object to supplying MCAs for carers (from qualitative 
responses); associated claims made that they save the NHS funding is as yet unsupported by 
evidence. 
 
3.3.2.5 Opinions about the patient groups MCAs are suitable for 
 
Just over a third of the community pharmacists thought that if a patient is purposely not going 
to take their medicines (intentionally non-adherent), it is unlikely that they are going to start 
just because the packaging has changed, even if MCA packaging makes that process easier 
(confirmed in three of the qualitative responses).  
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The opinion that they help patients with memory issues (confirmed in the qualitative 
responses) warrants further enquiry as to why community pharmacists believe this, by in-
depth interviews with community pharmacists. If a patient does not remember to take their 
medicines, they are not likely to remember to take them because the packaging has changed 
to an MCA. The respondents may not have interpreted the question this way; in Chapter 4, 
patients some were interviewed and found value in knowing whether they had taken a 
medicine or not by referring back to the MCA, which is different to using the aid to remind 
them to take the medicine in the first place. The community pharmacists may have been 
aware of this advantage; it is not clear which way they had interpreted this question. 
 
3.3.2.6 MCA use in complex drug regimens 
 
Anecdotally, allowing a carer to use an MCA to administer medicines could mean the 
difference between a patient being cared for in their own home instead of a care home, or the 
difference between a straightforward and more complicated care package. If there is 
perceived value in carers using MCAs to proxy-administer medication, this should be 
researched further. 
 
3.3.2.7 Involvement of social care 
 
Though most respondents disagreed with the legitimacy of MCAs being used to save time and 
with any blame placed upon them if they refused to supply an MCA, some (a third for each 
question) did agree with these statements. A community pharmacist may think time-saving is a 
legitimate reason for using an MCA if it means the carer can spend more time with the patient; 
there was one comment in the free-text responses that alluded to this notion (see Section 
3.2.2). Finding out more about the nature of communication between the community 
pharmacy and social care is a worthy area for future research, initially at least by quantitatively 
logging the method and frequency of communication between a sample of community 
pharmacists and GPs that concerned MCAs
33
. 
 
3.3.2.8 Pharmacy processes around MCA supply 
 
The finding that the majority of pharmacists doubted that the stability of medicines when 
dispensed into an MCA was severely compromised (confirmed in the qualitative responses) 
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was interesting; as the respondents went on to agree that they would check if this was the 
case. There is evidence in pharmacy practice that some medicines are de-stabilised when 
removed and stored outside of their original packaging
53
. Questioning community pharmacists 
further on how they checked stability and whether they found this easy or difficult would be a 
worthwhile future avenue of enquiry
54
. 
 
There is some emerging evidence that dispensing into MCAs increases dispensing errors
32
, 
though this was not a widely held belief in the community pharmacists who completed the 
questionnaire. 
 
The results suggest that community pharmacists assessing patients for MCAs was somewhat, 
though not unanimously, supported, and more research into what the potential barriers are to 
services such as this is needed before community pharmacists take on such services on a 
national scale. There are some examples of local arrangements described in Chapter 1
12-14
. 
 
3.4 Conclusion 
 
The questionnaire of community pharmacists was conducted in order to establish the extent 
and impetus for MCA initiation in Lambeth and Southwark, and to develop a topic guide for 
the qualitative phase of the overall study. The extent of initiation varied greatly, with extensive 
supply of MCAs in order to facilitate proxy-medicines administration by carers. Table 3.3 shows 
how the themes found in the quantitative part of this research study, the community 
pharmacy questionnaire, were used to formulate a topic guide for the subsequent qualitative 
investigation. The topic guides used for the case study, community health services (CHS) nurse 
interviews and CHS pharmacist interviews are discussed in further depth in Chapters 4, 5 and 6 
of this thesis. 
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Table 3.3 – Topic guide formation 
Theme Key results Related topic guide  
Intended purpose One third involved carers. 
Community pharmacist is not very 
involved in the decision to start an 
MCA. 
Case study with patients 
CHS nurses 
CHS pharmacists 
Impact on work pattern Labour intensive. High impact, is 
the error rate also high? 
All asked for 7-day scripts. 
What are the effects on patients 
e.g. delivery, responsiveness to 
changes? 
Case study with patients 
CHS nurses 
CHS Pharmacists 
MCA provision and 
assessment 
Lack of patient involvement 
Lack of community pharmacy 
input into assessment. 
No standardisation around 
assessment for MCAs. 
Case study with patients 
CHS Pharmacists 
Reasons for MCA 
supply to patients who 
live in their own homes 
Decision to start an MCA is usually 
the GP’s. 
Little patient involvement. 
Case study with patients 
CHS nurses 
CHS Pharmacists 
Opinion about which 
patients MCAs are 
suitable for 
Non-compliance (intentional and 
unintentional). 
Memory problems. 
Case study with patients 
CHS nurses 
CHS Pharmacists 
MCA use by patients 
and carers for complex 
regimens 
Strong support for patient use. 
Stronger support for carer use. 
Case study with patients 
CHS nurses 
CHS Pharmacists 
Involvement of social 
care 
Time-saving. 
Error reduction / safety. 
CHS nurses 
CHS Pharmacists 
Pharmacy processing 
around MCA supply 
Variation. 
Time-consuming. 
Costly. 
Case study with patients 
CHS nurses 
CHS Pharmacists 
Pre-conceived MCA 
disadvantages 
Disagreement that patients feel 
less involved in their care and that 
not being able to include all 
medication is a disadvantage. 
Case study with patients 
CHS nurses 
CHS Pharmacists 
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Chapter 4 Collective case study of MCA users 
 
4.1  Introduction 
 
This chapter explains the collective case study methodology - the qualitative part of the 
sequential mixed methods study discussed in Chapter 2 designed to answer the research 
question: How does what patients and carers believe about MCAs affect how they are initiated 
and used? The objectives were: 
 Use a collective case study methodology to explore the attitudes that MCA users 
(patients and employed carers) have about administering medication, and how this 
affects MCA initiation and use. 
 Use an opt-in strategy to recruit suitable individual patients and patient and carer pairs 
into the qualitative phase of the study. 
 Collect data to answer the qualitative research question by conducting semi-structured 
interviews of patients and carers and collecting qualitative data from other relevant 
sources within each case. 
 
4.1.1 Possible methodologies 
 
In any research project the strategy chosen depends on the purpose of the study and the 
nature of the research question
25
. Grounded theory, phenomenology and case study 
methodologies could each conceivably have been used to answer the research question. 
 
4.1.1.1 Grounded theory 
 
In the grounded theory approach, data are collected and coded, then worked up into concepts 
from which categories are formed and used to create a theory. In other words, a hypothesis is 
not formed at the start of the study; the theory is generated from the views of the participants 
as the study progresses
55
. This inductive theory generation requires systematic data collection 
and analysis
56
. Data analysis begins during data collection, and analysis of the emerging data is 
used to shape subsequent data collection; the researcher is able to amend the questions or 
method to capitalise on findings as patterns or new avenues worthy of more in-depth enquiry 
emerge
57
. The main advantage of using a grounded theory methodology to answer the 
research question in this instance is the emphasis on theory development; ultimately the 
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research aim is to develop a theory of how attitudes and beliefs affect initiation and use of 
MCAs. 
 
In 2011, Nunney et al used a grounded theory approach to understand how MCAs were used, 
which aligns closely with the aim of the research reported in this thesis 
28
. This study 
attempted to gain a deeper understanding of the initiation and use of MCAs; the analytical 
steps were iterative and data collection followed grounded theory; but the researcher’s used 
theory generated from previous research rather than emerging theory being generated from 
the study (conceptual theory) to inform the interview questions and determine the schedules, 
which is not a strictly grounded theory approach. The authors did not discuss their reasons for 
deciding on the methodology in the paper. 
 
The author’s view is that there is more to the initiation of MCAs than will be revealed from 
interviews with MCA users, and a strategy where theory is generated from a range of sources 
is called for. The author is a practising pharmacist and as such, events, knowledge and 
experiences in this capacity are likely to influence any theory generated. This has the 
disadvantage in grounded theory of being seen as “polluting” the empirical iterative data 
collection and theory generation process; the author’s view is that prior experience should be 
capitalised on in order to contribute to this research.  As well as concerns about capacity to 
stay true to the grounded theory philosophy, the data analysis process is time consuming. For 
these reasons, the author decided against a grounded theory approach. 
 
4.1.1.2 Phenomenology 
 
Phenomenology is sometimes considered a philosophical perspective as well as an approach to 
qualitative methodology. The aim of a phenomenological approach is to describe the lived 
experiences of people, not to generate theories or models of the phenomenon being studied
57, 
58
. The emphasis is on rich description, rather than cause. One of the research questions in this 
thesis looks at cause, or trying to explore how one thing (attitudes, beliefs) affects another 
(MCA use) and this is one of the reasons why the author decided against using a 
phenomenological strategy. The author’s view is that data collection from multiple sources 
rather than from just rich patient narratives is a better strategy to address the research 
question posed; interviewing MCA users only gives one perspective and other circumstances 
around MCA initiation would not be captured if a phenomenological approach was used. 
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Rivers et al 
29
 used a phenomenological approach in their study that looked at the extent to 
which NHS staff valued MCAs as compliance aids and determine the views of users where 
users were domiciliary carers or patients. The design of the study met the aims as results were 
reported in terms of the descriptive narratives of lived experiences of participants obtained 
from interviewing them, not from any other sources. In the study in this thesis, there is an 
element of capturing users’ views also. The study by Rivers et al did not aim to look at the 
circumstances of initiation of the aids, rather the experiences of the end users, so the strategy 
was appropriate here where it would not be for the study which is the subject in this thesis. 
 
4.1.1.3 Collective case study 
 
The chosen strategy for the research subject of this thesis was a collective case study. A case 
study is a strategy of inquiry where a program, event, activity, process or one or more 
individuals are explored in depth
59, 60
. In an instrumental (single) case study a particular case is 
examined to provide insight into an issue or theory refinement. In a collective (or multiple) 
case study, instrumental cases are studied jointly in order to look into the phenomenon or 
population
61
. This method is suitable where “how?” or “why?” questions are asked
60
, and was 
therefore very suitable for the qualitative research question here. Studying multiple cases 
instead of a single case strengthens findings and means it is possible to draw more powerful 
analytic conclusions.  Collecting more than one form of data is a common feature of collective 
(and single) case studies 
33, 37
.  
 
MacLure et al
31
 used a case study investigation in their study of MCA use in residents of 
sheltered housing sites. The case study methodology was appropriate to meet the aims as the 
focus was on understanding present circumstances from gathered data rather than from 
described lived experience alone. Cases included patient interviews but also interviews with 
HCPs who were a part of the patient’s care. This is a form of triangulation, which has been 
defined as the use of different methods or sources to extend inferences drawn from the data 
and confirm or clarify findings
59
. In the research presented in this thesis, HCPs were also 
interviewed but they were not matched to patients / instrumental cases; other sources were 
used to corroborate findings, as described further in Section 4.2.4. 
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4.2 Methodology 
 
4.2.1 Study design 
 
In this study each patient that used an MCA to administer medication and was in receipt of 
home care was treated as a case, and the scenarios, beliefs and opinions of medication 
administration from MCAs and MCA initiation explored in depth. The aim was to understand 
the process of how MCAs were initiated and used in real life and whether that was within the 
recommended circumstances (self-administration in line with the EA 2010). The collective case 
study methodology enabled the real life scenarios to be explored through interviewing 
patients, and multiple data collection methods were also employed to add further context and 
depth (e.g. patient care plans, medication policy documents, medicines administration records 
(MARs) or MAR charts) and service provider assessments of the level of patient support 
required). Understanding each case in depth and in context was a key part of theory 
refinement in this area, and was efficiently enabled with this collective case study strategy. 
 
4.2.2 Subject recruitment 
 
MCA users were identified via other pharmacists and pharmacy technicians who were 
personally known and in email communication with the author. These recruiting pharmacists 
and technicians were employed by Guys and St Thomas’ (GSTT) Community Health Services 
and managed caseloads of frail elderly patients with long-term conditions as part of their roles. 
The pharmacists distributed information packs compiled by the author (Appendix 7) to 
patients who met qualifying criteria of being housebound MCA users in receipt of some form 
of care that involved support with medication. There was one information pack for the patient 
that included information for the carer; the patient was asked to give the carer’s section to 
their carer on the author’s behalf (the author was termed the Chief Investigator in the patient-
facing materials). The carer section was printed on yellow paper for ease of differentiation. 
Both the patient and the carer sections contained a letter with a tear-off contact permission 
form to be completed with participant contact details and sent back to the author; alongside 
this was an information sheet about the study, some general information about participating 
in research and a consent form for the patient and a stamped addressed envelope for return of 
both of the contact permission forms. 
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The patients were not approached directly by the author; they were given the option of giving 
the author their contact details and permission to call them via completion of a “contact 
permission” form in the information pack, or via the pharmacist who recruited them. This 
meant the author was not involved in recruitment. This approach was chosen in order to 
prevent undue influence over the potential participants’ decisions to take part. 
 
Those patients willing to take part were contacted by the author individually and 
arrangements made to gain consent and conduct interviews. When the author visited the 
patient’s home, consent to conduct interviews and to collect other data related to each case 
was obtained face-to-face. 
 
Patients had the option of having a friend or relative present at the interview. The advantages 
of this were that they may have been able to remember key facts or clarify timelines, and they 
may have made the patient feel more comfortable during the interview. This is an important 
consideration when vulnerable people are participants in research. The friend or relative also 
signed a consent form to allow their responses to be audio-recorded and verbatim quotes to 
be published. The consent form for friends or relatives is also shown in Appendix 7 though it 
did not form part of the information pack for patients. 
 
4.2.3 Subject interviews 
 
The author used a topic guide to facilitate the process, and this was developed to allow 
exploration of pre-determined anecdotal issues as well as being partly informed by the results 
of the initial scoping phase where community pharmacists were surveyed. The areas 
considered within the topic guide are shown in Table 4.1 with brief explanation. The final topic 
guide is shown in Appendix 8. 
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Table 4.1 - Areas for coverage within the topic guide 
What happens when the patient takes their medication, how much does the carer do? 
Explain the process. 
Clarifies level of involvement from the carer; care agency notes were used to corroborate 
whether carers were performing only the duties that they should have been according to 
assessments. 
What are the perceived advantages and disadvantages of the MCA? How would the 
situation be different without it? 
Asked to patients from their own perspective, i.e. “what do you like about your blister pack? 
Is there anything you do not like? Would you be able to take your medicines without it? 
What do you think the purpose of the MCA is in the situation? 
Often already apparent, question used as a reminder during the interview and data source 
collation that the context of the MCA should remain at the forefront of these activities. 
What does the carer / patient think the purpose of the MCA is? 
Asked more casually: “why do you think people use these”, or “why is this different or better 
than medicines in their individual boxes?” - depended on the flow of the interview and the 
rapport established. 
Does the MCA make a difference to how you feel about taking / giving medication? 
Usually posed as “how do you feel about the blister pack” or “do you like the blister pack?” 
It would have been unusual for a patient to have very strong feelings about the packaging 
itself, and how they felt about having the blister pack manifested more as how they felt 
about the way it affected their decision making; this was established by probing further, 
using more than one question to get the interviewee to open up about their feelings at a 
pace that suited them. 
Does the MCA make a difference to how (the patient) feels about the overall package of 
care they receive? 
Used as a prompt to ask about the care package;  was not asked as a direct question but as a 
way of finding out what other support was in place for the interviewee and encouraging 
them to describe how independent they were with medication taking. 
What other health or social care professionals are involved in the management of the 
patient? 
Asked as “who else comes to see you as well as your carer”. This information could in most 
cases be seen from the other case study source information, but it was useful for the 
patients to put into words some of the experiences and perspectives they had on their 
situation and to discuss some of these relationships, so this question acted a useful prompt 
to yield other more general information about the patients’ situations. 
How did the MCA come to be started in the patient? Who was involved? 
Asked in a sensitive way that took into consideration that the patient might not remember 
why of when it was started due to any cognitive impairment. Interviewees were asked if 
they remember the circumstances around it being initiated, and also asked as a follow up if 
they remembered a time when they did not have the blister pack, as this might have elicited 
more information of jogged their memory. 
 
68 
 
The term blister pack was used throughout the interviews as the term MCA is the more formal 
description and patients were more likely to use the term blister pack themselves. Patient 
interviews were audio-recorded in the patient’s own home. They did not last for longer than 
an hour. 
 
4.2.4 Collection of other source data from the patient’s home 
 
The list below shows all of the documentation that was analysed alongside the interviews in 
order to add further context and depth
60
 and also to ascertain and verify facts upon which 
attitudes were based; whether these were employed in every case depended on availability 
and relevance of these materials in individual cases and whether consent had been given by 
the patient to obtain them on their behalf. Consent was gained in every case when the author 
visited the patient’s home for the interview via completion of the consent form.  
. 
 Analysis of the MCA itself (e.g. for omitted doses and dispensing errors); 
photographed with accompanying narrative description). 
 Community pharmacy dispensing records; other recorded assessments carried out 
by the community pharmacist (e.g. Medicines Use Review documentation). 
 GP medical records including medication records and prescription issue date 
information; discharge summaries from hospitals if otherwise inaccessible. 
 Historical case notes. 
 Patient care plans. 
 Medication policy documents. 
 Medicines administration records – historical and current. 
 Service provider assessments of the level of patient support required to enable 
medication taking. 
 
Audio recording equipment, an iphone camera and a portable scanner were used for data 
collection since many of the documents for analysis were kept in the patients’ homes. The 
additional sources to be photographed or scanned were collected at the same time as the 
interview (total visit length around 90 minutes). All materials were anonymised before leaving 
the patient’s home. 
 
4.2.5 Ethical issues 
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The ethics approval process is detailed in Chapter 2. Primary considerations for the author and 
the ethics committee were confidentiality, anonymity, and participant and researcher 
protection. Though talking about personal experiences can produce very rich data, it also has 
the potential to be very distressing for the participant, and how the author intended to 
prevent and manage this distress when it occurred was considered carefully and addressed in 
the research protocol and the patient information sheet (PIS). There was an obligation to stop 
the interview if the participant became distressed; this did not occur. 
 
The patient cases in the study were vulnerable; they were all in receipt of funded home care, 
elderly, frail, housebound and isolated. The approach was sensitive, and the author made 
conscientious efforts to establish trust and warmth with the interviewee
39
. 
 
4.3 Data Analysis 
 
Figure 4.1 shows how the data were analysed in this study. There were six patients in the 
study, and each of these was analysed as a “whole” case study. Within each case, multiple data 
sources were used including impressions, notes and observations made during the interview 
and a summary of the main codes apparent in the analysis of the individual interview. Sources 
that were available are listed within each case. 
 
The interviews of each case were analysed separately from the other case study data using 
Framework Analysis as discussed further in Section 4.4.1 below. Interview quotes are 
presented to illuminate findings and opportunities taken throughout analysis and presentation 
to use case study data from other sources to add context. 
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Figure 4.1 – Analysis of patient case study data 
 
4.3.1 NVIVO 10 
 
Computer Assisted Qualitative Data AnalysiS (CAQDAS) was employed as a tool to assist with 
the data analysis. The author attended a series of short courses hosted by the University of 
Portsmouth Graduate Development Programme in the practical use of NVIVO. The NVIVO 10 
software package was subsequently used to ensure an audit trail was kept throughout the 
analysis. Using NVIVO to organise the data in this project had a number of advantages over 
doing this by hand: there was a large volume of data from multiple cases, and it was possible 
to import different sources into the package in a variety of formats (photos, audio, word 
documents, pdf documents, scanned items in gif of pdf format, field notes) and keep them 
together within each case. Coding was enabled by the programme: it was simple to code 
excerpts from more than one subject (multiple codes) and to keep track of this using the 
“coding stripes” function. When audios were listened to during the familiarisation step 
(described below in Section 4.4.1.1) records of findings could be kept by adding annotations to 
each transcript, so they were not “lost” in the coding process and ultimately ensuring early 
impressions that were gleaned from the data were captured in the final analysis. The facility 
within NVIVO 10 to write memos about particular aspects of some sources and link these to 
other documents was invaluable when analysing this type of case study data, where data was 
from multiple sources; this would have been difficult to emulate without CAQDAS
62, 63
. 
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4.3.2 Analysis of cases 
 
Yin describes an analytic strategy for case study data that relies on theoretical propositions 
that led to the research question, study objectives and questions asked in the literature 
review
64
. The author, in developing her own template for case study presentation, developed 
some propositions that built upon the objectives, original questions and literature review 
findings. These are below in Table 4.2. Cases were analysed, including reviewing the interview 
data in the thematic chart produced in the framework analysis (see next section) and 
propositions considered and challenged in the conclusion drawing stage of each case study 
presented. 
 
Table 4.2 - Propositions 
 Adherence and the MCA are unrelated 
 Patients are not part of the decision to start an MCA 
 Patients are not taking their medicines as intended 
 
4.3.3 Transcription 
 
Interviews were transcribed by a third party agency and a sample of transcriptions checked for 
accuracy against the audio recordings by the first supervisor. All transcripts were checked by 
the author (see “Familiarisation” in 4.4.1.1 below); rather than a separate technical procedure, 
checking the transcription of every interview and listening to the interview audio recordings 
multiple times was employed as part of the familiarisation step of the framework analysis
65
. 
The author annotated the transcripts with observations apparent from the audio or field 
notes, e.g. if something was stated defensively, passively or with humour. 
 
4.3.4 Framework Analysis 
 
The multiple sources from the six cases introduced some very rich but unwieldy data and it 
was essential that the method of analysis chosen afforded close management during collation 
of the data and beyond. The author used the following five stages of analysis in the Framework 
approach
66
: 
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1. Familiarisation 
2. Identifying a thematic framework 
3. Indexing 
4. Charting 
5. Interpretation 
 
4.4 Results 
 
4.4.1 Stages in Framework Analysis 
 
4.4.1.1 Familiarisation 
 
The familiarisation step was a crucial to ensure the integrity of the entire structure of the 
ongoing analytical process. As the author had collated all of the data herself, including 
conducting interviews, the familiarisation step was on a smaller scale than in some other 
qualitative studies where there are multiple researchers and numerous cases and interviews. 
As transcripts were not created by the author, re-listening and repeated reading of the 
transcripts formed the familiarisation step, along with review of photographs and other 
documentation. Observations made during this process were recorded on NVIVO 10 using the 
memo function. The familiarisation process continued until the author felt that all important 
characteristics of the data set were understood. 
 
4.4.1.2 Identifying a thematic framework 
 
During the review of the interview transcripts and other sources recurring topics were 
identified. These were assigned a “code”. NVIVO 10 was employed as a tool to assist with the 
coding process. Some excerpts were assigned more than one code and the “coding stripes” 
function in NVIVO 10 made this multiple coding visible throughout. As there were only six 
transcripts it was possible to code all of them and use this process to contribute further to data 
familiarisation. The author kept the objectives of the study in mind whilst pulling significant 
ideas from the transcript
66
. 
 
A long list of codes resulted: some descriptive categories (e.g. “diabetes”) some values (e.g. 
“Independence”) and concepts initially introduced via the topic guide for the interview, where 
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specific responses varied across the data set (e.g. “Relationship with community pharmacist”); 
the latter type were often split later on where opinion was spilt as the coding progressed 
throughout all of the transcripts (e.g. into “positive relationship with community pharmacist” 
and “negative relationship with community pharmacist”). 
 
An original list of codes was produced, but with no hierarchical structure, links or relationship 
between the codes yet identified. The original code list is shown in Table 4.3. 
 
Table 4.3 – Codes from first stage of coding  (“open coding”) in alphabetical order 
Adherence 
Adverse effects of medication 
Advice about medicines 
Attitude towards medication 
Attitude towards privacy 
Belief about what the medicine is doing 
Better to leave things as they are 
Blister pack problems 
Blister packs benefits 
Blister pack brand issues 
Carer relationship 
Changes to appearance of medicines 
Comfort with Dr making decisions 
Comfort with not knowing what changes or 
medicine is for 
Comfort with original packaging 
Community pharmacist 
CP training on blister pack 
Decision influenced by others 
Decision making about medicines 
Decision to start a blister pack 
Delivery 
Dependence on others 
Desire to know what medication is being 
taken 
Diabetes 
Discharge from hospital 
Efficacy of medication 
Expectations of services 
Expectations on family 
Eyesight 
Familiarity with regime 
Family 
Giving up or fed up 
GP and registration with GP 
Health 
Identification of tablets in blister 
Independence 
Intended reason for medicine 
Interaction with other HCPs 
Knowing meds are taken or not 
Length of time on same thing 
Loneliness 
Making own decision about health 
Medication taking process 
Medicines not in blister 
Memory 
Mental health 
Misunderstanding about regimen 
Mobility 
Moving home 
Narrative over blister pack 
Non HCP support 
Not making own decisions 
Not wanting to be a burden or bother others 
Ordering medicines from GP or CP 
Perceived error or real error 
PILs 
Positive outlook 
Religion or faith 
Self-administration 
Shared decision making 
Supporting self-administration 
Suspicion about meds or intended non-
adherence 
Tedious 
Trying out new meds 
Uncertainty about the need for tablets 
Uncertainty with medication regimen 
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The next step after “open coding” was to create a thematic framework in order to enable 
application of a manageable index to the entire dataset, so that further sense could be made 
of the data to support later stages of interpretation. 
 
Construction of the framework was achieved through writing each of the “codes” from the 
open coding stage (those in Table 4.3) onto separate cards and sorting and re-sorting them 
until a workable structure was found that the author felt included all of the key issues and 
concepts, appropriately themed. NVIVO 10 was used to look at which data extracts were 
originally assigned under each code across the six cases during the open coding process. For 
each code the author read and reviewed the material across these cases to get a feel for the 
nature of the code. The author made notes on each card by hand so that this initial 
interpretation was available during the sorting process and a link back to the data set 
maintained. The handwritten notes included any suggestions to change the title of the code 
based on the final content, or other observations made by the author when reflecting on the 
data included under each code. The author kept the language used close to that used by the 
interviewee; firstly to keep the analytical process grounded in the data and secondly to avoid 
polluting emerging data with her own understanding and terminology
67
. 
 
During this process of code refinement, some codes were found to be overlapping to such an 
extent that they could be combined, for example the codes “fed up”, “tedious” and “mental 
health” were combined, as the “mental heath” code contained only descriptions of low mood 
without diagnoses. Some codes were only relevant to one patient (e.g. “loneliness”) so were 
not taken forward to the framework as a single code but combined with other more prolific, 
similar codes. Table 4.4 shows some of the notes made by the author during this code 
refinement process. 
 
Through this refinement process Initial draft structures for the thematic framework were 
created. The thematic framework that was applied to the entire dataset is shown in Table 4.5. 
In the framework the final list of codes / categories was organised under six broader headings 
representing the main emergent themes. 
 
4.4.1.3 Indexing 
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In the indexing stage, the thematic framework was applied to the whole data set. During this 
process the author checked that no important categories were missing and if further 
categories needed sub-dividing. The author remained open to further refinement of the 
thematic framework to reflect changes
68
; changes are shown in Table 4.5 with the final 
framework. Figure 4.2 shows the distribution of coding references made within each of the six 
themes. Patients talked most often about the supportive relationships in their lives, followed 
closely by their independence (autonomy). 
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Table 4.4 – Code refinement during thematic framework creation 
CODE NOTES / REFLECTION 
Loneliness Only coded in one patient. Associated with depression in this 
patient (as per medical history) therefore overlaps with mental 
health. 
Mental Health 
Tedious 
Fed-up 
Similarities, lots of association and overlap in coded text. 
 
Positive outlook Coded text more similar to accepting life as it is / the situation 
that genuinely positive outlook; aligns more with surviving, 
being “alright”. Rename code. 
Family expectations 
Family 
Lots of crossover. The family code includes support in the form 
of communicating with healthcare professionals as an advocate 
of the patient, or sometimes just by being there.  
Non-HCP support 
Carer support 
The non-HCP support code just included wardens and only for 
two patients. Codes could be amalgamated. 
Independence Contains lots of reference to decision making. 
Blister pack problems Contains most of the blister pack brand issues. 
Identification of tablets Linked to decision making about medicines / decisions to take 
medicines and PILs. 
Discharge from hospital Content only relates to blister pack issues at discharge. 
Comfort with Dr making 
decisions 
GP and registration with 
GP 
These codes appear together often but cover different 
phenomena. Consider amalgamating codes later on. 
PILs Patients want them but they do not seem to bring much benefit. 
Either they cannot be read or they are causing confusion as 
there are multiple indications or many side effects listed. 
Not making own 
decisions, Decision 
making about medicines, 
& Desire to know what 
medicines are being 
taken 
Overlap 
Decision making about 
health 
Is a distinct code with significant and meaningful content, 
though not a large amount of content coded. 
Trying out new 
medicines 
All content at this code is also coded elsewhere. Relegate code. 
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Table 4.4 – Code refinement during thematic framework creation (continued) 
CODE NOTES / REFLECTION 
Perceived or real errors 
Familiarity with regimen 
Some overlap of both of these codes with intended and non 
intended non adherence (suspicion). 
Familiarity with regimen related really to either the patient 
being familiar or breaks in familiarity such as moving home or 
going into hospital. 
Uncertainty with 
medication regimen 
Contents of this code are also covered elsewhere e.g. much of 
the uncertainty about the regimen is related to memory issues. 
Medication taking 
process 
Overlaps with lots of other, more meaningful codes. Consider 
withdrawing. (Was discarded then re-instated at the indexing 
stage). 
Length of time on same 
thing 
All content relating to this discusses length of time as being 
relevant to either (1) whether there is still a need for the 
medicine or (2) Familiarity with regimen. These two codes are 
independent codes; contents at “length of time on same thing” 
should be re-assigned to one of these two codes. 
Uncertainty with the 
need for medicines 
Desire to know what 
medicine is for 
Comfort with not 
knowing what medicine 
is for 
Co-exist frequently in the transcript texts, though are discreet 
codes. 
“Uncertainty with need for medicines” is a distinct code from 
“uncertainty with medication regimen” – the first is not knowing 
why a medicine is taken, the latter is not knowing how to take it. 
Decision making about 
medicines 
This code encompasses lots of other codes and content. 
Efficacy The data coded under this term relates more strongly to the 
need for the medicine and attitude towards taking the 
medicine, which is covered in other more suitable codes. 
Consider withdrawing. 
Community pharmacist 
training on blister pack 
Only one patient experienced this – amalgamate code with 
blister pack or community pharmacist. 
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Table 4.5 – The thematic framework 
Taking medicines 
 Adverse effects of medication 
 Belief about what the medicine is doing 
 Desire to know what medication is being 
taken 
 Comfort with not knowing what changes 
or medicine is for 
 PILs 
 Misunderstanding about regimen 
 Attitude towards medicines or regimen 
 Familiarity with regimen 
 Intended reason for medicine 
 Medication taking process 
 Perceived error or real error 
 Uncertainty about the need for tablets 
 Uncertainty with medication regimen 
 Ordering medicines from GP or CP 
Autonomy 
 Supporting self-administration 
 Self-administration 
 Shared decision making 
 Decision influenced by others 
 Comfort with Dr making decisions 
 Decision making about medicines 
 Independence 
 Making own decision about health 
 Not making own decisions 
 Suspicion about meds or intended non-
adherence 
 Adherence 
 Decision to start a blister pack 
 Moving home 
The blister pack 
 CP training on blister pack 
 Comfort with original packaging 
 Blister pack brand issues 
 Blister pack problems 
 Medicines not in blister 
 Identification of tablets in blister 
 Blister pack benefits 
 Changes to appearance of medicines 
 Knowing if medicines are taken or not 
 Delivery 
 Discharge from hospital 
Supportive relationships 
 GP and registration with GP 
 Community pharmacist 
 Carer relationship and other non HCP 
support 
 Dependence on others 
 Expectations of services 
 Not wanting to be a burden or bother 
others 
 Advice about medicines 
 Family and expectations on family 
 Interaction with other HCPs 
Outlook 
 Attitude towards privacy 
 Giving up or fed up 
 Religion or faith 
 Acceptance 
 Better to leave things as they are 
 Gratitude 
Health 
 Mental health 
 Memory 
 Mobility 
 Long term physical conditions 
 Length of time on same thing 
Audit trail of code changes 
 
Discarded: “Loneliness”, “Tedious”, “Trying out new medicines” and “Efficacy of 
medication” and “Supporting self-administration” 
Merged: “Health”, “Eyesight” and “Diabetes” into “Long term physical conditions” 
“Family” and “Expectations of family” 
“Carer relationship” and “Non-HCP support” are now merged 
Renamed: “Acceptance” previously “Positive outlook” 
Added:  “Gratitude” 
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Figure 4.2 - The distribution of coding references made within each of the six themes 
 
4.4.1.4 Charting 
 
In this stage, sorting and synthesising the data was enabled, and these happened concurrently. 
NVIVO 10 was used to create a matrix template for each of the six themes identified. Each case 
had a row and each sub-theme (refined code) had a column. The matrix contained a link back 
to the original coded text, and a version exported to an Excel file for population by the author 
during the charting phase. For each section of the matrix (each case coded at each sub-theme) 
the original text was reviewed and examined. 
 
As the text was examined, the author reviewed every piece of text within that sub-theme, 
working across cases within each theme (i.e. horizontally across the matrix), inspecting every 
word for meaning and relevance. The amount of material was reduced, with the essential 
essence of the evidence distilled and viewable within the matrix. The author was careful to 
retain the participant’s own language, phrases and terminology at this stage, instead of trying 
to interpret meaning too early. The process described is referred to as “synthesizing”, which is 
essentially summarizing without losing content or context of the data. 
 
80 
 
The author remained open to changes in the further development of analytic themes 
throughout the analytic process. At the start, the column titles were the sub-theme titles; but 
some dismissed codes were re-instated once analysed in this process, as their value was 
uncovered (e.g. the medication administration process) and though the author was prepared 
to separate some columns as sub-themes diverged, this was not necessary. 
 
At the end of this process six Excel tables were produced (one per theme) with all of the data 
in its reduced form. 
 
4.4.1.5 Interpretation 
 
In the next part of the framework analysis process, the reduced data were subject to higher 
levels of abstraction in order to find true meaning. The author looked at each sub-theme 
across all cases (i.e. vertically down the matrix) for the ranges of outputs in order to produce 
more refined categories. The categorisation process (the first layer of abstraction) required the 
author to identify and log all the different elements and constructs that were emerging. These 
were written out on a separate piece of paper. As every piece of reduced data was read, the 
author decided if this was a new category or a component of a category that has already been 
recorded. The result was a long list of descriptive items or elements. Every column (sub-
theme) was inspected, each time considered alongside other similar columns and the author 
challenged herself about whether the data warranted separation into its own category or 
belonged within an existing category, and whether the sub-themes were diverging or 
converging. 
 
To illustrate, one of the sub-themes was “intentional non-adherence”.  The matrix contained 
reduced data from some case subjects who said they would never do this and some who 
admitted to this during the interview only once rapport had been established. The case study 
source data was referred back to in order to corroborate findings throughout the unpacking of 
this reduced data, for example by examining the photographs of tablets left in the MCA. 
Analysing this sub-theme also revealed that there was a link between intentional non-
adherence, side effects, and not knowing what each tablet was in the pack. There was a 
different approach to managing side effects with some having no problems relaying issues to 
their GPs and others being more reserved. This meant there were different contexts in which 
81 
 
patients experienced either real or anticipated side effects and this affected their willingness 
to adhere to their regimens, even when they ultimately did adhere. 
 
The resulting categories are based on notes taken during this process that were much more 
interpretive than at the charting stage, where there was less desire to retain the participants 
original terminology and instead focus on what they meant and what their perspective was 
when they said it. Sometimes this meant going back to the original interview transcript to see 
what the context was, or reviewing other source data. 
 
The emergent categories that comprehensively encompassed all of the descriptive elements 
were: 
 Attitude toward medication 
 Decision to start a blister pack 
 Desire for independence 
 Information about medication 
 Relationships that support adherence 
 Benefits of the blister pack 
 The blister pack introduces new problems 
 Continued review of medicines 
 
These are shown in Table 4.6 along with the elements detected in the abstraction of charted 
data. 
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Table 4.6 – Elements and categories that emerged as charted, synthesised data were 
unpacked 
Category Elements 
Desire for 
independence 
 Fed up – meds, cooking, remembering things 
 Do not want to complain – mistakes, poor service, fear of offending 
 Other people making decisions (insulin, moving) 
 Will take them my way – privacy/interference 
 Depending on others is not good 
 Independence is important – do what you can for yourself 
 Makes own decisions 
 Trust own decisions to manage health and meds 
 Taking own medicines 
 Trust others (experts) advice and assessment of needs 
 Accept reminders from carers 
 Rejection of non-medical advice 
 Making decisions about treatment and managing long term 
conditions (LTCs) 
 Ownership of decision re LTCs / resentment if not enabled 
Decision to 
start a blister 
pack 
 Suggested by Dr or nurse – many tablets 
 Set up at discharge from hospital “that came with me” 
 Not part of the decision to start a blister pack 
 When  community pharmacist changed, blister pack was started or 
changed 
 Cannot remember when blister pack was started, or why 
The benefits of 
the blister pack 
are limited 
 Blister pack benefits: 
 Convenient, times altogether. Layout / easy to read 
 The community pharmacist is more involved – more care (ordering, 
delivery) 
 It is easier than pressing original pack strips 
 Hard to use original packs 
 Better than carers taking charge 
 Easier if taking a lot of meds 
 Works as part of medicine taking process in partially sighted 
 Works with a reminder 
 Can see if medicine has been taken or not / use as a check 
The blister 
pack 
introduces new 
problems 
 
 
 
 
 Hard to press out blister 
 They are “wrapped” differently every time 
 Medicines from hospital clinics are left out 
 Courses are left out 
 Indiscreet 
 Cannot fit all medicines in 
 Different brands – patient preference 
 Cannot identify medicines – taken all at once. Cannot match with 
PILs 
 Cannot decide what to take or miss as not sure what they all are 
 Have to shake to get them out of the blister; fall on the floor 
 Insulin dosing or supervision 
 Suspicion raised with changing company / appearance 
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Table 4.6 – Elements and categories that emerged as charted, synthesised data were 
unpacked (continued) 
Category Elements 
 
 
 
 
 
 
 
 
 
 
 
 Can only identify if tablets are changed in the pack (brand, colour, 
new/extra) but do not know what the individual tablets are. Cannot 
distinguish old ones from each other (so cannot make a decision 
whether to keep taking them or not) 
 Community pharmacist only keeps one brand 
 Some brands better than others 
 Side effects experienced – CNS medicines 
 Wish all could go in the pack – “disarray” with separate course 
 Can only tell if side effects are due to new medicines as can identify 
those 
 Identification easier with original packs 
 Preference for original packs 
 Do not get the PILs 
 Get the PILs but cannot read them 
 Get the PILs but cannot identify the tablets 
 Want the PILs to learn, as a reference, but identification is necessary 
 The blister pack is not essential 
 Misconceptions about what a medicine is for or how to take 
 Identified wrongly in blister pack 
Continued 
review of 
medicines 
 Interventions or medicines should increase quality of life 
 Reminding others / HCPs about blood tests, medicines due, running 
out, other tests 
 Drs prescribe to get rid of you 
 Drs prescribe and forget all about you 
 Forgetting what a medicine is for, whether taken or not 
 Patients and nurses know more than Drs 
 Drs starting medicines with no explanation 
 Do not want to take medicines unnecessarily (harm, overdosing) 
 Reassurance still working / why am I still on this? 
 Some must be unnecessary as there have been no changes 
(continued need has gone unchecked) 
 Drs make changes without informing me 
 Drs do not have time to explain 
 Drs prescribe medicines to settle your mind, whether you have the 
complaint or not 
 Worry about side effects 
 Think they work – not sure 
Attitude 
towards 
medication 
 Fed up taking medicines – but still do take them 
 I want to know why I am taking it 
 Happy without PILs but information still required 
 Worry makes things worse – just take them 
 Patients should get more information about their medicines 
 Taking medicines means something is seriously wrong with you 
 Unhappy to have to take medicines – but still not worrying / 
surviving / staying cheerful / acceptance (status quo) 
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Table 4.6 – Elements and categories that emerged as charted, synthesised data were 
unpacked (continued) 
Category Elements 
 Game of chance – heal one person, harm another 
 Does not like taking medicines – want to forget / keep private 
Information 
about 
medication 
 
 
 
 
 
 If unsure whether I have taken a medicine / missed a dose or not, 
will not take 
 Non-adherence due to forgetting – especially night doses 
 Side effects affect decision to take medicine – fear of 
(harm/overdosing) or actual 
 Refusal to take if unexplained new medicine, change, not part of 
decision 
 Expectation of reciprocated trust / communication – explanation of 
need, side effects and feeling able to report back so tolerable 
alternatives can be found 
 Identification of tablets is important – suspicion raised, affects 
decision whether to take or not, need to know side effects, all in a 
mixture 
 Knowing what medicines are being taken 
 Will take if can feel it working 
 Will take if part of the decision making process – even if reluctant 
and side effects experienced before 
 Continue to take medicines if unsure whether they are important or 
not 
Relationships 
that support 
adherence 
 Community pharmacists all have different blister packs – when you 
change community pharmacist, you change your pack 
 Mistakes at discharge 
 Showed blister pack before dispensed, but not used 
 Delivery does not include non blister pack items – carer has to go 
separately 
 Grateful – have family, carers, HCPs, god 
 Years with same Dr “they know me” – loyalty 
 Housebound can call surgery – privilege / kindness (special) 
 Continuity at GP surgery – different Dr every time; having to remind 
surgery staff re blood tests, scans, scripts 
 Have to accept medical advice / Drs are experts 
 Trusts Dr decision and those who talk straight – honesty 
 Erratic district nurse (DN) timing / insulin timing 
 Carers do not do much 
 Nurses (DNs) and carers do what they have to do 
 Community pharmacist makes changes without informing (company 
and appearance of tablets) 
 Community pharmacy mistakes – misdemeanours? 
 Community pharmacists caring and professional 
 
Classification is the next level of abstraction, and in this interpretative stage the author 
assigned groups of categories to three main classes. Figure 4.3 shows the classes and how they 
are linked. 
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The three main classes are: 
 
The value of the blister pack is limited. 
Patients are not involved in the decision to start a blister pack. 
Informed decision making encourages adherence. 
 
In order to explain the data, connections between main classes and themes were investigated 
and this required the author to go back to individual transcripts. The Framework approach 
meant that it was easy to revisit the synthesised data, look within cases across the whole range 
of phenomena and move between thematic and case based analysis within the matrix display. 
Movement up and down the “analytic hierarchy” – the iterative process that lead to the 
findings being built from the raw data – was enabled. 
 
The results are presented in the results section in terms of how these classes are represented 
across all six cases (see Figure 4.3). 
Figure 4.3 – The three main classes (bold, double rectangle outline) and how they link to the 
categories (single rectangle outline) and some of the elements (dashed oval outline). 
The value of the 
Blister Pack is 
limited 
Continued review 
of medicines 
Informed decision 
making encourages 
adherence 
The blister pack 
introduces new 
problems 
Benefits of the 
blister pack 
Information about 
medication 
Attitude towards 
medication 
Unable to 
identify tablets 
Check if 
tablets taken 
or not 
Desire for 
independence 
Relationships that 
support 
adherence 
Patients are not involved 
in the decision to start a 
blister pack 
HCP advised as 
polypharmacy  
X 
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4.4.2 Explaining case study findings 
 
In this section the cases are presented first (Section 4.4.2.1; Figures 4.4 - 4.9) followed by 
testing of the propositions stated in Table 4.1, with reference to the cases (Section 4.4.2.2). 
The results of the Framework Analysis of interview transcripts are presented next, where the 
main classes and categories of findings are described with reference to all six cases. The 
analysis is illuminated by interview quotes and information from other source data where 
applicable (Section 4.4.3). 
 
4.4.2.1 Presentation of the cases 
 
Cases 1-6 (Figures 4.4-4.9) were all housebound, frail elderly patients resident in the London 
Boroughs of either Lambeth or Southwark. They all used a MCA as part of their medication 
taking processes and had support from care workers, the degree of which varied across the 
cases. They all consented to take part in the study and had the capacity to make that decision. 
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Figure 4.4  Case 1 – FB 
Personal details: 77 year old female. 
 
Field jottings: Quiet street, Victorian terrace, bed 
and bathroom upstairs, downstairs toilet, entry 
on ground floor. 
Sources in the home: 
Care agency assessment. 
Carers log. 
CHS Pharmacist Medication Assessment. 
Diabetes notes, log and administration chart. 
District nurse (DN) assessment. 
District nurse progress notes and log. 
GP notes including summary care record 
(SCR) and repeat medication list. 
DHx with recent changes annotated: 
Insulin Glargine 100 units/ml – 26 units daily 
Glucose 40% oral gel 
Furosemide 20mg daily 
Naproxen 250mg three times a day*paracetamol 
added in order to reduce this to twice daily 
Cinnarazine 15mg three times a day when 
required 
Seretide 125 mcg inhaler two puffs twice a day 
Tiotropium 18 mcg inhalation capsules once daily 
Calcium carbonate 1.5g chewable tablets two 
tablets once a day Stopped by CHS pharmacist 
as not taken 
Mirtazepine 15 mg at night* 
Colecalciferol 3,200 units daily 
Omeprazole 20mg daily* 
Atorvastatin 40mg at night* 
Paroxetine 40mg daily* 
Ferrous fumarate 210mg twice a day* 
Gliclazide 160mg twice a day*reduced to 80mg 
twice daily at CHS pharmacist visit 
Metformin 850mg three times a day*reduced to 
1g twice a day at CHS pharmacist visit 
Folic acid 5mg daily* 
Diltiazem MR 60mg daily* 
*in blister pack 
 
November 2014 – Matron visit where ability to 
administer insulin was assessed. Concern that 
not remembering to take it twice a day, only 
once. GP contacted to change to once daily 
insulin. 
Jan 2015 - administered insulin twice instead of 
once in a day – led to insulin administration being 
supervised by DN. 
PMH with dates where available: 
Chronic Obstructive Pulmonary Disease 
(COPD) 
Diabetes 
Meniere’s Disease 
Memory loss - Mini–Mental State 
Examination  28/30 
Sjogren’s syndrome 
Incontinence 
Anxiety 
Depression (1998; 2014) 
Hiatus hernia 
Vitamin D deficiency 
Osteoarthritis of the knee 
Oedema 
Malignant melanoma of skin (2013) 
Diverticulitis – colon 
Agoraphobia (2000) 
Hypertension – mentioned in DN assessment 
only 
 
 
Clinical observations, bloods, scans, other 
investigations (all within 1 year of visit; with 
normal ranges in parenthesis): 
 Normal renal, liver and bone profiles 
 Vitamin B12 normal; Low serum folate 
2.6mcg/l (3.10-20.5 mcg/l) and ferritin at 
14 mcg/l (22-275 mcg/l). Indicates 
anaemia due to malabsorption or 
haemolysis 
 Vitamin D low at 12mmol/l (>50mmol/l) 
 HbA1C indicates poor diabetes control at 
9.6% (4.2-6.2%) 
 
Nov 14 – BP 141/88 mmHg; Pulse 68 bpm 
Other findings from source data: 
CHS pharmacist found issues: 
 Diabetes consumables running out so arranged co-delivery with blister pack. 
 Patient sometimes struggles to remember how and where to start using the blister pack 
from. Can this be checked at every delivery? 
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Figure 4.4  Case 1 – FB (continued) 
 Poor inhaler technique – spacer requested, follow up visit to demonstrate. 
 Unable to remember steps involved in taking tiotropium; try to get the carer to “load” 
device. 
 Does not take the things that are outside of the blister pack and cannot remember what they 
are for or when to take them: Furosemide (oedema), Cinnarazine (dizziness) Colecalciferol 
(vitamin D; was added to pack later on). Patient does not take the calcium as she dislikes 
large tablets - bad taste and nausea experienced. 
 Oedema and forgetting to take Furosemide; furosemide increases incontinence when she 
remembers. 
 Hypoglycaemia at night – change in therapy recommended. 
 
DN assessment 
Patient states she is worried about her sugar levels and that she cannot remember things. 
Cannot always remember to take her insulin or medications. 
 
DN log 
Patient administers her own insulin under supervision. Varied blood glucose tests (BGTs). 
 
Diabetes notes, log and administration chart 
Morning insulin administered from 8.10am to 10.45am depending on time of visit. 
Glargine missed a few evenings recently due to low BGTs. 
 
Carer assessment 
Level 1 – assisted self-administration 
Carers to assist with laundry, changing bed linen, shopping, all personal care tasks – 
showering/bathing and dressing, cleaning washing facilities. Check pendant alarm on. 
 
Carers log 
No mention of assisting with self administration, just personal care tasks. Repetitive entries all 
ending with “She is wearing her pendant, left her safe” 
Field note summary: 
Description and memories: Facts, what happened, sensory impressions, sights, sounds etc. 
Greeted by carer who is yet to bathe her “client”. FB is expecting this visit. I wait in the living 
room, FB says she will not be long. 
 
Whilst waiting the doorbell goes and the carer calls down and asks me to open the door. An 
occupational therapist (OT) from Guy’s and St. Thomas’ NHS Foundation Trusts (GSTT) is there to 
do an assessment of how the patient is coping at home. The OT waits in the living room with me 
and I tell her I am in no hurry, to do the assessment and I will ask FB if she wants me to come 
back later. We comment on the boxes that are stacked everywhere – it looks like FB is moving. 
OT says she was not aware of this and would ask FB when she comes downstairs. 
 
When FB comes downstairs the OT assessment starts. During this time I ask the carer how 
involved she is with medicines, she says she sometimes reminds FB to take her medicines and 
directs me to what she thinks is her current blister pack on the table. I ask if it is just these and 
she says yes. I ask if there are any inhalers anywhere she says she thinks so, she is not sure 
where. The blister is next to the care agency notes and the carer is now writing in these notes. 
The carer leaves. 
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Figure 4.4  Case 1 – FB (continued) 
The doorbell rings again; as the assessment is still going on I answer the door with FB’s 
permission. It is the DN who has arrived to give FB her insulin. I ask the DN if she comes every 
day and why. She says sometimes she gives the insulin and sometimes she supervises FB self-
administering. There is an insulin record book. It is not always her, usually her and one other 
colleague. 
 
The OT assessment resumes and after 45 minutes, the OT leaves. FB’s morning has been very 
busy with lots of visitors so I offer to come back another time, I do not want to tire her out. She 
says it is no trouble, she is not tired, and she is ready to be interviewed now. 
 
Analysis of was learned in the setting: with respect to the guiding question and other related 
points. 
FB is a first generation French lady who immigrated to England over 30 years ago. She was 
widowed a year ago. She has two daughters and one son, each playing a part in supporting her. 
FB is housebound and does not leave the house alone. She is moving soon to be nearer her 
daughter in Crawley (see above) and is in the process of packing. 
 
The carer has been asked to make sure FB takes her inhalers too – they were not kept with the 
blister pack. The carer says she just reminds FB to take the blister pack tablets, she does not 
know about any inhalers. 
 
After the interview during gathering of other sources: I notice there are many green pharmacy 
bags dotted around the living room area on surfaces, corners of packed (moving) boxes, plus 
some in the kitchen. I photograph what I can. 
 
Personal reflection: Comfortable, uncomfortable, connections. 
 Possible FB forgot so many appointments; she was aware of my visit as was the carer. Not 
sure either were aware of the OT or what this was for if she was to be moving out of area. 
 I could have asked to see upstairs to look for further blister packs or unused medication but 
this would have added little to the overall impression and would therefore have been 
unnecessarily intrusive; could have possibly ruined the rapport between us. 
 Impression of the carer was that she seemed very reluctant to get involved in the 
medication. She did not want to be interviewed. 
 The DN was only there to deal with the insulin, and only did deal with that. 
 At one point there were three HCPs all there at the same time. I wonder how common this is 
in this cohort of patients, this rarely even happens in a hospital. We form a fleeting, 
ineffective multidisciplinary team. 
Day / time of visit: Tuesday am BP brand: Easyblist 
The blister pack: 
 
Some blisters 
are empty and 
some 
unopened: 
sporadic 
approach. Visit 
is on a Tuesday 
but Tuesday am 
medicines are 
not taken. 
Neither are 
Monday night’s. 
90 
 
Figure 4.4  Case 1 – FB (continued) 
 
These are used 
blister packs still 
in the house; 
again some 
doses remain 
untouched in 
each. There is 
micropore tape 
that has been 
used to reseal 
rows of both 
empty and full 
blisters with no 
explanation. 
 
 
These are some 
old packs closer 
up; it looks like 
there is a bit 
more evidence 
of adherence 
here, with 
missed doses 
being restricted 
to the evening 
and night doses. 
 
There were 5 
blister packs 
found in the 
home. None 
were 
completely 
empty. 
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Figure 4.4  Case 1 – FB (continued) 
 
Coding summary (top 20 open codes) and notes made during coding 
 
The patient jumps from talking about the blister pack showing her whether she has taken the 
medicine or not to discussing an incident where her son-in-law checked her answer machine 
without her consent - suggests there have been occasions where others have used the blister 
pack to check her adherence. Also that this is an unwelcome invasion of privacy? 
 
The patient mentions her neighbours in the same sentence as her pharmacist and this is the first 
mention of neighbours - associates them together? Is it because the neighbours see the blister 
pack delivery? She has talked also about neighbours seeing nurses come to her house. Or 
perhaps the CP and neighbours have a similar status to her? 
 
The patient values her privacy and does not ask for help outside of her family. She is lonely but 
the loneliness is because she misses her family, not because she does not like being on her own. 
She does not want interference from anyone just because she is lonely, only her children. She 
does not include her neighbours, sister, sister-in-law or her son-in-law as being people who can 
remedy loneliness and views their input as nosiness. 
Case summary and conclusion 
 There are lots of medication problems that are unresolved by the blister pack, namely 
remembering and ability to use inhalers, poor diabetes control, running out of 
consumables despite weekly community pharmacist deliveries, forgetting things outside 
of the blister pack, intentional non-compliance with calcium and unintended misuse of 
the blister pack. 
 The patient is not able to use the blister pack properly, so adherence with the medicines 
it contains is unintentionally not enabled. She also forgets to take her medicines both in 
and out of the blister pack (mentioned in interview). 
0.00%
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FB top 20 open codes
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Figure 4.4  Case 1 – FB (continued) 
 Diabetes control is poor despite blister pack containment of oral anti-diabetics and DN 
insulin administration. 
 The patient is unlikely to still need the furosemide, cinnarazine, tiotropium as she has 
gone so long without them; the first two offer symptomatic relief. She had a swollen 
ankle that may be due to diltiazem and side effects of furosemide mean she would rather 
put up with the swelling – indication for diltiazem is unclear. 
 No recent clinical observations recorded in any of the source data – patient should be 
having routine blood pressure measurements as a diabetic. BP was above 
recommendations for diabetic patients in November 2014; no evidence this has been 
followed up. 
 The carer is not documenting any involvement in the medication, though in the interview 
the patient says she reminds her sometimes and the CHS pharmacist has involved the 
carer in assisting with inhalers. The care assessment says there should be assisted self-
medication in place, but it is unclear what is meant by this. 
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Figure 4.5 Case 2 - MB 
Personal details: 84 year old female. 
 
Field jottings: Quiet street, Victorian terrace, 
entry on ground floor, single level flat. 
 
 
Sources: 
DN Adult CHS assessment form. 
Diabetes chart. 
CHS Pharmacist Medication assessment. 
GP notes including SCR and repeat list. 
DN referral form. 
Hospital discharge summary. 
DN Treatment log. 
DN and Medihome assessment. 
CHS physiotherapist physical assessment. 
DHx with recent changes annotated: 
Diethyl salicylate 10% cream apply three times a 
day 
Daktacort cream apply twice a day 
Buprenorphine 5mcg patch weekly 
Atorvastatin 40mg at night* 
Bumetanide 2mg in the morning and 1mg in the 
evening* 
Ranitidine 150mg twice a day* 
Bisoprolol 2.5mg daily* 
Amlodipine 10mg daily* 
Cetirizine 10mg daily* 
Alfacalcidol 4mcg once a week on Wednesdays* 
Amitriptyline 30mg at night* 
Nicorandil 10mg twice a day 
Isosorbide mononitrate MR 120mg twice a day* 
Hydralazine 50mg three times a day* 
Lantus insulin in the morning 
Fluconazole (7 day course) recently 
Deep heat gel, over the counter (OTC) apply daily 
*in the blister pack 
Last hospital admission 6 months prior to this 
list: Patient was also prescribed warfarin, 
stopped and restarted once CHS pharmacist 
convinced her to take; 
ramipril 2.5mg daily, spironolactone 12.5 mg 
daily, glyceryl trinitrate spray. 
Different doses of bumetanide (2mg twice daily). 
PMH with dates where available: 
Atrial fibrillation 
Congestive cardiac failure 
Deep vein thrombosis (2006) 
Type 2 diabetes 
Hypertension 
Blind in left eye 
Transient ischemic attack (1989) 
Sarcoidosis 
Diabetic retinopathy 
Cataract 
Renal failure (only in DN community nursing 
assessment; secondary to 
hyperparathyroidism) 
 
Clinical observations, bloods, scans, other 
investigations: 
BP reading 145/70 mmHg; (prev 183/77 
mmHg) 
Body mass index 30.7 kg/m2 (obese) 
Estimated glomerular filtration rate (GFR) 
14ml/min (renal function poor but stable) 
 
Other findings from source data: 
CHS Pharmacist findings 
Patient unable to read labels or take insulin due to eyesight. Difficulty opening child resistant 
containers. Patient reports difficulty reading the blister pack, no mention of difficulty opening (as 
was raised in researcher interview). CHS pharmacist assessment states patient is unable to use 
the blister pack unassisted. Interview reveals help offered from husband or carer is accepted, but 
she does not necessarily need assistance. 
 
Creams are being avoided intentionally as they do not seem to be effective. Patient reveals in 
the interview she uses her husbands E45. The Daktacort cream is for a fungal infection, 
prescribed as a result of failed fluconazole course that was omitted because it was not in the 
blister pack.  
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Figure 4.5 Case 2 – MB (continued) 
Patient is not taking the amitriptyline as says they do not work. Interview findings are she avoids 
them because of side effects once she read the PIL. Changed to gabapentin 100mg daily. 
Intentionally omits the evening atorvastatin tablet sometimes, CHS pharmacist suggests putting 
it into the morning blister slot (MB confirms would then take it) and avoids the second 
bumetanide dose of the day due to nocturnal enuresis. CP to move to an earlier slot in blister 
pack (from “afternoon” to “lunchtime”). 
 
Running out of insulin and consumables – spoke to CP to order and deliver at the same time as 
blister pack. CHS pharmacist convinces patient to start warfarin as recommended previously – 
she is worried she would not remember but is assured by the CHS pharmacist that DN’s doing 
the insulin could remind her. 
 
Medihome assessment 
Medium risk of falls. Very high risk of pressure ulcers. 
 
DN referral form 
Trouble sleeping – denied in interview when discussing reluctance to take amitriptyline. 
 
DN adult community nursing assessment 
Check blood sugars every day before administering insulin. Check for ketones if < 4mmol/l. 
Check BP 1
st
 Monday of every month, aim 110-140/70-80 mmHg. If raised take three times in 24 
hours. If still raised check taking medication and inform GP. 
Weigh patient Monday, Wednesday and Friday (heart failure) DN to assist with heart failure (HF) 
care plan regarding monitoring for shortness of breath and other standard advice for HF 
patients. 
 
DN log 
Weight stable at 80kg throughout. BP was taken four times in three months – on three occasions 
BP was above the limit set out in the DN care plan at mmHg of 154/77, 148/92 and 153/75 one 
just over 142/58. Only one of these prompted the DN to seek out advice from the GP (advice 
given unclear / not documented). Pulse low but stable at 50-60 bpm. Had a fall that was 
managed by the DN – felt dizzy. Not admitted / was OK. 
Field note summary: 
Description and memories: Facts, what happened, sensory impressions, sights, sounds etc. 
MB’s carer answers the door; I am not sure if the carer is a family friend or paid carer but she is 
expecting me and I believe is staying past her usual time in order to let me into the premises. MB 
is housebound and spends much of her day lying down in bed. She is interviewed lying down in 
her bedroom. MB’s husband is out, I do not enquire where. He returns mid-interview. 
 
All MB’s medicines are in the living room. This is difficult to get to from the bedroom via narrow 
corridors and inclined passages. At the end of the interview MB leads me from her bedroom to 
the living room, slowly but without impedance. 
 
Analysis of was learned in the setting: with respect to the guiding question and other related 
points. 
MB’s husband is older than MB but not housebound. He does much of the housekeeping and 
caring responsibilities but struggles. 
There are lost of things in the house but the care notes are in their own place, and all the 
medicines are together. MB seems very familiar with them all, blister-packed and otherwise. 
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Figure 4.5 Case 2 – MB (continued) 
Day / time of visit: Friday am BP brand: Venalink 
The blister pack: 
 
 
 
The blister pack 
shows the 
patient has 
been adhering 
to the regimen 
in her blister 
pack at least. 
Those blisters 
that are 
expected to be 
empty are 
empty. 
 
This blister pack 
has a list of all 
of the 
medicines it 
contains 
attached to it. 
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Figure 4.5 Case 2 – MB (continued) 
 
Some medicines 
are out of the 
pack – the 
nicorandil is not 
stable in a 
blister pack, 
paracetamol is 
only when 
required, 
warfarin is a 
variable dose 
medicine and 
the other two 
are non-oral. 
The eye drops 
are bought over 
the counter 
(OTC) and not 
mentioned 
anywhere else. 
Coding summary (top 20 open codes) and notes made during coding: 
 
When MB talks about her medicines and memory, she says she cannot forget to take them as 
there are so many - this may mean her interpretation of the question is not the actuality of 
forgetting to take them, but more if it is possible for her to forget she is on them: can you forget 
you ever take medicines when there is so much wrong with you? 
 
MB is happy to "just take her meds and that's it", but this is probably because she is familiar 
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Figure 4.5 Case 2 – MB (continued) 
enough with them all now as elsewhere she has expressed wanting to know what each is for and 
knowing the pros and cons of each. 
 
Association between liking the blister pack for convenience of taking but not happy about not 
knowing what the medicines are for or how to identify which ones are giving her side effects. 
 
Case summary and conclusion 
 
 MB is in control of using the blister pack and the insulin and warfarin outside of the pack are 
taken regularly also as the DN leads that process. It is unclear if the other oral medicine not 
contained in the pack, the nicorandil, is being taken routinely. 
 There is some evidence of intentional and non-intentional non-adherence in the past and 
revealed during the interview. The measures suggested by the CHS pharmacist to aid 
adherence have only been partially adopted (the bumetanide second dose moved to earlier 
in the day, but the atorvastatin is still a night time dose). No evidence that gabapentin used 
instead of the amitriptyline, which the patient reveals in the interview she picks out of the 
pack due to fear of side effects. She also thinks it is working. 
 The patient wants to know what each of the medicines are for and the pros and cons of 
each. She wants the PILs of each. She likes the pack, but wants to be able to identify the 
tablets in it and read about them. 
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Figure 4.6  Case 3 – FR 
Personal details: 77 year old male. 
 
Field jottings: Warden controlled flats (ex-
tenement) with secure entry system. Ground 
floor flat. 
 
Sources: 
DN referral. 
CHS Pharmacist medication assessment. 
Carers log. 
DHx with recent changes annotated: 
Allevyn adhesive dressing 10x10cm twice a week 
and Prosheild plus cream (DN applies to 
pressure sore) 
Sodium bicarbonate 5% ear drops 
Diclofenac 1.16% cream apply three times a day 
Co-codamol 8/500mg tablets 1-2 four times a 
day when required; usually takes two once a 
day. (Also has paracetamol – not taking) 
Amorolfine 5% nail lacquer once or twice a week 
Amitriptyline 35mg at night (1x10mg and 
1x25mg)* 
Omeprazole 20mg daily* 
Irbesartan 300mg daily* 
Mebeverine 135mg three times a day* 
Metformin 1g twice a day* 
Aspirin 75mg daily* 
Simvastatin 40mg at night* 
Laxido 2 sachets daily 
*in blister pack 
PMH with dates where available: 
Type 2 diabetes 
Osteoarthritis 
Weakness of leg 
Ataxic gait 
Wax in ear 
Tinnitus 
Pressure sore 
Degeneration of lumber spine 
Diabetic neuropathy 
Epididymitis (2004) 
Essential hypertension 
Hypercholesterolaemia 
 
Clinical observations, bloods, scans, other 
investigations: 
None available 
Other findings from source data: 
CHS Pharmacist findings 
Patient thinks he does not need the mebeverine anymore, has resolved. Metformin give him 
cramps though. Not sure what the simvastatin is for. Intentionally non-compliant with laxido and 
paracetamol as not needed. Cannot bend down to apply the nail lacquer. 
 
General poor adherence as not sure what the medicines are for. Put on a blister pack since 
leaving the rehab centre and no longer recognises his tablets. So not taking them regularly. GP 
concerned he will not remember to take all his tablets if they were in the original containers. 
 
Advised GP to stop amitriptyline as patient does not feel he needs it for the pain and does not 
take it anyway. Advises mebeverine to stop also as bloating and cramping have resolved a long 
time ago. No diagnosis of IBS or other GI symptoms on GP system. 
 
Carers log 
Meals, shopping and cleaning. Twice daily visits. 
Field note summary: 
Description and memories: Facts, what happened, sensory impressions, sights, sounds etc. 
Mr FR lives alone in a sheltered housing complex. A warden is in charge of the block. The carer 
has visited today already. The carer notes are kept in a drawer in the kitchen. The room is 
cluttered with papers and magazines, and breakfast things have not been cleared away. The 
blister pack is on the table in the centre of the room. 
On the day of the visit, Mr FR is having a new door to his flat fitted; the whole floor is having new 
doors. He does not know why. 
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Figure 4.6  Case 3 – FR (continued) 
Mr FR walks very slowly and cautiously, his feet barely lift off the ground when he does this – he 
“shuffles” 
 
Analysis of was learned in the setting: with respect to the guiding question and other related 
points. 
Mr FR has lived here for about a year. He has infrequent contact with the warden, he would not 
recognise her though she is around today because the doors being fitted. Mr FR goes to the day 
centre once a week which is the day the warden is around usually. 
 
Personal reflection: Comfortable, uncomfortable, connections. 
 The carer is supposed to be doing cleaning but there is little evidence of that here today 
 There is a lot of stuff in this small space; some things look like they have stayed in one place 
ever since they arrived. 
Day / time of visit: Wednesday pm BP brand: Suremed (Nomad) 
The blister pack: 
 
(i) 
Current blister 
pack (i) and 
close up of 
omitted doses 
due at bedtime 
(ii). The orange 
tablet has been 
taken and the 
blue and yellow 
tablets left. 
 
The patient 
reveals in the 
interview he 
thinks the 
orange ones are 
metformin 
(which is 
incorrect, it is 
simvastatin, 
metformin are 
the large white 
tablets in other 
blisters) – he 
knows diabetic 
medicine is 
important to 
take so he picks 
it out to take it 
instead of 
avoiding the 
whole blister.  
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Figure 4.6  Case 3 – FR (continued) 
 
(ii) 
The two tablets 
being missed 
are both 
amitriptyline 
(yellow 25mg 
and blue 10mg); 
patient 
“suspicious” of 
them. 
 
The GP has not 
taken on board 
the CHS 
pharmacist 
advice to stop 
amitriptyline 
and mebeverine 
 
The blister pack 
contained this 
sheet that 
described each 
tablet / what 
each looked like 
in order to 
identify each. 
The patient had 
tried to use a 
combination of 
this and the PILs 
to find out 
which was 
giving him side 
effects but it 
was too 
complicated. 
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Figure 4.6  Case 3 – FR (continued) 
 
These packs are 
yet to be used. 
They come 
weekly so not 
sure how two 
came to be 
attached 
together 
Coding summary (top 20 open codes) and notes made during coding: 
 
When asked who is the oldest of him and his brother he says "I follow him" to express that he is 
the younger - suggests admiration. 
 
Stated firmly in audio, almost defensive - sense that services are free so we are all very lucky to 
have them, no right to question their quality? 
 
Patient thinks that the blister pack is a new way of packing medicines; original packs are the old-
fashioned way. The patient believes the pack was started by the pharmacist and the decision to 
start it was theirs – “this is the way they do things at this pharmacy” – he has not questioned 
why: “they are such lovely people I don’t want to offend them”. 
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Figure 4.6  Case 3 – FR (continued) 
Case summary and conclusion 
 There are potentially two medicines that the patient does not want to take but are still in the 
blister pack despite medication review. 
 The patient is intentionally non-adherent with the amitriptyline tablet. He brings up 
incontinence as a side effect of one of his tablets during the interview; he cannot identify the 
tablets so not sure which one is causing it but suspects the amitriptyline. 
 The patient does not want the blister pack but does not want to offend the pharmacist. The 
GP is worried that he will forget to take them all if they are in the original packs, but in 
reality he is not adhering with the pack either. No signs of forgetting his tablets, all non-
adherence is intentional. 
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Figure 4.7  Case 4 – JL 
Personal details: 85 year old male. 
 
Field jottings: Warden controlled flats (purpose 
built) with secure entry system. Ground floor 
flat. Sign-in book. 
 
Sources: 
CHS Pharmacist medication assessment. 
GP notes – medicines list and SCR 
information. 
DN assessment. 
Medicines administration record – Insulin. 
DHx with recent changes annotated: 
Humulin M3 (cartridges) 36 units in the morning 
and 24 units at night. (reduced from 28 units 
per night; sugars 3-5mmol/l) 
Bisoprolol 2.5mg daily* 
Furosemide 80mg daily (2x 40mg)* 
Lercanidipine 10mg daily* 
Simvastatin 20mg at night* 
Candesartan 16mg daily* 
Metformin MR tablets 500mg twice a day* 
Paracetamol 1g when required for pain 
Co-amoxiclav 625mg three times a day (course) 
*in blister pack 
PMH with dates where available: 
Type 2 diabetes 
Hypertension 
Retinopathy in both eyes 
Bifascicular block 
Osteoarthritis in hips (right one worse) 
Chronic kidney disease stage 4 
Protrusio acetabuli 
Vitamin D deficiency 
Neuropathic diabetic foot ulcer 
 
Clinical observations, bloods, scans, other 
investigations: 
BP: lowest 107/63 mmHg and highest 148/79 
mmHg. Low readings are recent and 
dizziness also experienced. 
Pulse: lowest 78 bpm to highest 101 bpm. 
History of out of range HbA1C’s indicating 
poor diabetes control; most recent is 6.8%, 
normal values are 4.1 - 6% though usual 
target for diabetics is 6.5-7.5% so result is in 
this range. 
Slightly raised urea and creatinine – not 
clinically significant. 
Normal lipid and bone profiles and white cell 
count. Full blood count almost in range / not 
clinically significant. Thyroid function normal. 
Other findings from source data: 
CHS Pharmacist findings 
Patient drops tablets on the floor when emptying a blister from the pack – pierced then tapped 
on table due to poor eyesight but observed them rolling off. Added plastic container and 
counting six morning tablets to this process to ensure it does not happen again. 
 
Forgets the evening statin – change to atorvastatin and can then be given once a day in the 
morning (unchanged at time of visit). 
 
Dizziness and low BP – recommended stopping the bisoprolol; GP wants to monitor for 4 further 
weeks first. 
 
Co-amoxiclav prescribed for a month, not in blister pack. Daughter is putting each dose under a 
glass and reviewing the three glasses to see if taken, DNs asked to remind also. Described in 
interview as “disarray”. 
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Figure 4.7  Case 4 – JL (continued) 
Insulin medicines administration record (MAR) 
MAR chart for insulin states 8.00am to 10.00am for the administration time, and actual times 
given are not recorded. On the day of the visit, the DN was an hour after the 10.00am. In the 
interview the daughter stated that the DNs seem to come “willy-nilly”. 
 
DN assessment 
Daughters mentioned frequently as assisting with everyday tasks (shopping, cooking etc.) 
Requires foot ulcer dressing changes, blood glucose level check and drawing up insulin dose due 
to poor eyesight. BP to be monitored monthly with escalation plan if out of range (>140 mmHg 
systolic or 90mmHg diastolic).  
Field note summary: 
Description and memories: Facts, what happened, sensory impressions, sights, sounds etc. 
Mr JL is a partially sighted gentleman who lives in a ground floor flat in a sheltered housing 
complex which has a reception and warden area and secure entry system, though he can allow 
visitors to enter himself also. JL’s daughter is heavily involved in his care and is present and 
contributes to his interview. The blister pack and other medicines and documents are on the 
table in the main living area of the apartment. 
 
Before the interview starts the DN arrives to administer insulin. I observe. The DN asks Mr JL 
what side the insulin was given yesterday, presumably to allow alternation. JL administers the 
insulin himself but the DN selects the dose on the dial of the pen for him. The patient’s daughter 
enquires as to why the DN is so late today; this is the morning insulin dose and it is approaching 
lunchtime. This is laughed off by the DN, she says she is very busy. Documentation from the DN 
is kept with the blister pack. The interview starts when the DN leaves. 
 
Analysis of was learned in the setting: with respect to the guiding question and other related 
points. 
The medicines are all kept together in a large, square, shallow Tupperware container; this 
container is part of the medication taking process. Mr JL has had previous issues with his 
eyesight and dexterity, where he was popping the blisters and dropping some of the tablets on 
the floor never to be found again. Mr JL knows he has six tablets in the morning blister; he pops 
them out into the Tupperware, not into his hand. He then licks his finger and picks up each of the 
six tablets and takes them. This suggestion was made by the CHS pharmacist who recruited the 
patient for me, and is working well. Mr JL also has simvastatin at night, which he usually forgets. 
The CHS pharmacist suggestion to switch this to atorvastatin and have it in the morning instead 
was made to the GP a few weeks ago but has not been actioned. 
 
Personal reflection: Comfortable, uncomfortable, connections. 
 The daughter has a high regard for the CHS pharmacist after he solved the tablet-dropping 
issues. 
 Mr JL will not do a thing without his daughter’s approval. 
Day / time of visit: Wednesday pm BP brand: Venalink 
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Figure 4.7  Case 4 – JL (continued) 
The blister pack: 
 
Visit was on a 
Wednesday so 
looks like 
Tuesday 
medicine doses 
were missed, 
along with the 
pm dose (statin) 
on Monday. 
 
 
The blister pack 
and the plastic 
container used 
to keep the 
tablets from 
falling on the 
floor. 
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Figure 4.7  Case 4 – JL (continued) 
 
Labels indicating 
the six morning 
tablets 
(including 2x 
furosemide 
tablets) and one 
night-time 
tablet. 
 
This blister pack 
is 1 of 4 unused. 
When the 
patient was 
discharged from 
hospital 
recently, there 
was a mix up 
that meant 2 
separate 
community 
pharmacists 
made up his 
blister packs. 
The patient 
stuck with the 
one he knew. 
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Figure 4.7  Case 4 – JL (continued) 
 
Coding summary (top 20 open codes) and notes made during coding 
 
The patient is talking about the process of punching the blister contents into a Tupperware 
container, a process recommended by the CHS pharmacist who found that sometimes tablets 
would fall on the floor and the patient would not be able to find them. The patient knows exactly 
how many tablets he has and accounts for them all in the Tupperware in this process. 
 
It is not clear if he wants to find out from HCP if the meds are working. Does not seem to be a 
priority. 
 
Patient seems frustrated that he keeps getting the same message about his foot ulcer 
(improving), but still needs the dressing changed. He starts talking about this straight after being 
asked about his attitude towards knowing whether his medicines are working or not, and being 
told if his medicines are working or not. 
 
Patient does not want to speak badly about his GP, though there have been prescribing errors 
reported during the interview by his daughter.  
Case summary and conclusion 
 The patient finds the blister pack useful but only when used alongside the plastic container – 
without this appendage he is not able to take the tablets out of the blister and ensure none 
are lost as his eyesight is not good. 
 The night doses are being missed. Advice of CHS pharmacist to change to atorvastatin to be 
taken in the morning not yet put into place so patient is not receiving a statin. 
 Patient still relies heavily on daughters and DNs reminding him to take his medicines. He 
would otherwise be unintentionally non-compliant. 
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Figure 4.8  Case 5 - SW 
Personal details: 79 year old female. 
 
Field jottings: Split level apartment in converted 
house. Kitchen and dining room in basement, 
rest is on ground floor. The front / living room is 
being used as the main bedroom; this is SW’s 
main living area. 
 
Sources: 
Discharge summary from facilitation team. 
DN assessment form. 
DN log of interventions and wound care plan. 
GP referral form to DN. 
DHx with recent changes annotated: 
Furosemide 40mg in the morning* 
Prednisolone 2.5mg gastro-resistant tablets once 
daily 
Solifenacin 10mg daily* 
Candesartan 32mg daily* 
Adcal D3 750mg/200unit two twice a day* 
Pantoprazole 40mg twice a day* 
Citalopram 20mg daily* 
Mycophenolate mofetil 1.5g twice a day 
Methotrexate 40mg weekly* 
Alendronic acid 70mg weekly* 
Folic acid 5mg weekly* 
Gabapentin 300mg three times a day* 
*in blister pack 
Omeprazole in a separate pack dispensed by the 
hospital at last discharge. 
Naproxen in a separate pack – retained by 
patient (a year old) dispensed by community 
pharmacy. 
Single strip of co-dydramol – unsure where from. 
Patient has various strengths and brands of 
prednisolone. 
Minocyline MR 100mg daily started recently by 
rheumatology and dermatology clinic. 
 
Acute: 
Oxycodone 5mg/5ml liquid 2.5 mg every 6 hours; 
250ml. 
Co-codamol 30/500mg 1-2 four times a day. 
 
OTC: 
Vitamins: (B12, D and E), multivitamin capsules 
and liquid tonic. 
Windeze tablets. 
PMH with dates where available: 
Hypertension 
Grade 2 pressure ulcer on sacrum 
Leg ulcer (recently infected) 
Bloating 
Bilateral cataracts 
Chronic kidney disease stage 3 
Lipoma 
Pyoderma gangrenosum 
Osteoarthritis both knees; plus ligament 
sprain in left 
Hearing loss 
Type 2 diabetes 
Spasm of oesophagus and / or functional 
dysphagia 
Hypopituitarism 
Adrenal hypofunction 
 
Clinical observations, bloods, scans, other 
investigations: 
155/64 mmHg; pulse 73bpm, 
126/57 mmHg 6 weeks later. 
 
 
Other findings from source data: 
DN log and care plan 
The frequency of dressing changes for the leg ulcer are not stated in the assessment, but it looks 
like this is happening twice a week. The sacral wound has healed. There is no plan to routinely 
monitor blood pressure but this is also being done approximately monthly. 
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Figure 4.8  Case 5 – SW (continued) 
Discharge facilitation team summary 
Patient engages well but progress hampered by stomach issues and leg ulcer. Under hospital 
review. Further referrals made to dietician to investigate weight lost, podiatry to assess her feet 
and DN to investigate incontinence. 
Field note summary: 
Description and memories: Facts, what happened, sensory impressions, sights, sounds etc. 
Mrs SW is a widowed lady who lives alone and has a carer and has DN involvement in her care at 
the moment. On the day of the interview I arrive at the property and the door is answered by 
SW. she states that she thought I was going to be the DN, she has been waiting all morning for 
her. SW has an ulcer on her leg and the dressing has to be changed every other day; this is due 
today. SW is worried that it will become infected again if it is not changed this frequently. The 
DN is very late. 
 
I ask SW if she wants to wait a while before we start as I am in no hurry and she says yes. The 
carer comes into the room with some soup; I did not realise she was there until this point. I ask 
SW what the carer does for her – just meals and sometimes housekeeping but she also has a 
daughter to help. The carer seems eager to go, assume to next client, SW says do not worry if 
the DN comes “this young lady” will let her in so she does not have to wait. I affirm to the carer 
that it is OK, I will let the nurse in etc. After about 20 minutes we decide to go ahead with the 
interview and if the DN arrives we will stop and carry on when she leaves. 
Mrs SW shows me her medication; there are 2 large plastic containers full of non-blister pack 
medicines, and also her blister pack. She starts to get some of her medicines out and lays them 
on the bed. The priest has just visited also she says, he comes every Friday, and she packs away a 
candle and prayer book that were on a stool next to the bed to make more room. During the 
interview, more medicines behind her seat on a bookshelf are noted. 
 
After the interview the DN has not arrived and Mrs SW is worried she will not come now until 
Monday. I reassure the patient that DNs do work weekends and it will not matter if the dressing 
is changed a day late as a one off. SW has the mobile number of her DN (F), so she rings it and 
the DN says she is on leave, advises SW to ring the main office and enquire about when her 
replacement is due. She assures SW that the main office would have covered her with a 
replacement DN. I phone the main office number and they say F is probably just held up. I say 
that we have spoken to F and she is off. They do not appear to be aware that F is on leave. They 
say they will ring SW back in 10 minutes. I use this time to take all my photographs and scan all 
pertinent documents (carers are kept downstairs in the dining room and DNs in the bedroom 
with the medicines). 20 minutes later nobody has rung back and nobody has turned up to 
change the dressing. I ring the office again and the manager says they had not accounted for F’s 
leave and are now having to cover all of her jobs; It would appear that none of F’s patents had 
their DN visit the whole day. I ask when SW can expect somebody to come and change her 
dressing and she said this pm but late, at about 6pm. SW sighs. 
 
Analysis of was learned in the setting: with respect to the guiding question and other related 
points. Mrs SW knew what all of her medicines were for, where they all were, which container 
they went in. Mrs SW had a poor relationship with her community pharmacist. 
 
Personal reflection: Comfortable, uncomfortable, connections. 
 Turned into patient advocate. 
 DN lateness an issue. 
 Carer involvement minimal; time pressures apparent. 
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Figure 4.8  Case 5 – SW (continued) 
Day / time of visit: Friday pm BP brand: Suremed (Nomad) 
The blister pack: 
 
 
Blister pack 
showing that 
patient has 
taken the 
medicines as 
expected – 
midday may 
have been 
omitted 
because of the 
visit or the 
priest’s previous 
visit. 
(i)      (ii) 
 
(iii)      (iv) 
 
Lost of 
medication is 
outside of the 
box (i). 
Prednisolone 
not included, 
usually a 
variable dose 
(iv), though 
fixed dose in 
this patient. 
 
Minocycline is 
new from the 
hospital and not 
made it onto 
repeat list yet 
(ii). 
Mycophenolate, 
omeprazole and 
naproxen are 
outside the 
blister pack. The 
first is unstable 
in the pack, the 
last 2 are not 
part of the 
current 
intended 
regimen (see 
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Figure 4.8  Case 5 – SW (continued) 
summary). 
Vitamins and 
other OTC 
products 
(windeze) 
cannot go in the 
box. Neither can 
Oxycodone 
liquid (iii). 
 
Labels for the 
10 medicines 
contained in the 
blister pack. 
 
Coding summary (top 20 open codes) and notes made during coding 
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Figure 4.8  Case 5 – SW (continued) 
 
The patient blames the pharmacist for the split between items in the box and out of the box. 
Later saying he does this to save money - other blister brands would accommodate the whole 
regimen. 
 
Case summary and conclusion 
 
The patient likes the blister pack but knows the medicines in it and when to take them already. 
Would like it more if more of her medicines fitted inside it as the blister pack is convenient for 
her. 
The patient is already motivated to take her medicines and the blister pack does not offer any 
further aid to compliance. There is no intended non-adherence with this patient. 
 
The patient is annoyed that the community pharmacist is not doing more to get all of her 
medicines in the box though realistically, the only 2 oral solid dose form medicines that are on 
her repeat prescriptions list are the prednisolone 2.5 mg daily and the mycophenolate. The first 
is probably better left out as the patient has so many courses that interfere with this daily dose it 
is not worth including it. The mycophenolate is unstable out of its original packaging. The other 
tablets she is taking are either not intended to be taken still or are OTC products. 
 
A number of medication issues were identified, none of which are solved by the blister pack: 
 Omeprazole in a separate pack dispensed by the hospital at last discharge; there is 
pantoprazole in the pack already and these are of the same class, so this should be disposed 
of. 
 Naproxen in a separate pack – retained by patient (a year old) dispensed by community 
pharmacy. Naproxen is not suitable for patients with chronic kidney disease and interacts 
with the methotrexate (increasing its accumulation by reducing renal perfusion). It should be 
disposed of. 
 Potential for paracetamol overdose - single strip of co-dydramol – unsure where from – and 
co-codamol on recent acute script. 
 Patient has various strengths and brands of prednisolone, having kept all previous unfinished 
courses. Should be taking 2.5mg daily routinely, which could go in the blister pack, but if 
there are frequent courses and a need to stop it this may explain why it is not in there. 
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Figure 4.9  Case 6 – MGY 
Personal details: 75 year old female. 
 
Field jottings: MGY stays in “very sheltered 
housing” – on arrival this felt very similar to a 
nursing home. MGY has an en-suite room in a 
purpose built complex. Nurse is doing 
“medication round”. Not like any sheltered 
housing I have seen before. Very protective 
environment. 
 
Sources: 
Pre-admission assessment. 
Life story. 
Care plans: 
Medication 
Mobility 
Personal 
Nutrition 
Sleep and rest 
Communication 
Emotional and psychological needs 
Beliefs, religious and cultural needs 
Social activities 
End of life 
Care plan monthly review. 
Daily records. 
Visitors record. 
DHx with recent changes annotated: 
Zero cream 
Buprenorphine 5mcg/hour patch weekly (Thurs) 
Co-careldopa (carbedopa and levodopa) 25 and 
100mg tablets one at 12pm, 4pm and 7pm, 
plus one at 8pm if needed 
Rasagiline 1mg daily at 4pm 
Ropinirole MR 16mg at 8am 
Stalevo tablets 25, 100 and 200mg one at 8am 
PMH with dates where available: 
Parkinson’s disease (PD) 
Breast cancer (2016) 
Hip pain (awaiting transplant) 
 
Clinical observation, bloods, scans, other 
investigations: 
Malnutrition Universal Screening Score: 0 (no 
risk). 
Other findings from source data: 
Medication care plan 
Outcome is to maintain independence with medication and self-medicate. Self-administration 
agreement has been signed. Team leader to ensure ordering of stock and prompting and use of a 
medication monitoring form to ensure doses not missed. Staff to administer creams. Staff to 
open packaging if patient unable to. 
 
Pre-admission assessment 
Was worried when admitted about falling and looking after herself. Self administration 
assessment to be carried out. She will require prompts at morning, lunch and evening doses but 
wants to administer her own medicines. 
 
Beliefs, religious and cultural needs care plan 
Not a religious person with no cultural preferences – believes in helping others and being an 
independent person. 
 
Visitors record 
Routinely visited by physiotherapists (weekly) hip pain. DN’s come weekly to change the 
buprenorphine patch. 
 
Care plan monthly review 
All care plans are being reviewed monthly and changes noted. Buprenorphine 5mcg patch added 
to medication care plan. 
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Figure 4.9  Case 6 – MGY (continued) 
Field note summary: 
Description and memories: Facts, what happened, sensory impressions, sights, sounds etc. 
Ms MGY is an Argentinean lady with advanced PD, physically frail but very astute mentally. She 
used to be an architect and art critic. The walls of her room are covered with pictures and 
doodles by very famous artists and illustrators (one she later tells me is a Picasso…she knew 
him). On her dressing table MGY has a laptop and some framed photos, and some small pottery 
items. She has her own phone-line, which is the line used to arrange the visit. 
 
When I arrive at the complex I have to “sign-in”. I am asked what I am doing here and I state it. I 
am directed to the first floor and told to report to one of the nurses on that floor. There is only 
one nurse on the floor that I can see and she is wearing a bib that says “medication round – do 
not disturb”, though she enquires why I am there so I explain. She directs me to MGY’s room. 
I knock at the door, MGY says to come in; I hear another person’s voice also. When I enter a 
carer is there and still in the process of dressing MGY. They are in the bathroom with the door 
open; I can hear but not see. MGY says she is very embarrassed; she says she told the staff I was 
coming at 10.00am and she had to be ready by then, and apologises for not being ready. I tell 
her I am in no hurry at all, not to worry about me I am happy to wait. 
 
When M is ready, the carer helps her into her wheelchair and leaves. MGY tells me she is very 
thirsty – the staff have forgotten her breakfast. Could I get her some water or apple juice (not 
orange juice as it’s not very nice here). I go back to the nurse in the bib and report this. The 
nurse says she will organise this, they have been very busy. She asks me to tell her if there have 
been any changes to make and says I will need to sign the HCP communication sheet in MGYs 
care notes before I go. Breakfast and apple juice arrive once the interview has started (approx 
10.20am). 
 
After the interview the nurse in charge (now without the bib) comes to the room with MGY’s 
care notes that she wants me to sign and tells me in MGY’s presence that there are some blister 
packs from last week that still had doses in them and she will get them for me to look at. She 
talks to me as if MGY was not there. When she returns she has no blister packs, stating they 
must have gone back to the pharmacy already for destruction. I tell her it is M’s choice if she 
wants to take her medicines or not. When the carer leaves M says thank you “she will take 
notice now you have said that, when I say it they don’t”. MGY tells me some of the staff are 
lovely but some are “bossy” – this one varies. 
 
I take my photos and scan the notes. MGY is very interested in my “gadgets” – she loves new 
technology. As I am scanning the notes, I start to read about “dementia” and “diabetes” – I 
notice that the notes of another (male) resident are mixed up with MGY’s. I separate them from 
the rest. When I leave, MGY gives me a kiss on the cheek “in Argentina we kiss!” and I hand the 
notes back to a different nurse with the separated other resident notes and state what I have 
found. I sign out downstairs. 
 
Analysis of was learned in the setting: with respect to the guiding question and other related 
points. 
Right to take own medication – goes against the grain in this environment. 
Perhaps because MGY not part of this “round”, other things get missed? – would explain late 
washing and dressing and forgotten breakfast. 
 
Personal reflection: Comfortable, uncomfortable, connections. 
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Figure 4.9  Case 6 – MGY (continued) 
 Turned into patient advocate – breakfast and right to refuse medication. 
 Staff very protective of MGY. 
 Delay in breakfast meant morning meds delayed as could not swallow tablets without a 
drink. Very important to maintain strict dose intervals with PD medicines. 
Day / time of visit: Thursday am BP brand: Medisure (Boots) 
The blister pack: 
 
 
The patient had 
two blister 
packs; it looks 
like the evening 
dose has been 
missed of the 
first and then 
dispensed 
separately as an 
“afterthought” 
(Patient’s 
words). There 
are often errors 
like this that the 
patient 
describes as 
“annoying”. 
 
 
Pack shows all 
expected doses 
have been 
taken; 
 
Thursday 
morning dose 
now taken, was 
delayed as 
breakfast 
missed (see 
field notes) so 
no juice to 
swallow them 
with. 
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Figure 4.9  Case 6 – MGY (continued) 
 
 
 
Coding summary (top 20 open codes) and notes made during coding: 
 
0.00%
1.00%
2.00%
3.00%
4.00%
5.00%
6.00%
7.00%
8.00%
9.00%
10.00%
MGY top 20 open codes
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Figure 4.9  Case 6 – MGY (continued) 
 
The patient wants to conceal from her carers the fact she is not always able to recognise their 
faces. 
 
Fiercely independent. Feels she knows the importance of timing her PD meds better than her 
carers do and can control her medicines better than they are able to. 
 
Case summary and conclusion 
 
The blister pack was a compromise that allowed MGY to take her own medicines – this was of 
paramount importance to her. The box is seen as the intervention that has enabled her to 
remain independent. She finds it easy to use. She still sometimes needs to be reminded to take 
her medicines so it has not solved all of her unintended non-adherence problems. The carer 
reported MGY missing doses, yet according to care plans the carers are still supposed to be 
reminding her to take them. MGY believes using the pack is better than allowing the carers to be 
in charge of her medicines. 
 
4.4.2.2 Explaining the case study findings by testing propositions 
 
The propositions made of the case study data were that adherence and the MCA are 
unrelated, patients are not part of the decision to start an MCA and patients are not taking 
their medicines as intended. Table 4.7 shows the results of proposition testing the case study 
data. 
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Table 4.7 – Testing propositions to explain case study findings 
 Proposition 1: adherence 
and the MCA are 
unrelated 
Proposition 2: patients 
are not part of the 
decision to start an MCA 
Proposition 3: patients 
are not taking their 
medicines as intended 
Case 1 Says MCA reminds her; 
least adherent patient 
overall. 
Did not know why or 
when the MCA was 
started. 
Missed doses in MCA and 
inhalers taken incorrectly. 
Case 2 Sometimes forgets to take 
medicine despite MCA. 
Advised by HCP due to 
polypharmacy. 
Deliberate avoidance of 
at least one medicine. 
Case 3 Deliberately misses at 
least one medicine 
despite MCA. 
Started at discharge from 
hospital; patient not told. 
Deliberate avoidance of 
at least one medicine. 
Case 4 Sometimes forgets to take 
medicine despite MCA. 
Did not know why or 
when the MCA was 
started. 
Cannot adhere to insulin 
or courses outside MCA. 
Case 5 MCA did not remind her 
to take; she took them 
anyway. 
Started at discharge from 
hospital; patient not told. 
Taking medicines that had 
been stopped. 
Case 6 MCA enabled home self-
administration policy. 
Started to enable self-
administration policy. 
Carer reported missed 
doses in MCA. 
Overall Proposition is supported Proposition is supported Proposition is supported 
 
Patients did not take all of their medicines as intended and were not a part of the decision to 
start an MCA. The MCA did not influence the decision to take medicines, though convenient 
for those motivated to take their medication. The MCA could be used as a retrospective check 
to see if medication was taken or not, though does not prospectively remind the patient to 
take their medicines. Further interview analysis of these same six case study patients in 
Section 4.5 revealed the effect that the MCA had on the way patients felt about their 
medicines, the supportive relationships they had with healthcare professionals and their 
overall health. 
 
4.4.3 The Framework Analysis 
 
In this section the results of the Framework Analysis are presented under headings and 
subheadings aligned to the three main classes and sub-categories as shown in Figure 4.3. 
 
4.4.3.1 The value of the blister pack is limited 
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One of the main objectives of the study was to understand the nature of MCA initiation in 
housebound elderly patients. In the community pharmacy questionnaire (see Chapter 3) there 
was support of the MCA as an aid for compliance and memory, and general feeling that they 
helped patients greatly. The relationship between the MCA and adherence was not established 
to any extent in this study. The only manifestation where the MCA affected adherence through 
enabling an informed decision was through acting like a check to see what medicines had been 
taken for those patients who could not remember – they were then able to choose whether to 
take the medicine or not rather than guess or err on the side of caution by omitting. The only 
other impact that the MCA had on enabling an informed decision about medicines and 
therefore encouraging adherence was an inhibitory one, with more than one instance of 
inability to identify medicines causing a mistrust of a medicine and consequent omission. 
 
It is fair to say that the MCA had little or no effect on adherence, and that any beneficial effect 
was outweighed by a negative effect via an inability to identify the medicines. It may be argued 
that the convenience of the pack was enabling adherence as patients could not use the original 
packs; there was only one patient (case subject 1) who said they really found original packs 
hard to use; the rest said they could do without the MCA even if they found them convenient. 
The patient who felt they needed the MCA was the least adherent patient of them all, with a 
scatter gun approach to choosing which blister to pop out and random MCAs all over the 
house that had been started and abandoned at various points. It cannot be said whether the 
situation would be worse with the original packaging, but would be improved by full review of 
all of her medication. 
 
There was definitely some value associated with MCAs in terms of convenience, and also 
prevention of unintended non-adherence, but only if used as part of an agreed process 
alongside other measures. The value of MCAs was limited by the disadvantages associated 
with their use. The disadvantages were that certain problems were introduced by the MCA, 
and that different problems remained unresolved by the MCA. This limitation is of particular 
significance as the MCAs are introduced by non-pharmacy HCPs with the intention of solving 
all the adherence problems with just this one intervention. 
 
4.4.3.1 a Benefits of the MCA 
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The patients found their MCAs easy to use on the whole, and liked the layout, finding the co-
location of oral dose units at scheduled mealtimes convenient and easy to understand. There 
was an appreciation that, though not perfect, opening the blisters in the MCA was easier than 
using the original packaging and some patients had found it hard to use the original packs, 
illustrated by the following: 
 
“No, no, I'm happy as they are, because, you see, “morning, lunch, dinner”…at least I 
know what I'm doing…maybe my English is not good but I can read.” (FB, Case 1) 
 
 “…it's much easier for you to get it out. Although sometimes it's hard to press out but 
it's still better than having to dish it out from the boxes.” (SW, Case 5) 
 
The ease of removal from the packaging would be more relevant for patients who took lots of 
medicines, though the time taken to take them was not cited as an issue by the patients. 
 
“I'm not too desperately short of time. In any case, it doesn't-- it's not an issue for me.” 
(MGY, Case 6) 
 
There were some instances of the MCA working well if used as an additional aid, alongside 
another aid to adherence, e.g. a reminder; so it was being used as part of an overall system 
designed to enable adherence. 
 
MCAs were shown to support adherence indirectly in two main ways; firstly when used as a 
check if a patient, through forgetfulness, was unsure if they have taken a medicine or not: 
 
“Because sometime even I wondered I have done the right thing…I don't remember I 
had taken the medication or not and I look in the tin and say yes its still there that 
mean I didn’t.” (FB, Case 1) 
 
“Yes, you are not too sure if you have taken it or not. You can always tell whether 
you've taken it or not using the blister pack” (MGY, Case 6) 
 
Secondly, the presence of an MCA appeared from the data to place the community pharmacist 
more centrally to patient care, via their increased involvement in ordering, delivery, or advice. 
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“Oh no. I am happy about it. No. No. It’s good to me because I don't have to call them 
every week. Once a week they bring it in that…I feel like they're taking care of me.” (FB, 
Case 1) 
 
4.4.3.1 b The blister pack introduces new problems 
 
Though convenient and offering some practical advantages to patients, MCAs were not 
essential in every case: 
 
“It’s neither one thing nor the other. I could do without it. It’s convenient because it 
shows you what you do in the morning the day evening and night.” (FR, Case 3) 
 
The MCA meant that the original pack was not available to the patient; sometimes but not 
always this included the absence of the PIL. Where PILs were supplied to the MCA user, it was 
not always possible to match it with the medicine in the MCA, so they were not always helpful: 
 
“I tried to see if I could find out what these represent…but I didn’t quite understand…I 
would rather know that the pill I’m taking is necessary than to just take it blindly, you 
see…when I found myself incontinent, I tried to find out from those—(PILs)” (FR, Case 
3) 
 
This absence of original packaging had an impact on the identification of medicines and 
ultimately the willingness and likelihood that they were going to be taken: 
 
“Yes they all look the same. Before this thing they used to come in packages and the 
package will tell you what is in it and how it should be used so I know which is the 
mebeverine because it’s in its own box. I know which is the metformin because it’s in its 
own box.” (FR, Case 3) 
 
Patients recognised their usual medicines even if they did not know what they were or what 
they were taking them for, and could see if a new tablet had been added to the pack. Patients 
however, could not distinguish which was which of their old tablets in terms of their 
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indications and could therefore no longer make a decision about whether to take them or not 
themselves. 
 
“The only one I can tell you about is that little green one [laughter] I can’t say anything 
about the other one, I don’t know because I don’t have a leaflet from them. I have no 
instruction or nothing else from them on how to take them.” (MB, Case 2) 
 
“Because I've been taking my tablets for so long you get used to your tablets. Once 
they put you on a new one and you begin to feel different, you know definitely that 
new tablet is causing that.” (SW, Case 5) 
 
Patients were unable to decide what to miss or take as they were unsure of what the 
medicines were or their importance and were unable to distinguish them in the pack as they 
were all in the same blister and taken together. Sometimes they were experiencing side effects 
and could not attribute these side effects to a particular medicine due to the inability to 
identify it out of the original packaging: 
 
“Then when the bad taste in my mouth, it’s so horrible…It's yuck [laughs] but I cannot 
tell you which one of them because I take it all at one time.” (MB, Case 2) 
 
“There is a tablet there that makes me incontinent I don’t know what it is for and there 
are tablets that I’m taking but again I don’t know what for…When I had in the old-time 
boxes [sic], each box had only what is for in it [sic]. But this is a mixture and I don't 
understand.” (FR, Case 3) 
 
All patients wanted the PILs as a reference to find out more about what they were taking. The 
PILs, however, were subject to misinterpretation and not all patients had them, or could read 
them: 
 
“When they give you the blister pack…they should put the leaflet in there so that you 
can read it and can see what these things are for. You are taking it and you don't know 
what you're taking. You already know the name of it but what it is for. What is the pros 
and cons about it.” (MB, Case 2) 
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“Yes…I want to know what it's for and how much you should take, and that, yes, I do. In 
fact, sometimes I don't have the time to read it now, but I’ll never throw it away, I keep 
it there till I have the time to read it…before the blister pack I used to have the leaflet 
to look at it.” (SW, Case 5) 
 
Some patients reported suspicions being raised about their medication when an 
unrecognisable tablet had just appeared in the MCA – either because the pharmacist changed 
the company that makes their usual medicines, or a new unfamiliar tablet was added to the 
regimen by the GP without their understanding why. There were cases where the community 
pharmacist either helped or contributed to this uncertainty. 
 
“…like that little tablet…when the doctor put me on it, I didn't not know what for. The 
blister pack came and I saw they put pills in it…My husband took it to the chemist and 
said, "What's the name of this?"…When he read the leaflet he said it's a medicine for 
several things…epilepsy…it helps pain...you find out for yourself…I said to them but why 
am I taking it? They said, "To help you sleep and for pain"…but I never complain to 
them that I cannot sleep.” (MB, Case 2) 
 
“As soon as he give me something and I don't know about it, I want to know why. He 
(community pharmacist) tells me, he changed the company…you're taking the blood 
pressure tablet, it's a pink tablet, next minute you get a white one…he don't tell me 
that he changed it.” (SW, Case 5) 
 
There were problems with the packaging itself experienced by patient participants; some 
reported the blisters were hard to pop out, and there was more than one case of unintentional 
non-adherence due to the patient having to shake the pack, releasing the tablet but dropping 
them on the floor in the process. One patient referred to their size: 
 
“I'd prefer it to be smaller…because I have these especially big bags for them just to 
carry that. They are not easy to pretend I'm not taking it.” (MGY, Case 6) 
 
The different brands available caused some difficulties, with two patients saying they had 
preferred using a different brand before the one they had now. Changing brands introduced 
some problems for both of them, and coincided with a change in community pharmacist: 
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“I don't like this blister pack…it's a bit tedious to open, to take all the tablets…some fall 
on the floor…I used to have blister pack before I leave my other address…that was very 
easy for me to take out more than this one. Because you have to press and to burst the 
pack to get the tablet out.” (MB, Case 2) 
 
“He could get a different blister pack, there’s loads of them out there, but he's looking 
for the cheapest one, because I've never seen this before…I didn't have to dish out all 
those tablets when I was with Lloyds pharmacy. No, he gives you the cheapest thing.” 
(SW, Case 5) 
 
The size of the MCA blisters and ability to fit the regimen into the MCA were not the only 
issues with medicines outside of the MCA; problems were experienced with courses and 
medicines from sources other than the GP repeat list, such as those initiated at a hospital 
clinic. Medicines started by hospital clinicians may be prescribable by hospital clinicians only 
according to locally agreed drug formularies, so may never be contained within an MCA as the 
FP10 prescriptions are supplied by GPs. Five of the six patients were diabetic, three of these 
requiring DN insulin administration; this adherence issue could not be resolved by the use of a 
MCA. There were instances of other medicines not being taken as prescribed, again unresolved 
by the MCA: 
 
“The grey one (inhaler) I can use any time, and the purple one just when I'm short of 
breath. I think that's the way I have to use it.” (FB, Case 1) 
 
“…as I understand they don’t put steroid in there because it’s changeable...this is a new 
tablet they put me on, on Friday when I went up. I saw the rheumatologist and 
dermatologist because I’m under the both of them…I wish he could get more in it to 
relieve me from having to take them out.” (SW, Case 5) 
 
4.4.3.2 Patients are not involved in the decision to start a blister pack 
 
The class “the value of the blister pack is limited” is included for reasons of saliency rather than 
volume of included content. Figure 4.3 shows a cut off between this class and the rest of the 
data set that refers to instances of medicine and MCA use; there was a very small amount of 
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data related to initiation, and what there was related to discharge from hospital and 
polypharmacy being noted by a HCP. There were no instances where the MCA was requested 
by the patient, and even in the only instance where the community pharmacist showed the 
patient the MCA before dispensing into it, there was no opportunity to try and pop the 
blisters. There was no scenario where a blister pack could be trialled before committing to 
using it all the time, or opportunity to change their mind about having it, with one patient 
believing this was just the way they package medicine in that pharmacy and he did not want to 
offend them by asking it to be changed back.  
 
“It was so many tablets after the agony for this heart attack which was in 2010. When 
the nurse come to visit me, she said, it's better if she get the blister pack for me…2011 I 
saw the blister pack.” (MB, Case 2) 
 
“I haven’t the foggiest idea. I’ve never seen them until I came here and I’ve been having 
them ever since...It just turned up. I think this is how they do things at the chemist…I 
left St Thomas’ and I come straight here. And that came with me.” (FR, Case 3) 
 
 “I think we went to the surgery…and the doctor suggested that he should use a blister 
pack.” (JL’s daughter, Case 4) 
 
“When I came from hospital, that was all set up. Nobody told me anything…I had a 
good district nurse dealing with me…but she never explained anything to me…I don't 
know who made the decision. It could be the hospital.” (SW, Case 5) 
 
“I don't remember when the blister packs started.” (MGY, Case 6) 
 
4.4.3.3 Informed decision making encourages adherence 
 
4.4.3.3 a Desire for independence 
 
All of the patients reported doing as much for themselves as they possibly could, without 
needing sometimes even the assistance with tasks that they already had from others (though 
stating it was a help). The stance of wanting to remain as independent as possible for as long 
as possible impacted on whether they were prepared, for example, to try a new medicine, 
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affecting their decision making profoundly. There were some views expressed that the quality 
of the time they had left was more important than the quantity, and extending life was not 
what they wanted. 
 
Patients were of the opinion that independence was crucial - including making their own 
decisions - and depending on others was a bad thing: 
 
“…there was less independence than I expected…I wanted to get my things from my 
home, there was a problem, and, "No, you can't. You can't leave. When you are here, 
you are here.” It was terrifying. I felt that I was being imprisoned. I left Argentina so as 
not to be imprisoned…so I’m not very happy about letting people put me in prison.” 
(MGY, Case 6) 
 
The patients took pride in taking their own medicines and trusted their own decisions about 
their health and their medicines, and did what they could for themselves: 
 
“But I don’t prevent them. But it’s not like I am depending on them to do, I don’t.” (MB, 
Case 2) 
 
“I do my medication myself.” (SW, Case 5) 
 
“Just habit here, give their medicine, give it to them. I don’t care. They are not in 
charge. They call it self-medication.“ (MGY, Case 6) 
 
The patients were aware that they sometimes required help from others; they accepted 
reminders from carers for example, and trusted the advice and needs assessment of HCPs, 
who they regarded as experts. In terms of performing activities of daily living (ADLs) they 
accepted the fact that others had to sometimes take the lead. 
 
“In the home, like cooking or anything like that, I can’t do that, I can’t stand to do 
anything really. But any little thing what I can help myself with, I do.” (MB, Case 2) 
 
“But then I am grateful to the staff here for making my meals, it was one reason I want 
to decide very suddenly to move.” (MGY, Case 6) 
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Dependence on others only went as far as performing tasks, with a strong desire for decision 
making to remain with themselves. There were instances where decision making by others was 
rejected or was dispiriting for the patient: 
 
“You can remind me if I took my medication, but don’t tell me what to do. You see?” 
(FB, Case 1) 
 
“I want to (maintain) certain independence obviously. At 75-years-old-- because I want 
to decide for myself.” (MGY, Case 6) 
 
There was a strong desire for ownership of decision making regarding medicines, and 
examples of resentment where this was not enabled by prescribers: 
 
“I am old enough to know if something serious with me, but that is why I take so many 
medication, I want to know.” (FB, Case 1) 
 
“If they're going to change my medication, they'll have to tell me that, why they're 
stopping it. Because when I want it stopped, I tell them…Then I know what's going on. 
You like to know what's going on.” (SW, Case 5) 
 
 (patient asked if she wants to know what her medicine is for before taking it) “Of 
course, I think so. At least, the information. I know people tend to try to do things 
without telling you…and I do resent it.” (MGY, Case 6) 
 
Rejection of advice and consequent decisions made by others was common in the patient 
participants, including with medicines, where a propensity towards taking medicines in a way 
that worked for them as individuals was apparent: 
 
“I need to eat but I can't say “Every day, eleven o'clock.” Or a certain time every day. 
It's when I'm ready...It's not “Lunchtime twelve o'clock.” That means twelve o'clock I 
have to take my medication. I prefer to have my lunch at two o'clock…Probably I'm 
wrong…but I tell you how I work myself.” (FB, Case 1) 
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Patients often knew exactly how to take their medicines, and knew the names and how to 
recognise them, even if they didn’t know what they all were for: 
 
“This is omeprazole. That's the co-codamol. That’s the mycophenolate. This is 
naproxen…I had that before to help the pain, but I don't have it anymore. This is five 
milligrams that I have here to take, and this is another 2.5 to make up because I've got 
to take 17.5...” (SW, Case 5) 
 
There was one example of where the decision to maintain a relationship with the HCP 
exceeded the desire to make a choice about having an MCA. Case three was reluctant to make 
a stand against the decision to use an MCA: 
 
“I was recommended this chemist and this is the way they do things you see so I never 
asked any questions so I never got any answer. They are such lovely people I didn’t 
want to offend them; so be it - the only thing that concerns me is I do not know what 
some of the tablets are for.” (FR, Case 3) 
 
4.4.3.3 b Continued review of medicines 
 
Continued review of medicine is a category that only emerged at the later, more interpretive 
stages of the analysis. This category covers the issue of patients wanting to know whether they 
need to keep taking tablets or not. Participants expressed a desire for medication review 
whether they were taking them and felt happy with them or not. 
 
Much of this category included experiences patients had with the GP or another prescriber at 
the point of prescribing. Patients wanted to be reviewed thereafter, and to be assured that 
they definitely still needed to take the medicine they were prescribed. This knowledge of why 
they were taking each medicine was the driving force behind deciding whether to take a 
medicine of not and ultimately adherence. There was an overarching feeling that lack of 
consultation time equated to a lack of care, whether the fault of the GP or not; some patients 
questioned the motives of the prescriber and described instances where changes were made 
to their medicines without explanation: 
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“They give you these things. They don't find out from you, if you have that complaint, 
yes or no, but they give it to you…Just take it because you have to take it, in a way. 
That's why you take them.” (MB, Case 2) 
 
Patients sometimes accounted for this short consultation time and consequent lack of 
information they received about new medicines as they were aware of time constraints of 
HCPs: 
 
“Who is prescribing it? They don't even have the time to explain to you properly what 
you're taking and what is the side effect to it. When I go to see my doctor one-to-one, 
straightaway I would ask him.” (SW, Case 5) 
 
Patients also cited a perception that medicines are started to pacify them but were medically 
unnecessary: 
 
“Because all you're going to say to yourself, “because they are doctors, they'll just give 
you something to get rid of you.” [laughs]…Settle in your mind and that's it. But say you 
do make a complaint about it…I can't be bothered. I have enough on me, [laughter] - 
more than enough.” (MB, Case 2) 
 
In general prescribing medicines for reasons other than increasing quality of life was not 
believed to be the right thing to do. Patients expressed feelings that they had been forgotten 
about and that they had been on their medicines for so long without change that they had 
forgotten what they were started for, and were unconvinced therefore that they were still 
necessary: 
 
“It's just the uncertainty of what they are for. I feel that I might not necessary need the 
tablets…I wouldn't like to continue taking tablets that I don't need.” (FR, Case 3) 
 
“..when I find I'm on this tablet for so long, “Is it necessary to be on it this length of 
time?” Because when they put you on a tablet they forget all about you. I want to 
know, is it necessary for me to keep taking that? Is it helping me in any way?” (SW, 
Case 5) 
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Patients expressed concern about side effects whether experienced or not, harm being caused 
and overdoses, and a desire to not take unnecessary medicines as a result. 
 
“You see the thing is, if I knew [what they were] I would be contented. I might be 
overdosing myself, it might hurt me. I might still be taking things I don’t need to take, 
that’s why I would like to know what they are and what I’m taking them for.” (FR, Case 
3) 
 
“I was on morphine for quite a long time and I begged them to take me off of it, 
because if you don’t take it on a regular basis and you don’t take it for a couple of days 
they start making you go funny. A bad feeling…you get very agitated and I didn’t know 
that about it. Nobody told me it was going to do that.” (SW, Case 5) 
 
“I don't like taking medicines…I'm very worried about side effects.” (MGY, Case 6) 
 
Some were unsure if their medicines were working or not and the desire for reassurance that 
the medication was still indicated after being on a medicine for so long was clear. The patients 
generally wanted to know for each medicine they had taken for a long time, why they were 
still taking it: 
 
“Yes, I want to know what-- it's not just “take that”. I want to know why…I want to 
know that I'm catching up.” (FB, Case 1) 
 
“I think they work. I think there are medicines there that isn’t necessary. I’ve been living 
here from July one year and there is no change in anything except for when the nurse 
came here she found I had too many Metformin so she took away one.” (FR, Case 3) 
 
There were some practical problems experienced by patients with long term conditions, in 
terms of processes in the surgery and community pharmacy. Having to remind other HCPs and 
surgery staff about blood tests, repeat prescriptions, re-ordering of medicines that are running 
out were mentioned by some: 
 
“You call him, he’s going to bring it, you don’t get it. Sometimes I have to get my carer 
to go down there and collect things.” (SW, Case 5) 
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“I take methotrexate and I have to have a blood test once a month. That I have to 
remind the nurses about because they never remember that…for me, it's not working 
as it should be because I shouldn't have to remind them…they should know.” (SW, Case 
5) 
 
4.4.3.3 c Attitudes towards medication 
 
Attitude towards medication, desire for independence and information about medicines all 
influenced adherence. The attitude towards medicine impacted on the baseline ability of some 
patients to accept a medicine. For example, there was more than one occurrence of patients 
only taking their medicine because they could feel it working, and also people not taking 
medication because they had experienced side effects. Many medicines did not offer 
symptomatic relief and were instead preventative, some with few side effects; it was likely to 
be more challenging to adhere to medicines where the benefit could not be felt. 
 
The participants described what it meant to them to have to take medicines with none liking 
the fact that they were taking regular medication. Sometimes patients expressed a desire to 
keep the fact they were on so many medicines private, wanting to forget that this was the 
case. 
 
There was a feeling among some that taking medicines meant something was seriously wrong, 
and for more than one patient this interlinked with the “continuous review of medicines” 
category, where there was some expectation that conditions would get better and medicines 
could therefore stop. This manifested for most part as a desire for continued medication 
review of all medicines. 
 
Though patients were unhappy at having to take medicines, were unsure of exactly what each 
was or fed up with the process of actually taking them, they reported that they still did take 
them and maintained an attitude of passive acceptance, as worrying made it worse: 
 
“I'm already fed up I have to take it…but I'm taking it. If I miss anytime, it's because I 
forgot. It's not because I didn't want to take it.” (FB, Case 1) 
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“I go to the hospital, the blood pressure doctor when he said to me “How do you take 
your tablets?” I said, “I just put water in my mouth and tablets and that’s it.” Because 
that’s what I do...Nothing else…Because if you worry about them you’ll get worse.” 
(MB, Case 2) 
 
“Sometimes I get fed up with taking the tablets. You take in and take in, you're fed up 
with them." (SW, Case 5) 
 
Once rapport was established at later stages of the interviews, there were some isolated 
instances described where medicines were deliberately avoided. All patients took their 
medicines when they could feel them working: 
 
“Well actually I have decided that I wasn't going to take them when I became 
suspicious.” (FR, Case 3) 
 
(patient asked if she thought her medicines were working) “Yes, I wouldn't be taking 
them otherwise.” (MGY, Case 6) 
 
Patients all wanted to know why they were taking each medicine they were prescribed. Even 
in those who had PILs, this information was still required. There was a strong belief among all 
MCA users that patients should get more information than they currently do. This information 
was more in-depth than could be covered briefly by generic information in a PIL. Patients were 
aware that medicines could have multiple indications and uses and what worked for one 
person would not necessarily work for another. Each patient wanted to know why they as an 
individual had to take each individual medicine, not general descriptions of what the medicine 
was for. This knowledge was important to feel independent with regard to decision making, as 
illustrated in the following quotes: 
 
“I want to understand not just “The doctor give me that, Oh you have to take it," I want 
to know why I have to take it.” (FB, Case 1) 
 
“I think we should get a little more explanation on the drugs that we take…because you 
don't know what you're taking. What you are taking it for?” (MB, Case 2) 
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“I should know what I'm taking. After all, it's me taking it. I should know, I should be 
told.” (FR, Case 3) 
 
4.4.3.3 d Information about medicines 
 
All of the patients wanted information about their medicines. The level and the types of 
information varied, but on the whole there was agreement that changes or additions to 
regimens should come with explanation and opportunity to make a decision about whether to 
take that medicine.  Without this opportunity there would be, and indeed were, instances of 
intentional non-compliance and a suspicion about what had happened; if the characteristics of 
a new medicine were unknown, and the patient felt happy before they were prescribed it, the 
indication would have to be explained before they would adhere. 
 
There was an expectation of reciprocated trust and good communication, where the need for 
a medicine and side effects would be explained, and a method to report back if unacceptable 
side effects were experienced so that tolerable alternatives could be found: 
 
“I would tell them…like how I did with the steroid, I said, “It's making me ill, it's making 
my stomach bad, and I don't want to take it anymore.” He would try and find 
something else…more tolerable…he’ll always say, “Well, I'm going to try this on you 
and you'll see how it go.” But put me on it without telling me, no, he wouldn't do that.” 
(SW, Case 5) 
 
Where there was a lack of information about what, or how important, a medicine was, the 
patient was forced into a decision about whether to take it or not and that decision was 
uninformed. Some patients carried on taking medicines without knowing what they were or 
why they were indicated; some did the opposite. The decision to take or not depended largely 
on the GP relationship, and this is explained more in the Section 4.4.3.3 e. Cases 1 and 2 
described not knowing what their medicines did, but taking them anyway: 
 
“Actually I wonder sometimes myself if I don’t take any medication how do I feel…don't 
know, I couldn’t tell you if I am surviving thanks to the medication…I wonder that 
myself.” (FB, Case 1) 
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“They say this is for the blood pressure, that for the…I can't explain anything about it. I 
don't worry about it because if I worry about it I make things far worse for myself. So I 
just take them and that’s it.” (MB, Case 2) 
 
Patients gleaned information about the indication and side effects from the GP consultation, 
backed up by PILs where available, and some patients used the MCA itself as a check of what 
was taken if forgetful. In these ways the MCA was not a barrier to informed decision making. 
However the MCA was a barrier to identification of tablets in some cases which stopped 
informed decision making about taking a medicine: 
 
“I know what the diabetic tablets are for. I know what the Aspirin is for. I know what 
the mebeverine is for. But I can't quite point my finger and say “This is mebeverine.” 
Because I don't know which is which. Where they are, you see.” (FR, Case 3) 
 
All reported sometimes being uncertain of whether things had been taken, taking them late, or 
outright forgetting to take medicines, especially night time doses. When this happened the 
default was to not take the missed dose or perceived missed dose, which was seen as the 
cautious approach: 
 
“Yes sometime (I forget), one time out of probably 20…Especially in evening time…I 
never forget in the morning.” (JL, Case 4) 
 
“Suddenly, you don't remember. Then if in doubt, I would then not to take it. Just in 
case, I'm more scared of overdosing…It's a confession as well.” (MGY, Case 6) 
 
4.4.3.3 e Relationships that support adherence 
 
Relationships that support adherence incorporated all of the relationships carers had with 
relatives, social carers and HCPs that enabled them to take their medicine: but the one 
relationship that stood out form the rest as being instrumental in deciding whether to take a 
new medicine or not was the GP relationship.  
 
Patients cited community pharmacists, GPs, carers and nurses as important persons who could 
influence adherence. Doctors were viewed as experts for the most part, whose advice had to 
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be accepted. Patients trusted their GP and the decisions they made and gave examples of 
where straight talking by the GP or other HCPs was appreciated and formed the basis of a 
trusting relationship. In one case, a patient even re-tried a medicine that she had previously 
reacted badly to because of a consultation where she was persuaded to give it another go and 
assured that there was scope to review it again if the side effects returned. 
 
“I don't know, if sometimes probably think they are wrong, thing like that. But I have to 
accept them yes.” (FB, Case 1) 
 
 “Doctors are experts. [laughter] I am not. But you see if a doctor were to say “Well 
alright change this – Some other tablets.” Even if they give me new ones - I would 
welcome it.” (FR, Case 3) 
 
Even if thorough consultation was enabled and trust established between the GP and patient, 
there was still strong will to retain decision making from participants 
 
“If they do a little more, that doesn't mean that the explanation they're going to give 
you, you will be satisfied with it, you know?” (MB, Case 2) 
 
Patients made a distinction between the professional relationship with the GP and the other 
staff in the surgery in some cases; in one case the GP was held in high regard but not the 
surgery staff or practice nurse. Continuity of care was mentioned by patients as an occasional 
problem, but on the whole, patients were appreciative of all surgery staff and were very loyal 
to the surgery. They were aware of how busy doctors were and felt they were still treated as 
special because they were housebound: 
 
“I mean you can rely on them…If they say something, they mean it…you can never say 
anything bad about them….” (FR, Case 3) 
 
“My doctor again, he is very, very, very supportive. He doesn’t like me coming down to 
the surgery. He said it’s too much for me. If there is anything, call him and if it’s 
something he can prescribe, he will then send it straight to the pharmacy or else he will 
come, which is very kind of him to do that…sometimes I don’t like bothering him 
because he’s very busy.” (SW, Case 5) 
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In terms of carers and nurses, they were viewed as doing what they had to or were paid to in 
most cases, and seen on the whole as being kind. There were no instances where carers had 
made decisions on the patients’ behalf and as a result they were viewed as contributing very 
little in more than one case: 
 
“She [carer] don't do nothing for me. They ask me if I took my medication, I said yes. 
But I take my own medication. They ask me if I've done that or that…She helped me 
with the bath…she do my hair, she do my bed yes…I do my own things.” (FB, Case 1) 
 
“The carer doesn't do much…and that's because I insist it…I have to persuade them to 
let me.” (MGY, Case 6) 
 
The DNs’ timing for administering insulin was erratic and problematic for more than one 
patient, and the reduced capacity of the DNs not tolerated, to the same extent as that of the 
GPs:  
 
“She's been telling me that I'm never happy because sometimes they come early, 
sometime they are late. Because yesterday…she come eleven o'clock, I said “oh you are 
late today”, but I talk about it, I don't complain...I know she writes in the book, that I'm 
never happy.” (FB, Case 1) 
 
“…because you see what time they come, willy-nilly.” (JL’s daughter, Case 4) 
 
The patients who had matrons held them in higher regard than DNs, and they were all 
complimentary about the CHS pharmacists and the support they had given them. Community 
pharmacists were viewed as caring and professional for the most part, rather than having 
expert knowledge like the GPs. This was despite a number of mistakes and shortcomings that 
the patients had picked up on. There was one error where two community pharmacists had 
dispensed MCAs for a patient post-discharge. It is not possible to know if both had FP10s from 
the GP surgery, but the patient took the ones he recognised. One patient had a very poor 
relationship with her community pharmacist, noting a number of problems that she had 
attributed to them: 
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“Oh Lord help us. No, I don’t (get on with the community pharmacist). He gives me 
headache…I’ll speak to the doctor now and he said to me, “I send it on to the 
pharmacist.”…When I phone him, he hasn’t seen it. I say, “Don’t you look at your 
computer?”…I have to be chasing.” (SW, Case 5) 
 
Community pharmacists kept only one brand of MCA; changing community pharmacist meant 
a change in MCA brand without the patient having a choice. Only one patient had the chance 
to see the MCA before it was used for their medicines, and they did not get to try it out first or 
change it if they didn’t like it: 
 
“I know when I first went to the chemist over here, he did show me…Well, I didn't 
refuse because I didn't know what it would comprise if I were to take them out. We 
continue with them but it's not very easy, though you can burst the bottom, but it's still 
not very easy.” (MB, Case 2) 
 
MCA users experienced a closer relationship with their community pharmacist than would be 
afforded if they were not housebound. The involvement of the community pharmacist was as 
a direct result of the MCA, and viewed by patients as a benefit. 
 
“I am happy with that because I know what I’m taking. I think the pharmacist knows 
what he’s doing.” (FB, Case 1) 
 
“They are ever so kind…I can’t expect more from the pharmacists. They are 100% 
caring…and if there's something he doesn't think is right about your prescription, you 
aren’t getting it. He is going to phone the doctors…have it confirmed.” (FR, Case 3) 
 
Other significant relationships were with family and religious faith.  All participants had some 
family, with daughters taking the lead with regard to HCP communication and enabling choice. 
The advice patients accepted about their medicines though was from HCPs and not family 
members. FB talked about her sister’s “interference” in her medication taking: 
 
“Because as my brother was diabetic, I’m diabetic too she wants to tell me what to do. 
I don't want to know…I got my own medication. You can remind me but it none your 
business what I'm doing.” (FB, Case 1) 
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4.4.4 Conclusion of Framework analysis of interviews 
 
In patients who were motivated to take their medicines, MCAs offered some patient 
convenience and did assist with unintentional non-adherence when used as part of a system 
aimed to overcome specific barriers. All patients forgot to take their medicines occasionally, 
even those who were motivated to take their medicines and found the MCA easy to use; using 
an MCA did not remind patients to take their medicines. 
 
MCAs were easier to open and understand than original manufacturer’s packaging. They were 
of use as a visual aid for patients to see if they had taken a dose or not in cases of 
forgetfulness. MCAs were not entirely easy to use in themselves, with patients describing 
difficulty popping the blisters, and having to shake tablets out of the pack resulting in them 
landing out of reach on the floor. Patients expressed a preference for using particular brands, 
based on size (smaller MCAs offered discretion, larger ones, inclusion of more medicines) and 
ease of use. The brand of MCA given depended on the community pharmacist used, and there 
were no cases where a chance to try the MCA was offered first. 
 
There were disadvantages associated with not having the original manufacturer’s packaging 
and PIL available; patients were unable to identify the dose units in the MCA even if they did 
have the PILs, so were unable to match the PIL to the medication. This meant that the patients 
were unable to assess the importance of each medicine, or attribute side effects experienced 
to an individual medicine. Making an informed decision about whether to take the medicine or 
not relied on the patient being able to assess the benefits and the risks associated with each of 
them. Patients who recognised what their medicines looked like in the MCA were able to 
identify newly added medicines only, and use the PIL to make a decision to take it or not. Most 
patients wanted the PILs to keep as a reference and find out more about what they were 
taking, even when they had difficulty with their eyesight (and therefore reading them) or 
understanding them, and couldn’t tell their medicines apart in the MCA. 
 
Patients became suspicious of their medicines when new tablets were added by the GP 
without an explanation first, or when a change in the company supplying the medication to the 
community pharmacist had changed and this altered the appearance of the medicine. Patients 
were intentionally non-adherent in instances where they had noticed something unusual or 
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something had changed, refusing to take either all of their medicines or just those that were 
isolated. Patients were resentful towards the GP or community pharmacist when changes 
were not explained to them. It would have been easier to isolate and discuss changes if the 
MCA was not used. 
 
Patients wanted to be as independent as possible, including regarding decision making about 
medicines. Patients were not involved in the decision to start an MCA, the main initiation 
being from the hospital at discharge and HCP instinctive reaction to polypharmacy. Some 
patients were unhappy about this, and those who were happy with the MCA in general were 
still unhappy about the circumstances of initiation. 
 
Patients taking medicines for long-term conditions wanted ongoing periodic reassurance that 
the medicines they were taking were still required and effective. Patients did not want to take 
unnecessary medicines and were concerned about side effects, overdoses and other harms; 
they did not want to be forgotten about or prescribed medication in order to be pacified in the 
absence of a genuine indication. All patients wanted information about their medicines as they 
were the ones taking it, viewing this as a right. Patients were more likely to take a medicine 
when they knew what it was for and the side effects of it, especially if they could feel it 
working and had an opportunity to discuss the need for the medication with their GPs. The 
decision to take a medicine or not was only negatively affected by the MCA, and this was via 
an inability to identify the tablets; there were no findings that suggested that having an MCA 
meant a patient was more likely to take their medicines. 
 
Patients viewed GPs as very busy but experts; other HCPs were seen as kind and professional. 
The community pharmacist was more involved in the patient’s care if that patient was an MCA 
user via an increased input into the re-ordering and supply process. DNs administering insulin 
late and non-GP staff led processes in the GP surgery were irritating to some and 
demonstrated disorganisation, which was not appreciated. Family members were not used as 
advisors, but rather as advocates for some of the patients. 
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4.5 Discussion 
 
Patients take their medicines only when they have made the decision to do so. MCAs have a 
place in patients who are already motivated to take their medicines but not as a reminder for 
those who simply forget to take their medicines. The issuing of medicines in an MCA does not, 
in itself, encourage patients to take their medication when they do not want to. MCAs should 
not be issued without proper assessment of adherence, including individual preferences for 
having an MCA and the brand, and consideration to the patient’s baseline motivation level for 
taking medicines. Where MCAs are issued without full assessment, they may to more harm 
than good to the patient through inhibiting identification of medicines, thereby prohibiting an 
informed decision about whether to take them. The patient should be included in any decision 
to issue their medication in a MCA and empowered to change back to the original 
manufacturer’s packaging if they wish. 
 
Many of the problems associated with MCA use could be eliminated if community pharmacists 
offered patients trials of MCAs before dispensing into them in perpetuity. Trials of one or two 
months followed up with a consultation with the community pharmacist would allow time for 
the patient to get used to the MCA and give them the opportunity to express any problems 
that they were having with the brand, with the MCA itself or any other pertinent aspect e.g. 
re-ordering issues. The patient would have the option of trying other processes devised with 
the community pharmacist that would work for them and their situation. These assessments 
could be carried out as an additional service as part of the community pharmacist national 
contract, or as a specialist type of MUR commissioned locally
69, 70
. Attracting an additional fee 
would allay some of the concerns expressed in the community pharmacist survey (see Chapter 
3) about the burden of MCA supply among contractors, and would prevent some of the cases 
where MCAs are started by well-meaning HCPs as a knee-jerk reaction to polypharmacy. If 
community pharmacists are remunerated at equivalent fees for any adherence consultation 
they had, whatever the outcome, there would be less of a propensity towards supplying MCAs 
and greater use of other methods and tools to improve adherence. Incentivising community 
pharmacists to have honest conversations with patients about their medication taking would 
be good for the pharmacy profession as it would capitalise on the opinions expressed by 
patients that on the whole, pharmacists are professional and caring and their increased input 
into patient care is desirable. 
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Patients want independence, utilising the expertise and skills of others to make informed 
decisions about their medicines. Examples of where patient autonomy and choice are limited 
include when new medicines are started without the patient being informed, MCAs started 
without patient involvement, appearance of medication changed without explanation, MCA 
brands changed and when patients move home and their community pharmacist changed. 
Decisions such as these are made without the documented input of the patient, yet scrupulous 
documentation kept demonstrating patient involvement in and consent to other, often less 
important decisions (e.g. carer’s logs of patient activity and clothing preferences). Putting 
patients at the centre of care improves outcomes; it is expected that the only circumstance 
under which a decision is made on behalf of a patient is when the patient lacks the capacity to 
make their own decision, with strict documentation requirements when this is the case 
71
. 
HCPs like community pharmacists and GPs and social care professionals may not be applying 
this ethos consistently across all decisions that are made about patients’ health
72
. Further 
research into the motives behind making decisions on behalf of patients by those managing 
their care is warranted in order to understand this tendency and perhaps differentiate 
between the types of decisions that are left to the patient and those hijacked by the 
professional. 
 
There is a place for pharmacists in the management of long term conditions, de-prescribing 
unnecessary medicines and continually reviewing therapy in easily accessible consultations 
with patients. GP practice pharmacists, CHS pharmacists and community pharmacists with 
access to summary care records could perform this duty and patients would welcome it. 
Pathways could be set up that meant MCAs could not be started at hospital discharge, but 
instead referral made to a suitably qualified clinical pharmacist in the community, working at a 
location convenient for the patient; the result would be a supportive medication taking 
process and named HCP lead for these patients taking lots of medicines, and adherence 
support tailored to them. Training requirements for pharmacists carrying out such a role would 
depend on the experiences of individuals, but would be likely to include an independent 
prescribing qualification and training in motivational interviewing techniques. Patients had 
very good relationships with their GPs, and this may be because, having live access to the 
patient’s medical notes, the GP consultations felt more personalised. Access to medical notes 
is an essential requirement for full clinical medication review, whoever carries it out. 
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In this study the only HCPs performing medication reviews that assessed patient beliefs about 
medicines were performed by CHS pharmacists, who were not the HCPs involved in starting 
MCAs. 
 
The role of the CHS pharmacist tended towards retrospective problem solving, with many of 
the recommendations made being corrective actions. Ideally, CHS pharmacists and other 
clinical pharmacists working in the community would be working as part of a multidisciplinary 
team, prospectively reviewing patients and assessing adherence before problems occur. 
 
The findings about how the ability to identify medications in the MCA affected patient decision 
making, along with how patients wanted ongoing reassurance that they were on an optimised 
regimen, were significant. When people do not know what their medicines are, they do not 
know how important they are. It follows that when patients appear to be non-adherent with 
their medicines, they are not saying “I cannot take my medicines”, as is often the 
interpretation by the HCP; they are instead saying “I do not think I need these medicines”. 
There was an overarching expectation from patients that their medicines were going to make 
them “better”, though many medicines for long term conditions are preventative in nature; so 
this preconception the patients had was not always the case. If patients know they need all of 
their medicines, they are more likely to decide to take them, and this study has demonstrated 
that decision making about medicines and consequent adherence is influenced positively by 
receiving enough information about the medicine, supportive relationships, continued review 
of medicines, patient attitude towards medication and desire for independence. These are all 
much more difficult for HCPs to identify and make recommendations about than just noticing 
that somebody is taking a lot of medicines in an apparently haphazard way. 
 
Areas for future research could focus on some of the errors experienced by patients in this 
study; one case had duplicate medication dispensed into MCAs at discharge from hospital and 
another reported the MCA looking different some weeks, with the night time doses having a 
separate pack in the week of the visit. Though the errors observed were unique to MCA 
dispensing in this study, it cannot be shown that dispensing errors with MCAs occurred more 
frequently than dispensing errors with original packaging. A prospective, quantitative analysis 
of error rate and type with demographically matched pairs of patients, one MCA and one 
original pack users, would show if the use of MCA increased or decreased dispensing error risk. 
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The knee-jerk reaction to polypharmacy causing HCPs to initiate MCAs also warrants further 
qualitative enquiry, examining why the HCPs think MCAs will work and if they are aware of any 
other methods of increasing adherence.  
 
In this study there were instances where the patient’s right to make decisions about their own 
care were flouted and the reasons for this are also worthy of further research. There was also 
some evidence that patients felt uncomfortable expressing their wishes to HCPs. This study 
was qualitative, with low patient numbers so it is impossible to generalise; it would also be 
inappropriate to stratify results for any demographic variance. Ageism and other forms of 
prejudice, however, cannot be ruled out, given that all patients were housebound and elderly, 
and none were white British. These demographic particulars may have had a bearing on 
attitudes towards medication also, but without quantitative investigation it is not possible to 
say. 
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Chapter 5 Individual and paired interviews with Community Health Services Nurses: the 
community nursing and the social carers’ role in MCA supply and use 
 
5.1 Introduction 
 
In this chapter the author presents the carer’s role in MCA initiation and supply, and the 
nature of interaction between the carer and community health services (CHS) nurses (and 
consequently social care and NHS care) is explored. The carers’ perspectives on the use of 
MCAs are presented from the viewpoint of those who interact with them in their working lives. 
 
This chapter addresses the objective of the study: 
 Collect data to answer the qualitative research question by conducting focus groups 
with domiciliary carers and focus groups with community nurses. 
 
Nurses who work in CHSs have contact with patients who live in their own homes
73, 74
. 
Community matrons at Guy’s and St. Thomas’ NHS Foundation Trust (GSTT) have caseloads of 
complex, frail elderly patients who are frequently admitted to hospital. Specialist nurses at 
GSTT have a role in improving outcomes or optimising therapy in a particular therapeutic area 
for their patients, e.g. respiratory, heart failure or palliative care. District nurses carry out a 
general role, and are often employed to administer complicated medicines such as insulin or 
other injections. They also change dressings and catheters, take blood pressure and pulse 
readings and perform other general nursing duties, some of which are invasive
74
. Nurses have 
remits greater than social carers; social care activities are limited to activities of daily living 
(ADLs) which include things like dressing, bathing, cooking, cleaning and shopping
75
. 
 
As well as the nurse interviews, a separate content analysis of policies from local brokered care 
agencies was performed and is presented in Section 5.4; results are discussed with reference 
to the results of the CHS nurse interviews in Section 5.5. 
 
5.2 Methodology 
 
Focus groups are where groups of four or more participants are interviewed jointly, enabling 
multiple data to be collated at the same time
76
. Researcher influence on the data is minimised 
as the moderator of a focus group has less control over the discourse than an interviewer 
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would have over an interview. Logistical and recruitment difficulties exist however, as focus 
groups rely on everyone being in the same space at the same time. They are difficult to 
manage keep on-topic, and lack subject depth obtainable with interviews
76
. 
 
If the number participating in a focus group is less than four,  some of the qualities of being a 
group are lost
77
; interaction illuminates the data. The author anticipated the possibility that 
only one or two CHS nurses would be able to attend each group session organised, and was 
prepared to conduct individual interviews or paired interviews if the numbers were too small 
to conduct focus groups. It was not essential to the methodology to conduct focus groups with 
large numbers of participants; rich data could be collected from just a few participants in 
interviews, individual or paired
76
. 
 
Paired interviews are in-depth interviews conducted with two participants at the same time, 
providing opportunity for individual depth of focus whilst enabling participants to incorporate 
what they hear from others into their own thinking. They are valuable when investigating two 
subjects from a naturally occurring unit (e.g. colleagues), when the subject matter is complex 
and there is benefit in interactive or joint reflection
38
. 
 
5.2.1 Carer focus groups 
 
No patient-carer pairs were recruited into the study as originally hoped (see Chapter 4). In 
order to get the carers’ perspectives, the author applied to ethics for a change to the study to 
incorporate carer focus groups. This change was approved by the Northern Ireland Research 
Ethics sub-committee (HSC REC A) in April 2015 (see Appendix 3). 
 
In September 2016, 44 care agencies were contacted to request focus groups with their carers. 
Addresses were obtained via a freedom of information (FOI) request for names and addresses 
of all brokered agencies to each borough (Lambeth and Southwark). An invite letter, 
information sheet for carers and a consent form were posted out to each agency by mail with 
a stamped self-addressed envelope, requesting the return of a contact details sheet to speak 
to them in person to arrange focus groups. Only one agency responded, but would not assist 
without payment beyond expenses and refreshments. This was not authorised as part of the 
ethical review. The invite letters and information sheet are shown in Appendix 9, the consent 
form is in Appendix 10. 
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Carers may not have wanted to take part because this study looked closely at an area which 
they may already have felt they were not very well equipped for. It may have been that some 
carers and agencies already knew that they were not handling medicines appropriately and to 
highlight this without recompense, despite assurances of confidentiality, was not in their best 
interests as businesses. Another plausible explanation is that carers and agencies may have 
been too busy to participate. 
 
In Chapter 3, it was shown that MCAs were often supplied for the purposes of carer 
administration. In Chapter 6, the CHS pharmacist perspective is presented; carer use of MCAs 
to administer medicines was described by one interviewee as ”ubiquitous”. It was important to 
determine the carer perspective in order to understand how and why they rely on MCAs, even 
if this could not be completed with carers in person. 
 
5.2.2 Nurse interviews and focus groups 
 
Carers have close contact with clients and some contact with the CHS nurses. As it was not 
possible to find the care perspective from either the carers themselves or their clients, the 
next step was to approach the CHS nurses. There were already plans to recruit CHS nurses into 
the study as they have their own role in the patient’s care, with views and opinions about 
MCAs that were valuable in answering the research question in their own right. Once it 
became clear that recruiting from care agencies was not possible, the topic guide (Table 5.1) 
for the nurses was amended to enable further exploration of the carers’ part in the initiation 
and use of MCAs; the questions that were particularly pertaining to the experience of working 
with carers are in italics. 
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Table 5.1 - Topic Guide for Community Nurse Focus Groups and interviews 
 What do you think blister packs are for? 
 What type of patient do you think would benefit from using them? 
 What do you think the disadvantages of blister packs are? 
 What are the advantages to using them? 
 What do you think are the safety issues with blister packs? 
 What sort of problems do you think are encountered with their use? 
 Any other thoughts? 
 Do you find that care agencies insist on blister packs being in place before they accept a 
patient? 
 Why do you think they do this? 
 Have you ever been asked to organise putting a patient on a blister pack in order that a 
carer could give medication? 
 How did you feel about this? 
 Blister packs were designed for self-administration by the patient; What do you think 
would happen (good and bad) if blister packs were restricted to only be used by patients 
who could take their own medicines? 
 
5.2.3 Recruitment 
 
Nurses from the different sub-teams of the CHS were invited to participate. Six nurses were 
recruited, two were interviewed individually and then there were two joint interviews of two 
nurses each. Recruitment took place via the consultant pharmacist for elderly care at GSTT 
who put the nurses in contact with the author and via the author herself who had worked 
closely with nurses within the same organisation before (but not during) the recruitment. The 
author sent an explanatory letter, an information sheet and a consent form to the nurses via 
email. These are shown in Appendix 10.  Written consent was gained from the individual 
nurses in person before each interview. Interviews were conducted in meeting rooms at the 
nurses’ place of work, each was audio recorded and lasted between 25 and 45 minutes. 
 
5.2.4 Analysis and results 
 
The interviews were transcribed by a specialist outside company. The author checked the 
transcription and used this as an opportunity to familiarise herself with the dataset. The 
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recordings were listened to several times to assist with the familiarisation process. During this 
process it was found that with such small numbers, the two joint interview transcripts read 
more like two separate, concurrent interviews than a true focus group; the separate 
participant contributions were therefore analysed as such, with separate coding of each nurse 
contributor
66
. 
 
The data were analysed using a thematic analysis model, chosen for its flexibility and because, 
in line with the approach in this study, it does not make philosophical assumptions. There is 
opinion that thematic analysis lacks the substance of other analytical processes such as 
grounded theory or phenomenology, and therefore has limited interpretive power 
78
. Thematic 
analysis was in keeping with the nature of the study and data collection. It was not possible to 
interview all of the nurses individually, so any methodology that required an in-depth 
discourse with the study subjects would have been unsuitable. There was an ulterior 
phenomenon that the researcher wanted to capture in terms of the carer perspective, and any 
recounts of this from the CHS nurses were descriptive rather than interpretive to begin with; 
any style of analysis that was deeply interpretive would make bigger claims on the data than 
could have truly been the case. 
 
The analytical process is shown in Table 5.2; though the separation between data collection 
and analysis is not always clean in qualitative research
79-81
. The initial codes are shown in Table 
5.3 and Table 5.4 shows the process of code refinement, where overlapping codes were 
combined or larger codes split depending on further review of the coded data that sat within 
in code. 
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Table 5.2 – Steps taken in thematic analysis 
Reading and familiarisation 
 Things of interest noted in order to refer to later to help develop the analysis (observations 
noted, not systematic) 
 Complete once intimately familiar with the content of the dataset. 
Complete coding 
 The entire dataset was coded (as there were only four transcripts and six interviewees), 
without any selectivity introduced by the author. 
 Anything and everything of interest or relevance to answering the research question was 
identified; the aim was not to reduce the data – selectivity was apparent in later stages. 
 Transcripts were systematically coded. NVIVO 10 software was employed at this stage for 
expediency, comprehensiveness and to maintain an audit trail. 
 Once coding was complete, each code was copied onto index cards to allow the author to 
manually sort the data. This meant the author felt closer to the data and prevented 
interpretative distance from it. The initial codes are shown in Table 5.3. 
Searching for themes 
 Index cards organised and re-organised until they each belonged in an organisational 
group that represented a psychologically or socially meaningful pattern. 
 The patterns identified during the code-sorting process were then developed into themes. 
Table 5.4 shows the process of code refinement and theme formation. 
 It was important at this stage to identify features of the dataset, and make note of these. 
Features are concepts that appear differently across the data
80
. An example of a feature of 
the data was the general feeling about carers using MCAs; some strongly opposing the use 
of MCAs in this way and others seeing some advantages. 
 Unpopular codes discarded, popular codes highlighted for further investigation when 
forming themes. NVIVO used to find most and least popular codes; see Appendix 11. 
Reviewing themes 
 Themes were reviewed to ensure that they fitted the data and told the story of the dataset 
in a truly representative way. 
 Coded and collated data reviewed, including by referring to the entire dataset. Themes 
were considered individually and relationships between them explored. 
 Because the entire dataset had been coded instead of a sample, minor tweaks only were 
required and slight reorganisation of concepts within each theme. Continued until themes 
felt coherent, distinct and told a whole story when altogether. 
Defining and naming themes 
 Boundaries and the focus of each theme defined; each distilled to a few sentences 
encompassing what is unique and selective about them. See Section 5.3 below. 
Writing and finalising analysis 
 Extracts selected to illustrate the different aspects of each theme; interspersed in the 
narrative so that together the reader is told a story about each theme (see Section 5.3). 
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Table 5.3 – Initial codes from CHS Nurse interviews 
Care agency management and policy 
Carer training 
BP disadvantages 
Carer or agency insistence on BP 
Carers use of BPs 
Documentation of medicines given 
Examples of good practice and services 
Care agencies poor standard 
The CP including variation 
Fragmented system 
Lack of assessment or MR when BP started 
Safety disadvantages of BP including carer 
administration 
Patient suitability 
Medicines outside of BP 
Delivery 
Discharge from hospital 
Appreciation or sympathy with carers 
Continuous MR and monitoring 
Nurse administration is different 
Assessing patients for medicines support  in 
general 
Carers not giving non-BP meds 
Communication problems 
NHS funds 
Nurses picking up slack 
BP does not mean they are taking it 
Adherence - Following up and monitoring 
Unnecessary medicines and polypharmacy 
Benefits of MR 
Social services impact 
Delays in discharge from NHS to social care 
as BP requested 
CHS nurses asked to start BPs 
inappropriately 
GPs do not do proper MR frequently 
enough 
BP advantages to patient 
Assessing patient for BP 
Social care insisting on BPs 
NHS administration is different 
Identification of tablets - hampered 
Unused medicines 
Safety issues with and without BPs as no 
MR 
Carers find BPs quicker 
BPs are not the only answer 
Adherence - untaken BPs and other meds 
Carer general medication management 
Variation in carer quality 
Poor communication within the care agencies 
Support for carers 
Interaction between nurses and carers 
Lack of gaining consent when BP started 
Missing medicines & disorganisation in the 
home 
Independence 
Disadvantages of carer proxy admin 
Monitoring adherence 
Dementia 
Own (team) social workers 
Care agency inconsistency 
Carers and others think BPs are safer 
Pharmacist MR 
Adherence – patients do not know what their 
medicines  are for or why they are on them 
Patient consenting to BP 
Discussion about  communication between 
primary and secondary care 
Social care funds 
Advantages of carer proxy BP admin 
Fiddling the system for patient benefit 
Giving information to patients & decision 
making 
BP advantages to carer 
Medication not a priority for carers 
Unsafe to remove a BP once started 
Patient preference 
Care quality commission (CQC) and inspection 
Non- adherence causes unverified 
Patients still forget 
Brand conversation 
Discussion about PILs 
Discussion about self use 
If BPs for proxy admin stopped suddenly 
NHS care is preferable to social care for 
patients 
Adherence – patient daunted by volume 
 
KEY 
MR=medication review 
BP=blister pack) 
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Table 5.4 - Code refinement 
CODE NOTES / REFLECTION 
Blister pack (BP) 
advantages to patient 
Split into those advantages related to safety and those related to 
convenience. 
Adherence Can be split into adherence and non-adherence, and nuances 
within each (e.g. some non-adherence is because patients do not 
know what they are taking or what for, and some of this is due to 
being on a BP). 
BP disadvantages Some disadvantages are inherent to the practical use of the BP; 
some are just related to the use of the BP. Many of the 
disadvantages are related to patient safety. Code can be split into 
safety issues, and disadvantages related to self administration 
and proxy-administration. 
Fragmented system This code is interpretative rather than descriptive. Look again at 
data coded here. Fragmentation may be an emergent theme.  
BP does not mean they 
are taking it and BPs are 
not the only answer 
Both codes point towards BPs being ineffective for their intended 
purpose in certain circumstances. There are different ways to 
address adherence and different types of adherence that need to 
be addressed. 
Interaction between 
nurses and carers 
Includes an element of monitoring the carer, or a belief from the 
carer they are being checked up on. 
Carer training and nurse 
administration is 
different 
Belief that carers training is absent, though is also just common 
sense; however nurses describe that their own jobs are hard 
(liaising, assessing, monitoring, administration from a nurse 
perspective). 
Nurses are comforted by knowing what they are giving, carers are 
not. 
Discharge from hospital Problems with communication and advantages of inpatient 
medication review are discussed here, which are not necessarily 
related. 
Consent and lack of 
consent 
Combine; where consent to a BP is discussed, it is always in the 
context of failure to gain consent before BP commenced. 
Assessing for a BP Code includes examples of where this happens and where it does 
not. It also includes examples of where re-assessment happens or 
is lacking, and how people who initiate BPs do not have the time 
to assess or think assessment is not needed. Code feels like a 
higher category (possible theme) at this stage. 
Social care funds 
NHS funds 
Merge as both composed of wasting public money, and not 
always clear whether this is health or social care funds from the 
excerpts. 
Nurse administration is 
different and NHS 
administration is 
different and 
Medication is not a 
priority in social care 
These codes appear in close proximity to each other and all 
indicate a general feel that social care does not treat medication 
with the importance that it deserves. There is potentially a 
broader theme in this data pattern and this theory warrants 
further exploration. 
Care agency 
management and policy 
Composed of what agencies and carers should be, but are not, 
doing. Lack of actual care from carers and agency management is 
also raised. A disconnection between policy and reality are 
apparent within this code.  
5.3 Results of the CHS nurse interviews 
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Figure 5.1 shows the emergent themes and how they relate to each other. Each main theme 
and associated sub-themes are described in depth in Sections 5.3.1 - 5.3.3 below.  
 
 
Figure 5.1 – The three main themes and associated sub-themes from CHS nurse interviews 
(*sub-themes are linked) 
 
5.3.1 Theme 1 - Communicating in a fragmented care system 
 
This theme describes the problems experienced when patients transfer from one care provider 
to another with regard to the transfer of information about the patient. The three sub-themes 
are: 
 
 The primary-secondary care interface. 
 The social care and NHS interface. 
 Variation in services from community pharmacists. 
 
5.3.1.1 The primary-secondary care interface 
 
Within this theme difficulties with documentation at patient admission to hospital and 
discharge are discussed. The CHS nurses talked about delays in changed medicines being 
•Primary - secondary care interface and discharge
•Social care and NHS interface*
•Community pharmacy variation in services
1. Communicating in 
a fragmented care 
system
•The use of MCAs for proxy-administration
•Social care treat medication differently to the NHS*
•The carers are not to blame, it is the managers
2. The quality of care 
provided by private 
agencies is deficient 
•The reality of medicines use in peoples' homes
•The reality of MCA initiation and use
•Benefits of clinical medication review and continuous 
monitoring
3. Supporting 
adherence is 
onerous
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communicated to the GP and new medicines being started at discharge from accident and 
emergency (A&E) without full medicines reconciliation being carried out. 
 
“If changes have been made, then it's not always filtered through so then you get the 
difference in the discharge summary to what the GPs have.” (CHS nurse 1) 
 
“…they sent the patient home with two new medication…[an] antibiotic and the 
medication she had at home was a different antibiotic…she could have easily thought 
“I've got to take them both” when she got home.” (CHS nurse 4) 
 
MCAs being started at discharge also emerged in this theme, where CHS nurses went into 
detail about how detrimental this practice was, and how it signified a non patient-focussed 
system. CHS nurse 2 was concerned about the patient not needing the MCA and questioned 
the reasons for starting patients on a MCA. 
 
“Nobody explain, nobody give them information, nobody ask them.”…how were you 
managing your medicine?" Maybe this patient was managing medicine independently 
in an original box.” (CHS nurse 2) 
 
CHS nurses 5 and 6 pointed out the importance of checking that the patient can use an MCA 
first, and also the safety issues of not allowing the patient to try the MCA first. 
 
“…nobody had actually shown her how to use it…I just felt like it was, putting a blister 
pack in, and then discharging, at that point is not care. Because who’s to say that 
patient can use it?” (CHS nurse 5) 
 
“Until you're confident that the patient has understood and knows how to use it…the 
hospital has issued one…but the patient needs support to get to understand it.” (CHS 
nurse 6) 
 
5.3.1.2 The social care and NHS interface 
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This sub-theme describes how the difference between how social care manages medication 
versus the NHS leads to the inappropriate use of MCAs. The various ways in which the NHS 
supplements when social care is deficient are also raised here. 
 
Interviewees believed that social services did not understand medicines administration or give 
it high enough priority. Some said they thought that plans with respect to medicines were not 
detailed enough. Nurses described instances where HCPs had to work to the schedules or 
constraints within social care administration, rather than what was best for the patient as this 
was the best option available to them. CHS nurse 6 describes making changes to timing of an 
evening medicine in order to ensure it was given. 
 
“…there's no evidence to show that the Statins work better at night…you know the 
patient's going to get it, if there's a carer in the morning.” (CHS nurse 6) 
 
The CHS nurses described cases where the transfer from NHS services (such as the services 
they provided) to social care were delayed specifically because a MCA was requested. Agencies 
refused to accept patients unless they had a MCA, putting the nurses under pressure to supply 
a MCA to facilitate a speedy discharge, not because it was in the patient’s best interest for self-
administration purposes. 
 
“For the carers who are from social services because they won't give out of boxes… 
[they]…will always ask for medication to be put in blister packs. But then there's no 
scope for the patient to be independent with it and they may not want blister packs.” 
(CHS nurse 1) 
 
Interviewees described how social care workers insisted on MCAs; the CHS nurses liaised with 
the social worker assigned to the patient, whose role it was to arrange a package of care 
(POC). The CHS nurses did not liaise with the care agency at this stage, with the social worker 
acting as a conduit. The care agency put pressure on the social worker to arrange MCAs, and 
subsequently the CHS nurses were asked to start MCAs inappropriately by social workers. 
 
“If the care agency want them, they must sort it out…the care agencies on the other 
hand are saying ‘No, you need to sort it out before…’.” (CHS nurse 1) 
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“There’s so many packages of care that have been delayed because the blister pack has 
not been set up and we still have to keep bridging the gap.” (CHS nurse 2) 
 
”And in the beginning when I first started…we gave in under pressure. But then we as a 
team said “No - Whatever you think is needed for the patient, you need to put it in 
place”. We don't.”  (CHS nurse 3) 
 
Sometimes the social worker had advised that MCAs were necessary and it was evident that a 
full review of how the patient already used their medicines had not been carried out. 
 
“They would just come and say, “nurse can you put a blister pack in place please." I 
have been to a patient like that and he was furious, he said, "I have been doing this for 
almost 50 years and do you take me for a child," because whoever went to do the 
assessment…did not have a proper conversation with the patient” (CHS nurse 2) 
 
“Because the social worker just put whatever she felt was needed. Forgot all about 
medication. Patient never took their lunchtime medication, got readmitted…then we 
had to come in.” (CHS nurse 3) 
 
The initiation of MCAs was unfortunate in some other cases as it reversed the hard work the 
CHS nurses had completed with the patient who did not need an MCA in devising a system 
that worked for them. 
 
“Our social workers sometimes will get a blister pack, when we've said they don't need 
one….Really, they should say, “This is what they need, you can give medication in 
boxes.” …every single time they have to escalate it, and it's just so time consuming so-- 
They give up.” (CHS nurse 4) 
 
Funding was discussed in some interviews, and frustrations regarding the brevity of NHS care 
post discharge from hospital that could be afforded, versus the high cost of social care touched 
upon. Examples of where the NHS “picked up the slack” were described, some nurses giving 
personal examples of the extra work they face in their own practice that is not part of their 
remit. Other areas where NHS funds were wasted were also described, including duplication of 
tasks. 
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“..they will say, "carers don't do eye drops." Well, why not? You can't put nurses in 
place just to go and do eye drops. Look at the resources that you're going to be 
wasting.” (CHS nurse 2) 
 
“They have carers, district nurses, still we have to go in and do medication. It's like 
there's three services now, all for one.” (CHS nurse 3) 
 
“Nearly every new patient you get, you've got sort out the medication. Whereas if 
they've got carers, it should all be okay, but it never is.” (CHS nurse 4) 
 
Some of the responses showed an opinion that reflected potential negligence on the part of 
social care and private care agencies with respect to their responsibilities in ensuring proper 
medicines management. 
 
“We do it all within 24 hours, that is a care plan, a package of care, risk assessment, 
everything is in place…then we charge probably half of what they charge as a service, 
and they have no responsibility whatsoever to what they are doing…as a whole, the 
agencies are just taking the money, nothing else.” (CHS nurse 3) 
 
“And you know what's annoying?…they accepted responsibility to administer 
medications to patients. They didn't say at that point, “It’s only going to be from a 
blister pack.”…I feel like they are not being held accountable by the commissioners who 
are paying them this money to provide a service that they’re not.” (CHS nurse 5) 
 
CHS nurses talked about the interactions they had with carers and when patients were being 
looked after by both the NHS and social care simultaneously, after the POC was set up. These 
interactions were sometimes frosty. 
 
“…as soon as you call to say, “This patient was this, this and you need to do this, this.” 
They get all, “Oh but--” “No, there’s no “but”, I'm just telling you information”. But 
there’s all this defensiveness that you get.” (CHS nurse 3) 
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“Sometimes you have to ring up the agency while you're there and say, “Can you make 
sure they get this medication?” As soon as you start asking them anything they get on 
the phone straightaway, because they’re worried. Even though…you're just trying to 
help; they make you feel a bit like you're an inspector.” (CHS nurse 4) 
  
In the theme 2: “The quality of care provided by private agencies is deficient”, under sub-
theme “the carers are not to blame, it is the managers”, the CHS nurses described the 
empathy they had for the carers as individuals (In Section 5.3.2.3). 
 
5.3.1.3 Community pharmacist variation in services 
 
This sub-theme is under the main theme of “communication problems in a fragmented 
system” as community pharmacy approaches did not capitalise on feedback opportunities to 
GPs about individual patients, and services offered by the pharmacy were based on their 
capacity as contracted NHS providers rather than patient need. Medication delivery to 
housebound patients was prominent in the CHS nurses’ working lives, with frustration at 
variance between contractors. Several CHS nurses raised concerns about the nature of 
delivery, including quantities, delivery sites and the non-clinical approach of drivers. 
 
“I recently had a chemist who knocked on the door, the patient couldn’t get to the door 
quick enough, so he put them on…an external letter box…I tried to phone and say 
things like that are not acceptable…because those tablets could have got into anyone’s 
hands.” (CHS nurse 6) 
 
“I just contact the pharmacy and I say, "I know you want to save on visit times, but on 
this occasion this patient would benefit from a weekly delivery, and not a four week 
supply.”…they just happen to think it’s one for the bedroom and one for the living 
room, that’s why each blister pack has been issued.” (CHS nurse 6) 
 
Some pharmacies did not deliver at all, posing problems for the nurses and ultimately the 
patient: 
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“I’ve come across some who just say, "We don’t have delivery facilities," but yet they 
want the patient to be their customer…the patient’s been with them for a long 
time…doesn’t want to change.” (CHS nurse 6) 
 
Though some pharmacists reported medicine related issues to the GP, most did not: 
 
“Some…have reported it to the GP that the patient's not taking the medication, 
because when they do take the old pack away, there's still tablets in…20% maybe 
would do that.” (CHS nurse 5) 
 
One nurse described the tensions between the community pharmacy asking for weekly scripts 
and the GP surgeries who did not want to supply weekly scripts; this tense communication 
posed problems in her role: 
 
“…because it's in a blister pack, the chemist insists on having a weekly prescription...I 
know some GPs who are really anti that. They want to give you a month's supply, a 
month prescription, and they're not wanting to change. And you have this battle, and 
you kind of feel like the piggy in the middle.” (CHS nurse 6) 
  
5.3.2 Theme 2 - The quality of care provided by private agencies is deficient 
 
This theme describes how MCAs are used by social care and care agencies, and why. The 
impact that MCA use has on care quality, and the impact of care quality has on the drive for 
MCA use, are also covered in the data presented here. There are three sub-themes: 
 
 The use of MCAs for proxy-administration 
 Social care treat medication differently to the NHS 
 The carers are not to blame, it is the managers 
 
5.3.2.1 The use of MCAs for proxy-administration 
 
CHS nurses believed the overarching reason MCAs were used was to substitute for 
comprehensive medicines administration training. Care agency insistence on MCAs was 
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universal and was the first thing requested by the agencies, social workers and GPs as an 
attempt to address anticipatory non-adherence, without an assessment of adherence first. 
 
One CHS nurse described her view that much of the administration of labelled medicines in 
original packs in common sense, and it should not be difficult for carers: 
 
“If you're going to give a medicine from blister pack…you should be able to read, why 
can you not give a paracetamol from a box?…I think it's just to make things easy for 
them…they feel because the carers are not trained, there is potential for errors.” (CHS 
nurse 2) 
 
Nurses described situations where carers believed they could not give medicines without a 
MCA, provoking referral to care agency polices to resolve this situation. 
 
“They’ll tell you, “It’s our policy.” When you ask them to show the policy they can’t 
show you, because there isn’t one…whereas we’re instructed from NHS side of things 
that we give boxes with labels.” (CHS nurse 1) 
 
“…they’ve all got their policies and procedures but most of them don’t even know what 
they are…they’ll tell you they’re not allowed to give medication out of boxes and 
they’re all supposed to…anything else like cream and eye drops--they always think it’s 
got to be district nurses.” (CHS nurse 4) 
 
There were instances described where carers had refused to give non-oral medicines as they 
were not in the MCA: 
 
“They all say all sorts of beautiful things. The other day I heard somebody saying, “Oh 
no. I can’t give this nose cream”….then we literally had to go through the whole of 
management and the care agency. Then eventually she suddenly was able to.” (CHS 
nurse 3) 
 
All of the CHS nurses spoke of deficiencies in carer medication training, stating it was 
unknown, absent, insufficient or ineffective. The CHS nurses also thought that, despite policy 
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and in the absence of properly funded medication training, the reliance on MCAs was so strong 
it would be potentially unsafe to remove them completely. 
 
“I think they’re so reliant on it, they would probably panic about the prospects of giving 
out of boxes with labels. For me personally, it’s not an issue…I'm trained to do that. For 
someone who may not know…I think it will be utter chaos.” (CHS nurse 1) 
 
“I think a lot of them are very scared when it comes to medication, especially in boxes.” 
(CHS nurse 2) 
 
“Sometimes, if you go in and they are not in blister pack, and the patient is a bit 
confused and then the carers are going to give them the tablets separately…they have 
actually no idea what they are doing and that can be even worse than a blister pack. So 
it’s not like cut and dry is it?” (CHS nurse 4) 
 
One CHS nurse described concerns regarding the administration of medicines prescribed for 
use only when necessary, termed “when required” or “PRN” medicines (PRN: common 
abbreviation of pro re nata), and of variable dose medicines like warfarin, as more clinical 
knowledge is required for these medicines than for those suitable to go into an MCA. 
 
“When we were learning to be a nurse…you know it’s a two, three year course, you 
slowly build up your competence and your knowledge of medications. If they’re going 
to ask them to do all these PRN stuff, they need to be training them and getting the 
correct records as well. I mean warfarin is just a nightmare.” (CHS nurse 5) 
 
The CHS nurses could see why agencies liked their carers to use MCAs, even though they also 
thought it was a shame and certainly not ideal that speed was of the essence with respect to 
social care visits and POCs. 
 
“…if the blister pack takes them a few minutes and the MAR chart would take…15 
minutes…then it is probably better to give them a blister pack. But I don't agree that’s 
how it should be.” (CHS nurse 5) 
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The other overarching disadvantages of proxy-administration of medicines using MCAs, as 
described by the CHS nurses, were prevention of patient choice and carers not giving any 
medicines outside of the MCA. All of the CHS nurses had experiences where MCAs for proxy-
administration use by carers had proved disadvantageous for the patient. 
 
“I‘ve seen it recently, a carer will say, “Okay, I’m giving them from the blister pack, but 
these aren’t in the blister pack, so I’m not giving them”. Like antibiotics or something.” 
(CHS nurse 4) 
 
“Some of them won’t even take on things like patches, it’s a conversation…and it’s just 
not realistic…because the patient’s condition changes. They become unwell, they might 
need antibiotics, more painkillers, and that side of things to me just gets completely 
lost with care agencies, because it’s not in a blister pack.” (CHS nurse 5) 
 
Non-oral medicines administration is discussed further in the policy analysis section of this 
chapter (Section 5.4). 
 
5.3.2.2 Social care treats medication differently to the NHS 
 
The standards of social care were considered to be lower than those of the NHS, with 
inadequate medicines management provided by carers, inadequate documentation, poor 
communication within the agency and unreliable escalation of problems to GPs. The CHS 
nurses reported that the carers were often unaware of the contents of their own medication 
policy, and it was rarely the case that drug histories were obtained using accurate sources. This 
was investigated further in Section 5.4 where policies were analysed. 
 
“So, the morning ones are all being given by the carer, but the afternoon, evening ones 
aren’t being given because she has another carer in the evenings. For ages, those have 
been untouched and they are still in blister pack. And you would think that the carer 
would report it back to the agency.” (CHS nurse 1) 
 
“…whoever does the assessment from the agency, if they identify that there is a 
medication there…they [are supposed to] put a MAR chart in place or some sort of 
means of the carer knowing that they have to give medications…it’s supposed to be in 
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the patient’s folder which stays in the home…we see a lot of patients and I’ve seen it 
once in over 10 years.” (CHS nurse 1) 
 
Some nurses cited their own service as an example of where NHS high standards were met, 
describing negative experiences after handing patients over to social care: 
 
 “All the medication, the regular meds, was in the blister pack, and because warfarin, 
the patient’s normally given one, three, and five milligrams in the house so that they 
can be adjusted. A carer was planning to give one from each box, and that scared 
me…and it normally says take as directed because the INR fluctuates…I don’t think they 
understand…they are reliant on the patient, but when the patient cannot 
communicate, then there’s a big gap.” (CHS nurse 6) 
 
“…whether the patient has taken the tablets, swallowed the tablets, or it sometimes 
comes out of the blister pack and it goes into a saucer, and that was since breakfast 
and you visit at lunch time and you find those tablets still there. It’s not like, "Oh no, 
you got to take them now." It's not a priority.” (CHS nurse 6) 
 
The poor quality of documentation kept by the carers was discussed: 
 
“I would say from my experience, if 10% of the patients up there had MAR chart will be 
lucky. And from that 10%, if 2% had them filled that would be very lucky…there’s 
nothing. They literally copy from the previous day.” (CHS nurse 3) 
 
“I had the other day a patient that had signatures, meant to receive visits three times a 
day. And you can see they were visiting in the morning they were signing for the 
afternoon, because I came at lunch time between the times she signed that she was 
there, nowhere to be seen.” (CHS nurse 3) 
 
5.3.2.3 The carers are not to blame, it is the managers 
 
The CHS nurses had experienced variation in the quality and capability of individual carers and 
care agencies, and stated that some were more caring than others, possibly those that had a 
nursing background. 
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“…like you may have-gliclazide - the patient will have 80mg tablets but thy only need to 
take 40, so you’re to break in half to give half. Are they understanding how, or has it 
been written properly so the carers understand that?” (CHS nurse 1) 
 
“It’s that one individual who has some sort of caring or nursing background back home 
or something like that. Apart from that, you give up, because they don’t even want to 
do what they are meant to.” (CHS nurse 3) 
 
Some thought that the individuals made a difference, not the agency: 
 
“You’ll find the individuals that are really caring, they will do left, right and centre to 
care for that person. I had, the other day, “My patient’s constipated, I called the GP, I 
organized the GP to give him laxatives and I’m giving it twice a day nurse”, and I 
thought, “Oh, can you work forever?” (CHS nurse 3) 
 
Generally the nurses had huge appreciation and sympathy for the individual carers, revealing 
the hardships they were aware carers experienced (travel costs, blame culture, training gaps) 
and the unreasonable expectation put on them. 
 
“They will have under the time constraint as well because they can have like four, five 
clients in the morning and most of them are not driving. They have to go by public 
transport…waiting for buses…when they're with the patient, they're thinking “I need to 
get out…”. They're not paid for the time travel which is really bad.” (CHS nurse 2) 
 
“I understood was the carer received less than half of what the agency makes…The 
expectations are definitely unreasonable. I don’t blame them, I blame the system. Very 
upsetting.” (CHS nurse 3) 
 
“Can you imagine you do a whole day’s work…and then one of your visits might be like, 
go away for two hours then come back, you might be working for over 12 hours but 
only actually doing three hours’ paid. It’s just terrible isn’t it?” (CHS nurse 4) 
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Carers had more contact with the patient than any other HCP or social care worker, and it was 
deemed important to raise their profile for patient benefit. 
 
They need to be looking at what training they need, the salary, things like that maybe 
that will boost their morale and their confidence and their knowledge as well.” (CHS 
nurse 2) 
 
“Lack of education, lack of training, lack of communication, lack of time, they're 
worked so hard and not paid enough. If you get somebody unskilled who you’re not 
paying enough they’re not going to do a high quality job.” (CHS nurse 5) 
 
5.3.3 Theme 3 - Supporting adherence is onerous 
 
This theme describes how the MCA fits into the wider area of medication adherence. In 
explaining why MCAs are not the only adherence aid, the difficult and resource intensive task 
of assessing medication adherence is explained. There are three sub-themes: 
 
 The reality of medicines use in peoples' homes 
 The reality of MCA initiation and use 
 Benefits of clinical medication review and continuous monitoring 
 
5.3.3.1 The reality of medicines use in peoples' homes 
 
This sub-theme explains the reality of medicines in peoples’ homes with polypharmacy, 
infrequent medication review, and a lack of adherence checks. Some examples and causes of 
non-adherence were discussed by the nurses. 
 
There were safety issues reported in instances where the MCA was used and where an MCA 
was not used, and this was attributed to lack of clinical medication review and not checking if 
the patient could use their MCA. Doubling up doses and intensifying therapy inadvertently, 
sometimes at discharge from hospital, were also reported, as were cases where temporary 
courses of medicine for acute conditions had been wrongly incorporated into the patients 
repeat medication list. There were some instances of carers not reading care plans and not 
knowing what to do with PRN medicines, as it was not known what they were for. 
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“Some of these conditions are just something acute that they take a medicine and it 
would stop, but they just keep putting it on repeat…the initial medicine that was 
prescribed was not reviewed.” (CHS nurse 2) 
 
“They went to the GP, they did a blood test…thyroid function. It was quite low, they 
doubled the dose of thyroxine. I said, “You don't need to double anything, she never 
took any drugs for six months.” Instead of actually investigating the root of the 
problem, they actually just doubled the dose…That's where the root is, there is no 
assessment.” (CHS nurse 3) 
 
The CHS nurses all reported frequent cases of polypharmacy, with some patients never taking 
medicines the way the prescriber would have expected. There was general feeling that, if the 
patient had managed to go for so long without a medicine that they had not adhered to, they 
did not really need it at all and prescribing should stop. Non adherence was apparent both in 
cases where an MCA those where they were not. 
 
“There’s one time I removed about three bags worth of blister packs…I took them all 
back to the chemist…We got the GP to review everything, cut a lot of stuff…That 
patient is taking them now, no problem…no one had reviewed or no one had checked 
to make sure that the patient was taking them and they actually needed what they 
were taking.” (CHS nurse 1) 
 
“…one of our questions when we do our meds reconciliation is, "Have you been 
reviewed by a doctor in the last six months in terms of your tablets?" And if they say 
no, then it does prompt us…we would have that conversation with the doctor.” (CHS 
nurse 5) 
 
There was some opinion that not knowing what they were taking or why, and the sheer 
volume of medicines prescribed, were frequent barriers to adherence for patients. 
 
“…there’s bags of stuff…it can be quite overwhelming when they know it’s there or they 
see it. It probably puts them off taking them.” (CHS nurse 1) 
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“I have a had a patient, because the patient doesn't want to take a particular tablet 
and she wasn't sure that which one this tablet is, she doesn't even take any…in the 
afternoon I think she had three, she would just skip the afternoon because of that.” 
(CHS nurse 2) 
 
There were many situations where medicines were omitted or disorganised in the home, 
whether there were carers or not and whether there were MCAs used or not. 
 
“Very expensive. Waste of money. Sometimes you go in and there’s a year’s supply, not 
touched in the corner.” (CHS nurse 4) 
 
“80% of the time you need medications moving away, sorting out. A lot of the times it 
is blister packs, but then it's just other medications they’ve got lying around. People 
have a ridiculous excess out of date -- a patient told me to give her a cream the other 
day, and it was in went out of date 2013…I've had psychiatric medication from the ‘80s 
just in brown bottles; I was like “what the hell’s this?” “(CHS nurse 5) 
 
5.3.3.2 The reality of MCA initiation and use 
 
This sub-theme describes the lack of assessment and consent gained from patients before 
MCA initiation, and the nurses detailed the disadvantages of MCAs generally and in specific 
patient groups. The impact of patients not having clinical medication reviews, or the GP 
receiving information regarding adherence from the home on a frequent basis are touched 
upon. 
 
CHS nurses said there was a lack of assessment and medication review when MCAs were 
started. They did these themselves, but the view was that they were the only ones who did. 
 
“There's a phone call to the GP, “Your patient is not taking tablets, oh let’s put a blister 
packs in place, nobody knows if the patient is suitable for a blister pack, but let's just do 
it”. And the patient continues to not take drugs…then my phone call is always, “Why is 
your patient on all these drugs? If he hasn't taken for six months and they're still 
living?....” (CHS nurse 3) 
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Patients rarely consented to MCAs and cases where the patient did not want an MCA were 
described, impacting on the patient’s independence and ability to make decisions about their 
own health. The nurses felt that there was a need for more information to be given to the 
patient at initiation, and general information about medicines was lacking (e.g. lack of PIL 
supply, or no descriptions of tablets issued with the box). 
 
“It's sometimes automatically done without really the patient having a full knowledge 
of why it's being done. They just get this care package, they get a blister pack and then 
someone helps them or gives them.” (CHS nurse 1) 
 
“…this patient was definitely, “No, no, no. I like my boxes, I know what I’m taking”…She 
hasn’t been referred back, so I’m sure she’s fine, but it was really interesting. There is 
some people that want their boxes and they don’t want anything else.” (CHS nurse 3) 
 
The CHS nurses were aware that MCAs were not the only answer with respect to adherence, 
and an MCA being in place offered them no assurance that the patient was taking their 
medicine correctly; this could not be said for the other HCPs they liaised with. 
 
“People give people a blister pack, because they think it’s the easiest thing and don’t 
really think about whether this is suitable for that patient. It’s like a first response to 
someone not taking the tablets properly is give them a blister pack.” (CHS nurse 4) 
  
“Who says because they have blister pack that they've taken it?...I've been to a 
patient…on blisters and all of them half used, there's none of them was empty, none of 
them was fully used…"What happened to this?" "I used it." Because there's a lot of 
confusion so you don't even know which one he's using.” (CHS nurse 2) 
 
“…for example they don't like the Calcichew -- they will take it out and it will be stacked 
up in another ashtray or bowl or something…if it's blistered, you'd think that the 
patient's been taking it, and yet they're not.” (CHS nurse 6) 
 
The CHS nurses thought that patients had to want to take their medicines, whether there was 
a compliance aid or not; patients still forgot to take their MCA and non-MCA medicines or 
chose not to take them. 
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“Some of them they just chuck it…you will see in the bin, you will see everywhere…If 
they don't want to take their medicine, if you give them a blister pack they don't want 
take it, they won't take it.” (CHS nurse 2) 
 
 “The thing with the blister pack is, yes, it’s a good device as in organizing your tablets. 
But it doesn't remind you to take them.” (CHS nurse 5) 
  
The CHS nurses described cases where patients were not suitable for MCAs, but there were 
also many instances where they had been an advantage as medicines were co-located and 
they were generally easy to use for self-managing patients. 
 
“The advantages for some patients is they will have all their medicine dish out, they 
don't have to be popping, opening boxes and looking for this and looking for that, they 
can have everything in one place and they can have it at the same time.” (CHS nurse 2) 
 
“What I do like about it is – the blister packs – is the tablets all in one place, in this 
pack. Whereas otherwise you will have different boxes of meds and then they could be 
all over or not in one central place.” (CHS nurse 6) 
 
Identification of tablets is difficult with MCAs because there was no description supplied, or if 
it was supplied it was not understood. This was a problem for both patient and carer 
administration from MCAs. 
 
“It's not easy to identify what the tablet actually is. So in a sense you're taking that 
control away from the patient…you can't always go by looking at it. Different 
companies will do different colours so it's almost impossible to know exactly what it is.” 
(CHS nurse 1) 
 
“…in terms of getting you knowledge about your medications, and also being able to 
identify, “Ok, I've done my blood sugar today, I know what it's like, actually I’m going 
to choose not to take Glicazide.” What if you can't identify it?…I think you lose 
knowledge and control of your medications in a way with blister packs.” (CHS nurse 5) 
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The CHS nurses talked of occasions where medicines were excluded from the MCA because 
they were not yet part of the repeat medicine list, and there was a period of time where the 
patient had to cope with this before the next cycle of MCAs incorporated the new medicine. 
 
“Sometimes they’ve got blister pack, because it’s just been initiated. They won’t put the 
[e.g.] thyroxine in, and say he’s got to wait until the next one. So you got to have it 
outside the blister pack and then it just never gets handed over to the chemist to put it 
in the next one. That just carries on.” (CHS nurse 4) 
 
With respect to safety, the CHS nurses' experiences focussed on delivery issues, patient 
inability to use the MCA, carer reluctance to administer medicines outside of the MCA and 
carer administration of complex, variable dose medication. Safety issues with incomplete 
medicines reconciliation and potential double- or over-dosing were also discussed. 
 
“I’ve seen a few of those, actually, where they just took the whole thing. Also it’s very 
common that they deliver a four weeks’ supply, and I find that to be very disturbing, 
because you are giving this massive amount of drugs at the same time, you don’t know 
what the patients are going to do with it.” (CHS nurse 3) 
 
“Sometimes people can’t see very well, so they’re not good for them and then suppose 
if they couldn’t read, it’s a bit difficult knowing breakfast, lunch, evening meal and you 
remember it.” (CHS nurse 4) 
 
 “…you see patients that put their finger through them and there’s some still under the 
seal.” (CHS nurse 5)  
 
5.3.3.3 Benefits of clinical medication review and continuous monitoring 
 
This theme describes the benefit of clinical medication review, continuous review of clinical 
appropriateness and adherence, and follow-up of patients, all within the context of insufficient 
capacity. 
 
GPs did not do clinical medication reviews frequently enough, and this deficiency of 
assessment along with a knee-jerk use of MCAs was the root of many of the medicines 
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management problems apparent in patients’ homes. Often GPs did not understand the social 
situation of their patients, were too busy and their practice therefore restricted to problem-
solving and reacting when problems were escalated to them. Routine review and prospectively 
preventing medicines management problems in this patient group was not within the capacity 
of GPs. 
 
“We find that most of the time when patients are admitted in the hospital, that's when 
the medication is reviewed…I know the GPs are busy but medicines are not reviewed in 
a timely manner for loads of patients…when you're concerned and you just call the 
GP…then they review it.” (CHS nurse 2) 
 
“I think it was on the first initial intent of making them take the drugs, but nobody 
reviews, until we come in. And we take bin bags worth of medication of their house and 
then the GP thinks, ‘Oh, I need to review this medication.’” (CHS nurse 3) 
 
Instances where regimens were altered and manipulated to fit in with social care demands 
were described, suggesting that the clinical review of the need for medication is not prioritised 
over ensuring the patient is given it. 
 
“We try to fit as much as possible in the blister pack, when we get involved…when 
there’s painkillers and things, and they know they are taking it every day, like 
paracetamol, I always call the GP back and say, “Can you put it max three times?” 
…because at least that will ensure that the patient will have at least one dose or two 
doses, whatever visits.” (CHS nurse 3) 
 
“…someone has got a twice-a-day package of care, and then the GP decides to put QDS 
Paracetamol in. They haven't considered who's looking after the blister pack, which is a 
real problem. If somebody will only accept a once-a-day package of care, I'll ring the GP 
and say, "Can we condense them down?”…So you can work around it, but often the GP 
doesn't understand the social situation.” (CHS nurse 5) 
 
The CHS nurses talked of their practice and the need to check if patients could use the MCA, 
plus the monitoring of adherence post-initial assessment; they said that though initially 
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performed in hospital, continued monitoring and medication review were not in place from 
the GP. 
 
 “Because what we do is, when we put a blister pack in, we go in every week. We make 
sure that they understand it. They can pierce, they can use, we do all these checks. That 
is time consuming and nobody else does it.” (CHS nurse 3) 
 
“The thing is with blister packs, they’re so difficult to continuously monitor them. 
Because if somebody gets a UTI, they might have been fine using it before…how do you 
long-term monitor that? That's a real challenge….In terms of whose responsibility it is, I 
couldn't even tell you whose responsibility it is because name anyone that's got the 
resources to actually go do it.” (CHS nurse 5) 
 
There were cases of good practice and services that the CHS nurses had either heard of or 
proposed themselves as future models. Some CHS nurses described working with trust 
pharmacists and pharmacy technicians as being beneficial to them and to patients. Some had 
ideas about what the community pharmacist could do to help. 
 
“I think there should be somebody there that can be going in maybe periodically to 
review medicine for patients and that way compliance too.” (CHS nurse 2) 
 
“We keep finding there’s loads of medication in the house; wouldn’t it be an idea for 
the chemist to be responsible to carry the empty ones away? And that's a way of 
checking whether the patient’s actually taking.” (CHS nurse 6) 
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5.4 Care agency policy review – methodology and results 
 
From the author’s experience, and from some of the content of the interviews with nurses 
(and CHS pharmacists - see Chapter 6), care agency managers and staff often referred back to 
their own policies for reasons why they would not perform particular duties, e.g. instilling eye 
drops or applying patches. Reviewing these polices and analysing the content was therefore 
another method of looking at the carers’ perspective. Interviews also raised further questions 
about the documentation of medicines given and the training that carers received, prompting 
the author to explore the policies of the agencies further. This policy review is included here as 
part of the objective to understand the carer perspective. 
 
There were a number of different ways that policies could have been analysed. There are 
established methodologies for appraising policies and analysing their impact
68
. The author 
decided that these were too in-depth for this analysis, and the spirit of the thesis is not 
generally to enquire about individual care agencies in any depth. Other policy analyses in the 
literature have a purist qualitative approach, with the objective to find out the impact that the 
policy is having, or has had, in the setting it related to, or to otherwise understand the context. 
In the scenario of carers in Lambeth and Southwark, there was a priori knowledge that policies 
were not being used in the context in which they were written, so the objective was not to 
assess the impact of each individual policy. The analytical aims were to find out what is 
included in each policy, what is missing in terms of expected standards covered by each and to 
be able to produce a summary outlining the extent to which policies differ from each other. It 
would be useful to know exactly how they differ as this may be an area where there is 
contention among health care workers and clarification and agreement is required.  
 
Policies were obtained from care agencies via the CHS pharmacists who work at GSTT. The 
author attempted to gain them first by issuing FOI requests to both borough councils (Lambeth 
and Southwark) requesting that they send a list of brokered agencies and a copy of each of 
their policies. One borough sent instead a policy produced by GSTT that covered all of the 
agencies. This policy was analysed along with the others, acting in part as a control; at the time 
the interviews were conducted, all care agencies in Lambeth should have been operating 
under this overarching policy produced by GSTT. The other refused to issue the information 
requested on the basis that it could be obtained directly from each care agency. This is likely to 
be untrue because the agencies are private companies and not subject to the same FOI laws as 
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publicly funded organisations. It was not clear from any of the websites of the agencies how to 
go about requesting a policy. This response is a research finding in itself, demonstrating that 
the borough did not review the policies of the private agencies brokered to take care of people 
with social care needs at the time of brokering. The author obtained the policies instead from 
the CHS pharmacists who had accumulated them in the process of carrying out their roles, and 
these policies were analysed using content analysis. Content analysis is where the text from a 
body of data is compared, contrasted and categorised
68
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Table 5.5 shows the different stages of content analysis that were used. 
 
Table 5.5 – Stages used in the content analysis of care agency policies 
Reading and familiarisation 
Selectively coding entire dataset with the following codes: 
1. Managing refusal to take medicines 
2. Defining the level of support and assessing this in the patient 
3. Medication that can and cannot be given 
4. Documenting administration and maintaining other records 
5. Medication training and competency checks for carers 
Analysis 
Finalising analysis 
 
The first step of analysis was to selectively code the policies. A selective coding strategy was 
employed rather than complete coding. In complete coding, data are analysed and codes 
found and documented whatever they are. In selective coding, the codes being searched in the 
data are predetermined
79
. The author derived the codes from a mixture of the RPS guideline
82
, 
the NICE guideline
83
 and the CQC medicines management advice
6
. The NICE guideline based its 
advice on the RPS guideline. These codes represented what should be included in a policy 
pertaining to the safe handling of medicines in domiciliary care by carers, and represent just 
those areas where the nurses reported inconsistent application or content of policies in their 
interviews. The codes are numbered as shown in Table 5.5. As the policies were coded, the 
author was looking for similarities and differences between the researcher-derived expected 
standards and the policies themselves. Results of the content analysis are shown in Table 5.6 
and are discussed in Section 5.5. 
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Table 5.6 – Results of care agency policy analysis 
Code Description 
1 Managing refusal to take medicines 
 All policies addressed the issue of patients refusing to take medicines, including a 
requirement that the nurse complete some form of documentation, either written in the 
care notes or documented on the MAR.  
 With regard to escalation, some policies signposted the carer to the branch, some to the 
GP. One required the carer to decide how important the medicine was before deciding 
what to do about refusal, i.e. whether to tell the GP or not, inferring the carer had to 
have a clinical understanding of what had been missed. 
2 Defining the level of support and assessing this in the patient 
 All policies defined different levels of support their employed carers could give, and for 
all but one policy this was in line with national recommendations (where 0 means no 
support, level 1 translates to assistance, level 2 translates as administration and level 3 is 
specialist administration like injections). 
 What did differ between polices was what constituted specialist administration; one 
policy put the administration of eye drops in this category and most did not; but all 
mentioned them as something where extra training was required before being given. 
3 Medication that can and cannot be given 
 One policy put eye drops and nose drops in the category of “specialist administration”; 
so the carer could refuse to give them if they felt it was outside of their competence. 
 Some policies said carers could only give eye and ear drops after special instruction from 
a HCP or qualified person, without stating what was meant by a qualified person. Other 
policies did not make any reference to special circumstances under which eye or ear 
drops should be administered. 
 One policy excluded giving crushed tablets, one only allowed this if the pharmacist had 
said this was satisfactory and their name documented in the care notes, and the rest did 
not mention crushing tablets at all. 
 No policy precluded the administration of patches by carers, and no policies said that 
carers could only assist with or administer medicines if they were packaged in an MCA. 
4 Documenting administration and maintaining other records 
 No policy said that individual medicines had to be recorded by name for level 1 support. 
 All policies said that when medicines were administered (levels 2 and 3), the medicines 
should be documented on a MAR; none drew any distinction between the records kept 
depending on the presence or absence of an MCA. 
5 Medication training and competency checks for carers 
 All policies mentioned the need for both training and competency checks before carers 
could assist with or administer medicines. 
 Some policies included lots of detail about what medication training should entail. 
 Some agencies required repeat training every two years, some every three years and 
one made no mention of updating training after initial training. 
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5.5 Discussion 
 
There were many examples of communication breakdowns and the negative impact that these 
had on patient care, within and across organisations. One example of this was that medicines 
reconciliation in secondary care was not adequate according to the nurses, with medicines 
started sometimes without confirming or considering what existing medicines were taken by 
the patient or their social situation. Duplication of tasks between the NHS and social care, 
delays in transfer from NHS to social care and frustrations around the lack of feedback to the 
GP (from the community pharmacist, the carers and anybody else who was aware that the 
patient was not taking their medicines properly) were apparent. None of these issues were 
remedied by the use of MCAs, and delays in transfer were actually caused by an insistence on 
them. The nurses, and ultimately the patients they looked after, had experienced wide 
variation between care agencies practices, carers, and between community pharmacists in 
terms of the extent and quality of services they provided. These variations impacted negatively 
on the working lives of the nurses interviewed. 
 
Further research into community pharmacy service variation would be useful to help shape 
patient-centred services in the future. In the patient interviews (Chapter 4), patients benefited 
from having close involvement of the community pharmacist in the ordering and supply of the 
MCAs; the results of the CHS nurses interviews show somewhat contrarily that the nature of 
MCA delivery may have a detrimental effect on patient safety. Whether the delivery problems 
described ultimately negate the benefits of community pharmacist involvement felt by the 
patient is unknown; it may be that delivery problems described were only apparent in an MCA 
population not studied here, e.g. dementia patients. A quantitative approach, using short, 
structured telephone interviews of community pharmacists, would be a one way of uncovering 
practices of individual community pharmacies with regard to MCA delivery. 
 
The nurses believed the NHS took medication more seriously than social care, prioritising 
correct administration and documentation higher than social care professionals. Despite carers 
finding the use of MCAs quicker and easier, general feeling among the nurses was that proper 
medication administration took much more time than the social workers, carers and agencies 
allowed. Following years of professional training and practice, the nurses were able to 
appreciate the importance of documentation, labelling (i.e. knowing what is being given) and 
taking time to do this properly. The nurses found comfort in knowing what they administered, 
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understanding the implications. They did not believe carers had this focus, though standards 
carers had to comply with, including maintaining an administration audit trail, were the same. 
 
CHS nurses were unsure of the contents of carer training, doubting that it even happened. 
Carers used what the nurses considered to be inadequate approaches to reconciling 
medication compared to them, with the GP records rarely being included in determining a 
drug history. Overall, the nurses empathised with carers as individuals, but frustrations 
regarding the management, the system, waste and the reliance on the NHS to maintain 
standards were apparent.  
 
It was not possible to recruit carers themselves into this study, and this was a limitation. It is 
possible that carers or care agencies would agree to take part to future research of similar 
methodology if there was financial incentive. Despite this limitation, the study has given some 
insight into the initiation of MCAs and the carers involvement in that process via CHS nurses 
accounts. 
 
The use of MCAs for proxy-administration of medicines was described by the nurses in terms 
of a non-ideal scenario, where the carer does not know what they are giving and does not 
document what has been given appropriately. It was unclear before this study what the 
process was for MCA initiation, and how it became necessary to use MCAs for reasons other 
than self-administration. 
 
Any future research into the use of MCAs for proxy-administration of medicines by carers 
should include social workers. Both quantitative and qualitative methodologies would be 
appropriate, the first in the form of a questionnaire to assess their knowledge of medication; 
this is because social workers are entrenched in the MCA initiation process and their 
understanding of the law, medicines administration and potential patient safety issues that 
could arise from MCA use are unknown. A qualitative approach would be able to capture the 
motives that social workers have for engineering the scenarios described in this study - where 
MCAs have become essential - and individual interviews or focus groups could be used to 
uncover the perspective of the social workers. 
 
The care agency policy review explained to some extent the reports that nurses gave of carers 
refusing to administer non-oral medicines like eye-drops and patches. The insistence on an 
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MCA before accepting a patient, the refusal to give oral medicines that were not in an MCA 
and the apparent lack of training that nurses suspected was not explained by policy. At the 
time of the interviews being conducted, all agencies in one borough were supposed to be 
following one policy, that devised by the CHS pharmacists working at GSTT; the interviews 
revealed that agencies were sticking to their own policies still. Having a policy that covers all 
agencies could eliminate the variation seen across different agencies so those patients in the 
boroughs get an equivalent service despite the agency that employs their carer, but only if the 
same policy is followed and is used to train all carers. A pharmacist inputting into the brokering 
process would be important in ensuring that non-clinical managers in social care in charge of 
the brokering process are reviewing and insisting upon levels of service that are to an 
appropriate standard. This approach has been used by other boroughs in order to ensure a 
consistent service at acceptable standards. 
 
CHS nurses spoke with certainty about the benefits of medication review in terms of reduction 
in waste, polypharmacy and unnecessary medicines prescribed; the benefits of patients being 
prescribed fewer medicines were reduction in medicines costs, improved adherence and 
easier enablement of self-administration. These benefits were manifested via gaining an 
understanding of the root of why the patient felt they did not need or want to take the 
medicines prescribed. The nurses appreciated that full medication review was time consuming 
and felt that it was only really done thoroughly when the patient was in hospital as an 
inpatient. The presence or absence of the MCA, and the presence or absence of a care 
package, appeared to have no impact on either adherence or the complex medicines 
management difficulties described by the nurses in the interviews. 
 
The CHS nurses drew a distinction between clinical medication review and checking to see how 
able the patient was to take their medicines with or without an MCA. There were some 
instances where they had carried out assessments like these that were not adopted, and 
agency-focussed rather than patient-focussed plans put into place instead with regard to 
giving medicines. There was opinion that a need existed for not just assessing management 
initially but also ongoing support. Nurses stated that it was unusual outside of their own 
practice area to have HCPs actually verify the cause of non-adherence, as there was no initial 
clinical review. MCAs were considered disadvantageous in dementia, and many further 
disadvantages were raised by nurses with respect to tablet identification, medication not in 
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the MCA, and safety issues. All of these disadvantages were apparent with or without carer 
administration. 
 
Communication to the GP from carers was inadequate, and community pharmacists did not 
feed-back to the GP about adherence problems, meaning there was no way of determining 
what has been taken or picking up other safety issues. This lack of feedback to the GP meant 
that, even if they had the resource to address adherence issues in their patients, GPs were 
unaware of those issues until there was an explicit clinical problem. This may be why GPs and 
other HCPs use MCAs so readily in cases of non-adherence, though this cannot be determined 
from the results of the study. Future research could focus on the understanding that GPs have 
about adherence, GP understanding of the tools to help patients improve adherence and 
qualitative enquiry about what the GP sees as their role in improving adherence. Quantitative 
enquiry into capacity within GP surgeries to address non-adherence, including consideration of 
the GP list demographics, would be a good starting point for research that could see a re-
shaping of services around patient need. This could include HCPs other than GPs taking more 
responsibility for adherence assessment and ongoing follow-up of complex caseloads of frail 
elderly patients who struggle to take multiple medicines. 
 
5.6 Conclusion 
 
The findings of the CHS nurse interviews were that communication in a fragmented care 
system is difficult, with interfaces of care and variation in services presenting challenge. 
Equally, the quality of care provided by care agencies is deficient and supporting medicines 
adherence by individual patients is onerous. 
 
In terms of the research question, it may be that pressures such as unreasonable working 
conditions of the carers influence the use of MCAs more than individual beliefs about them. 
Social workers also have influence in the initiation of the devices, and the extent and nature of 
this involvement is not yet fully understood, making this a novel option for future research. It 
is likely that care agencies insist on MCAs because it saves them time and money as a 
substitute for training or enabling more visits per day per employed carer. 
 
Care agencies and social workers organising POCs are likely driving forces behind the initiation 
of MCAs for proxy-administration by care staff. At initiation, there is little resistance from NHS 
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professionals, despite much frustration, as time and resource to correct the problems that 
MCAs mask is simply not there. GPs have a role in MCA initiation, either as the only known 
option to correct adherence problems or as passive providers of weekly prescriptions enabling 
community pharmacist supply for carer proxy-administration, and the GP perspective has yet 
to be explored using quantitative or qualitative approaches. 
 
Medication policies vary across agencies, but their contents are not followed by the carers or 
the agencies unless for retrospective decision making support. More research is needed into 
the training that carers receive: is it sufficient and to what extent does training focus on 
policy? In particular, what is the detail around competency checks and what training records 
are there? In an ideal scenario there would be one policy that all care agencies adhered to that 
was in line with national guidelines, a central requirement of the care agency brokering 
process for care providers to follow, and forming the foundations of training and competency 
checks of the carers. In this way, reliance on MCAs would fall, as would the problems that their 
use in proxy-administration presents. 
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Chapter 6 Interviews with Community Health Services Pharmacists: MCA use in the 
housebound elderly population and elderly care 
 
6.1 Introduction 
 
In this chapter the author presents findings from interviews with pharmacists working in NHS 
community health services (CHS). The term community health service describes provision of 
health care to people in their own homes, and is where non-acute healthcare services, 
including district nursing, reside
73
. The six pharmacists interviewed for this part of this study 
were employed by either Guy’s and St Thomas’ NHS Foundation Trust (GSTT) or Sussex 
Community NHS Foundation Trust (SCT) in roles where they conducted clinical medication 
reviews and assessment of how patients took their medicines, upon referral from other HCPs 
or as part of an MDT decision. 
 
One of the objectives of the author’s research was: 
 To conduct interviews with community health services pharmacists to further 
understand the issue of MCA use. 
 
This chapter presents the views and perspectives of CHS pharmacists, and these are compared 
with the findings of the CHS nurse interviews presented in Chapter 5. 
 
6.2 Methodology 
 
6.2.1 Recruitment 
 
Six CHS pharmacists working for either GSTT (two) or SCT (four) were recruited into the study 
after permission was gained from the research and development departments of each trust; as 
GSTT was the host organisation this authorisation formed part of the approved initial proposal. 
Before interviewing the SCT pharmacists, permission was granted by the Research and 
Development department of SCT in the form of a Letter of Access (Appendix 12).  
 
The GSTT pharmacists were previous colleagues of the author in GSTT CHS; the interviews 
were conducted once the author had left GSTT. The author sent an invite letter, information 
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sheet and consent form (Appendix 13) to both GSTT CHS pharmacists for them to read before 
the interviews were scheduled. 
 
The SCT pharmacists were recruited via the team leader of the CHS pharmacists in the 
organisation; the author sent an invite letter, information sheet and consent form (Appendix 
13) to the team leader via email and was contacted by her with contact details of pharmacists 
who wanted to take part in the study after reading the information sent. 
 
All six pharmacists were contacted individually by email to make arrangements for the 
interviews. Written consent was obtained in person before the interview commenced in every 
case. 
 
6.2.2 Interviews and the topic guide 
 
Interviews took place at a time determined by the CHS pharmacist and in meeting rooms on 
their work premises that were available to them. Interviews were audio-recorded and lasted 
between 35-55 minutes. A topic guide (Appendix 14) was used to guide the interview and 
ensure consistent questioning. 
 
The interview started with questions that allowed the CHS pharmacist to explain where MCAs 
featured in their practice; they were asked if they had ever assessed patients for a MCA and, if 
so, whether this was a standalone activity or part of a broader assessment they carried out. 
They were asked who they thought benefited from a MCA and what other compliance aids 
they recommended; this would lead to greater understanding about the value of MCAs as 
compliance aids. This specialist question related closely to the CHS pharmacist role. 
 
Asking the CHS pharmacists how MCAs were used by care agencies or carers, and the 
prevalence of this, was important; patients reviewed by CHS pharmacists were likely to be 
more complex than those reviewed by the CHS nurses interviewed, having confirmed issues 
with their medicines that prompted the CHS pharmacist’s involvement. This question, and the 
question about which types of housebound patients were more likely to have MCAs, helped to 
determine if there were any specific patient characteristics that meant they were more likely 
to be put onto a MCA. 
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CHS pharmacists’ opinions of carers using MCAs to administer medicines, and the advantages 
and disadvantages of both carer use and of self-administration with MCAs, opened up the 
conversation allowing the CHS pharmacist to discuss their experiences of MCA use. 
 
Remaining questions focussed on the carers’ use of blister packs; why they thought MCAs were 
relied upon and what would happen if withdrawn suddenly. Further questions were asked in 
order to safety issues, errors and problems caused by MCAs use. 
 
6.2.3 Data Analysis 
 
Interview recordings were sent to a specialist company to be transcribed, and the 
transcriptions checked by the author. The author used this transcription checking stage as an 
opportunity to familiarise herself with the data. 
 
The analysis followed a thematic analysis model; further discussion regarding the nature of this 
analysis and data collection is described in Section 5.2.4 in Chapter 5. The analytical stages are 
described in Table 5.2 in Chapter 5 and the analysis is discussed here under headings that 
mirror those stages. 
 
6.2.4 Ethics considerations 
 
Ethical approval for CHS pharmacist interviews was awarded by the Northern Ireland Research 
Ethics sub-committee (HSC REC A) in April 2015. This approval was part of a substantial 
amendment made to the original protocol (obtained November 2013). 
 
6.3 Results 
 
Table 6.1 shows the initial codes that derived from the first stage of the analysis. Table 6.2 
shows how these initial codes were refined during the next phase of the analysis. 
 
Figure 6.1 shows the emergent themes and how they are related. Each of the main themes and 
related sub-themes are described in Sections 6.3.1 to 6.3.3 below. 
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Table 6.1 – Initial codes from CHS pharmacist interviews 
CHS Pharmacist working practices 
Community pharmacy 
BP - assessing need 
Adherence and compliance, including PRN 
Other compliance aids and BPs are automatic 
Full medication review or MUR 
Carers using BPs 
Polypharmacy 
BP disadvantages in SA 
Referral from HCPs and disparity with CHS 
Pharmacist objectives 
Contribution of GPs 
BPs do not make patients take medicines 
BPs used incorrectly 
Inconsistency in care 
Communication across organisations 
HCPs do not understand the complexities of 
BP use 
BPs started inappropriately, difficult to 
reverse 
Carers using BPs is easier or quicker 
Family and medicines 
Care staff not trained 
Lack of communication at discharge 
Waste of money, time or work 
Patient types seen by the CHS pharmacist 
Carers and policy or law 
Expectations of carers (vs HCPs) 
BPs empower the compos mentis patient 
Examples of BP incidents 
Delivery 
Patients who benefit from a BP 
Carers do not give the things remaining 
outside of the BP 
MR can prevent need for BP 
BPs hamper medication changes 
Carers using BPs appropriate in a pressured 
system 
Pharmacy profession and training 
BPs not one size fits all 
Carers administering non-BP meds 
HCPs do not know what pharmacists do 
Medicines put in BP to ensure it is given only 
BPs prevent identification of medicines and 
PIL reading 
Misuse of current workforce 
Medicines and qualification for POCs 
Medicines administration error 
BP brand issues 
BPs are of use in patients with dexterity 
problems 
BPs and changes in regimen 
Limited resources 
Education of care staff is the answer 
Patient need for medicines 
Care agencies paid to do medication but do  
not do it properly 
Carers using BPs means we do not know 
what's being given 
Non-BP medicines and self-administration 
Carers may feel reassured by BP 
BPs not fire and forget 
Ongoing support with medicines after BP 
initiation 
Need to work across health and social care 
Tunnel-visioned workforce 
Randomness of BP user types 
Carers using BPs is not right 
Carer quality and motivation 
BPs in patients happy with their regimen 
Improving adherence 
Carers and original packs 
Dispensing errors 
BP supply and delivery 
BP and prompting vs. admin 
BPs are a last resort 
Very few people suitable for BPs 
Education of HCPs re care staff scope and MR 
Care agencies refusing to administer things 
BPs mean patients can see what they've 
missed 
BPs mean the community pharmacist can 
keep an eye on compliance 
Decision to start BP not the patients own 
Examples of problems caused by carers using 
BPs 
False information 
Scale of DNs having to administer non-BP 
meds 
BP patients do not have to worry about when 
to take etc. 
BPs as a substitute for Medicines 
Reconciliation 
BPs as a method of knowing what was given 
Referrals from social care 
Carers deskilled by BP 
BPs are not for carers they are for patients 
Patient circumstances and suitability change 
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Table 6.1 – Initial codes from CHS pharmacist interviews (continued) 
Preventing BP initiation 
Assessing adherence of non-BP medicines 
BPs can remove control from the patient 
Carers using BPs is unsafe 
BPs generally easy to understand in the 
motivated patient 
BPs cause confusion and rely on cognition 
BPs and stability 
BPs and duplication errors 
Potential future working models 
CHS pharmacists making live changes to 
regimen including BPs 
Variable dose meds including warfarin 
Better to not let carers do some things 
Patients want BPs 
Care agencies think BPs remove liability 
Social services request BPs because they are 
quicker 
Private funding for care 
BPs mean others do not do MR 
Patient education 
Non-oral meds means proper administration 
Reviewing care agencies 
Referring on 
Impact of carer refusal on district nursing 
Seeing original pack is important to some 
Social care request BPs to see if need prompt 
Hoarding 
Social care and other compliance aids 
BPs and incorrect slots, absent advice 
CHS caseload demographic changing 
Table Key: 
BP = Blister pack 
CHS = Community Health Services 
MR = medication review 
PRN = “when required” 
POC = package of care 
MUR = medicines use review 
HCP = health care professional 
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Table 6.2 – Code refinement 
CODE NOTES / REFLECTION 
“Full medication review and MUR” Occur concurrently therefore do not split code. 
“BP supply and delivery” and 
“Delivery” 
Merge. 
“Community pharmacy” Includes perceived over-ordering of non MCA medicines. 
“Adherence and compliance” 
Includes when some patients just do not want to take 
their medicines and have capacity. 
“Education of care staff” 
Split into “Education of care staff” and “Education of 
HCPs”. 
“Carers using BPs” Consider promoting to a theme. 
“BPs – assessment of need” 
All examples of assessment for MCAs include full MR and 
MUR; BP assessment is part of a broader assessment 
carried out by the CHS pharmacist. 
“BPs and changes in regimen” and 
“BPs hamper medication changes” 
Merge – no instances of changes where the BP had not 
hampered the process. 
“CHS pharmacist working 
practices” and “Other compliance 
aids” 
Both codes include techniques that CHS pharmacists use 
to improve adherence that are not strictly compliance 
aids. Consider separating examples out into new code. 
“Carers administering non-BP 
medicines” 
Includes PRN medicines and the use of MAR charts. 
“Carers using BPs is quicker or 
easier” 
Includes some descriptions that this in turn means more 
time can be spent with the patient. Code also includes 
examples of where it may be safer (due to inadequate 
training?) – consider changing to “Carers using BPs is 
quicker safer or easier”. 
“Community pharmacy” 
Includes variation of services and also the advantages of 
increased proximity that MCA patients have with the 
community pharmacist (e.g. re-ordering, synching 
ordering). 
“Polypharmacy” 
Rename as “Polypharmacy, stockpiling and de-
prescribing” to describe data coded more accurately. 
Several disregarded as not salient 
“Reviewing care agencies”, “Social care and other 
compliance aids”, “Referrals from social care”, “Private 
funding for care” and “Hoarding” 
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Figure 6.1 – The three main themes and associated sub-themes from the CHS pharmacist 
interviews (dashed lines denote weaker links between themes and sub-themes than those 
indicated by solid lines) 
 
6.3.1 Pharmaceutical care of the housebound, frail and elderly population 
 
This theme explains the role that the CHS pharmacists had in providing pharmaceutical care to 
patients. The sub-themes are described below in Sections 6.3.1.1 to 6.3.1.3. The theme relates 
to the role of the community pharmacist with respect to the pharmaceutical care of the same 
patient group, and an appreciation of the use of MCAs by carers, and so is linked to others. 
 
6.3.1.1 The CHS pharmacist role 
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The CHS pharmacists all saw housebound, frail and elderly patients as part of their roles, with 
multimorbidity, polypharmacy and complex medication regimens. Many of the patients were 
not able to manage their medication or ADLs. 
 
Patients who qualified for a carer and seen by the CHS pharmacist were so complex that both 
difficulty handling their own medicines and ability to communicate lucidly with their carer 
were inevitable; relying on robust patient or carer-led medicines administration processes in 
these cases was unwise. Patients who could potentially use MCAs themselves would not 
usually be seen by the CHS pharmacists: 
 
“Unfortunately a lot of the patients that have carers, the reason that they have carers 
is because they can't do ADLs…if you can't wash and dress yourself and cook a meal, 
you might not be able to do medicines as well…if they have…only medicines needs, the 
likelihood is they wouldn't have qualified for a care package in the first place.” (CHS 
pharmacist 1) 
 
“with some form of cognitive impairment when they can’t care for themselves but at 
the level when they need that kind of input, they generally need help with washing, 
dressing, cooking and with that comes meds.” (CHS pharmacist 4) 
 
There were implications for the CHS pharmacist service in terms of resolution of complex 
issues and freeing up capacity: 
 
“Most patients you visit and maybe follow up and then you kind of consider you finish 
with them and you take them off your waiting list. I've got a handful that, because of 
the nature of what you're dealing with, they stay on your list forever.” (CHS pharmacist 
4) 
 
CHS pharmacists described complex situations; unused medicines, stockpiling and 
polypharmacy were omnipresent in their day to day roles, and frustrations regarding the waste 
of time and money observed were apparent. All of the CHS pharmacists described carrying out 
medication reviews and medicines use reviews as part of their roles The CHS pharmacists did 
not assess patients as being suitable for a MCA as a standalone activity; this formed part of the 
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larger medication reviews they each performed. The CHS pharmacists were clear about which 
patients they thought would benefit from an MCA, and described a random approach to MCA 
initiation when other HCPs were the initiators. Instances where a medication review had 
prevented the need for a MCA were described, and instances where medication review 
reduced the number of medicines to the point where assistance from the carer was no longer 
necessary: 
 
“I go back to the beginning again and think, "Well, actually are they all on all the things 
they should be on?"…if we simplify their medicines as far as possible and they have 
only got like a morning dose or twice a day dose, then we could actually enable the 
patient to start self-medicating." (CHS pharmacist 6) 
 
The CHS pharmacists used other adherence aids and techniques; sometimes the use of a MCA 
was averted and sometimes recommended. Sometimes the help of family members was a part 
of the adherence plan. Other examples included educating the patient and using common 
sense approaches to fit the patient’s lifestyle: 
 
“I gave her a medicine reminder card and she liked it. We tried it for a week. I went 
back to visit her, she is like, "I can do this. I've got it all arranged. Look, these are the 
boxes, this is what I'm doing so I'm taking." So not rushing into the blister, it was a 
good idea for her.” (CHS pharmacist 6) 
 
“Sometimes they don't need a blister pack. We say, "This is your morning pile and this 
is your afternoon pile." You can do away with the blister pack quite nicely in certain 
patients…It's how I would take them if I had that many medicines.” (CHS pharmacist 3) 
 
One of the key approaches to adherence and regimen simplification used by the CHS 
pharmacists was to reduce the number of medicines that the patient was prescribed. This “de-
prescribing” step was described as the first step in the medication review process, and each 
CHS pharmacist saw it as an important intervention that they made: 
 
“…often when you're going through this with people, people are usually complaining 
about side effects for taking too many medicines. You need to address all of that before 
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you get to whether or not they're now suitable for a blister pack or may benefit from 
one.” (CHS pharmacist 2) 
 
“I think I’ve stopped them as well when patients have had medicine stopped and 
they've gone from like five medicines down to two…and really there was no need, they 
could manage the two medicines from original packets.” (CHS pharmacist 5) 
 
“De-prescribing” was not always easy; one pharmacist described feeling deflated when 
medicines could not be stopped with one complex patient with lots of specialist input: 
 
“I had this lady like with two to three pages of meds and I could de-prescribe one thing. 
She had really bad severe arthritis under the rheumatologist, under the respiratory 
team, she had been under the renal team, she had a cardiologist…I managed to de-
prescribe ferrous fumarate…and that was it…I felt a bit of a failure really, for not 
finding more to stop.” (CHS pharmacist 4) 
 
The CHS pharmacists described cases where their input had improved adherence. MCA use 
was not automatic for CHS pharmacists, though perceived by them as being the first port of 
call for other HCPs. Often, the HCPs requesting an MCA and referring to them was the trigger 
that the CHS pharmacists used to initiate a full medication review, improving adherence in a 
way that was expertly driven and tailored to the individual patient. The general view was that 
the complexities of MCA use were better understood by the CHS pharmacists than other HCPs, 
who referred patients to them without really understanding the depth of clinical input 
required by the CHS pharmacist to problem-solve in these complex cases: 
 
“I often get people referring patients to me and saying, “This patient needs a blister 
pack.”…I then take that as an opportunity to go in and assess everything…sometimes I 
think blister packs wouldn't actually solve the issue and that the issues are a lot more 
far-reaching.” (CHS pharmacist 1) 
 
“I don’t see how it would be very effective…because really the blister pack is around 
improving compliance and adherence, and there are lots of other things which impact 
compliance and adherence.” (CHS pharmacist 2) 
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 “…to me, getting a request for a blister pack often means actually this patient needs 
their medicines reviewed to begin with. So I start at the very beginning rather than 
halfway through thinking, "Let's just organise a blister." Most pharmacists do that. 
That's how you’re trained, isn't it?” (CHS pharmacist 6) 
 
CHS pharmacist 5 had sympathy with other HCPs, and understood the “knee-jerk” reaction to 
adherence issues that meant those HCPs initiated them without proper patient assessment: 
 
”There aren't lots of people like us that are going to patients' houses and spend an 
hour with a patient working exactly what the problem is, why they're not able to 
manage their medicines and therefore finding the right solution…I can understand 
why…the GP says, ‘Okay, well let's start a blister pack’." (CHS pharmacist 5) 
 
Scenarios where the CHS pharmacist had to make quick decisions for the best with regard to 
regimen changes were described, including instances where the MCA was amended by the 
CHS pharmacist as the option to organise a new supply was impractical: 
 
“We go and edit blister packs, because that's the only way to get to them to do it fast 
enough for the patients, because we're working in real-time. There's no other service 
that works in real-time. Everyone else, you refer, and then two or three days later they 
come along and assess you.” (CHS pharmacist 3) 
 
“Where you want to alter the medicines in a kind of acute situation where patient is 
unwell…you would ideally get out the next blister pack as soon as possible with the 
correct medicines in but you might have a few days…until they can actually produce the 
next blister…you are removing things that would put the patient at risk of being 
admitted to hospital.” (CHS pharmacist 6) 
 
6.3.1.2 Appropriate blister pack use for self-administration 
 
The CHS pharmacists thought that on the whole, MCAs were easy to use and understand in the 
motivated patient, but required cognition to ensure correct and safe use: 
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“They're great for people that are really motivated but maybe they have a regime 
that's very time-consuming.” (CHS pharmacist 1)” 
 
“The main thing for me is that they've got to be happy with what they're taking and 
overall in the sense--I know I can't tell you whether that's 5 or 10 medicines but I'm 
generally happy with what I've got, it's working for me and I'm not complaining of any 
side effects.” (CHS pharmacist 2) 
 
In the right circumstances of patients having cognition, being happy with their regimens and 
being already motivated to take their medicines, MCAs could empower patients and promote 
independence. MCA patients were able to see what they had missed and reduce the amount 
of time it took them to take their medicines from all the individual packs, particularly if there 
were dexterity issues or polypharmacy: 
 
“I think blister packs mean that the patient can retain independence. They can be 
empowered to say, “You know what? I'm doing my medicine…I am able to manage it. I 
can see if I've forgotten to take them one day, then I can look back and say today's a 
Tuesday. And actually I should have taken that tablet on Monday night.” You can keep 
on top of all of your compliance.” (CHS pharmacist 1) 
 
“So the ones I can think of that I recommend it for, often people with dexterity 
problems wherein them popping lots of pills out of blister strips. I had a lady with 
arthritis that struggles to do that on with lots of medication.” (CHS pharmacist 4) 
 
“It's really a help for a patient who has multiple medicines, many times a day. They're 
clued up with what they're taking. They know why they take things. And then, it's really 
a case if it's organized nicely for them and makes life easier.” (CHS pharmacist 6) 
 
One issue raised by the CHS pharmacists was that MCAs only helped with the oral medicines 
that went in them; there were cases where this made the use of the MCA pointless (described 
by CHS pharmacist 1 below) and others where the MCA removed some of the burden and still 
helped the patient overall (described by CHS pharmacist 5): 
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“…if you've got 10 medicines and actually four of them can't go in a blister pack…It 
could be that you've got inhalers or patches. Then you've got blister packs…that's 
introducing another way of taking medicines which is going to then confuse you 
further. That's a disadvantage.” (CHS pharmacist 1) 
 
“…If they've got a lot of them PRN meds or inhalers or whatever, then it may or may 
not be appropriate for them to have another system for their oral meds. Sometimes 
that's difficult to tell, and some patients are fine with the two systems or three systems 
or whatever it is, but don't always know until you try.” (CHS pharmacist 5) 
 
Patients, relatives, HCPs, carers and social care professionals wanted MCAs, but there were 
very few patients for whom the CHS pharmacists deemed them suitable. The CHS pharmacists 
commented that they knew which patients would benefit from an MCA, but they saw patients 
already on MCAs inappropriately. MCAs helped in strict, narrow circumstances but potentially 
made things worse outside of those circumstances: 
 
“They can be advantageous in the right setting, it's just that I hardly ever see them 
being used in that way.” (CHS pharmacist 1) 
 
“I haven't found that will be useful for the majority of people I've tried them on…They 
solve some problems, they create some problems and they're not a solution to 
everything…[patients] can make as much of a mess of a blister pack as they can with 
normal tablets in boxes.” (CHS pharmacist 5) 
 
Because cognition is required for their use, the patients who really want MCAs and could use 
them correctly actually probably did not need them in order to be adherent; they are a way of 
organising regimens, not promoting adherence. They could not positively influence the patient 
decision about whether to take a medicine or not, or remind a patient to take them: 
 
“If somebody doesn't want to take their medication, putting it in a blister pack isn't 
going to change that. Because they don't want to take it, doesn't matter where it is.” 
(CHS pharmacist 1) 
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“The people that are wholly appropriate are the people that we don't tend to get asked 
to assess…who know exactly what they're doing, they've just got too much to 
manage.” (CHS pharmacist 3) 
 
MCAs did not remind patients to take their medicines but did help forgetful patients see if they 
had taken them or not: 
 
“People who are forgetful seem to be a big group that we encounter…if you don't 
remember your medicines full stop, you're not going to remember a blister pack but it 
can help to be a visual prompt to remind them whether they have taken.” (CHS 
pharmacist 4) 
 
6.3.1.3 Considerations and cautions for blister pack use in self-administration 
 
The CHS pharmacists reported that there was rarely patient involvement in the decision to 
start an MCA unless they had recommended it as part of their own review: 
 
“I think the majority of the time the patients don't even get involved in the decision. 
Someone else does it. Doesn't ask them about it. I found that some people have even 
refused to have it.” (CHS pharmacist 1) 
 
“I think when a GP makes the decision, I don’t think there’s much discussion or 
consultation around it. It’s very much a question of they have a feeling that the patient 
is not taking their tablets and it is generally elderly as well….almost an automatic 
solution is just to do a blister pack.” (CHS pharmacist 2) 
 
For some CHS pharmacists, there was an assumption that once a MCA was initiated, other 
HCPs would no longer review the medicines and that it was very hard to reverse an MCA once 
initiated: 
 
“Because you know that once they actually have a blister pack in place no one's going 
to review that medication…they're never going to get reviewed again probably until 
they have a problem.” (CHS pharmacist 6) 
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The difficulty with removing a MCA once in place was especially frustrating when it was not 
initiated appropriately and would not have been the CHS pharmacists recommendation; even 
so, there was reluctance to reverse an MCA once initiated and a feeling that this could do 
more harm than good: 
 
 “…it’s been quite hard to take the patient off it. My view generally is if the patient's 
already on it and they’re happy using it, after we’ve gone for the assessment and 
they’re taking the whole thing that they should be taking, then I wouldn’t really push 
that so far.” (CHS pharmacist 2) 
 
“I can’t say that I would particularly spend a lot of time changing it if I'm honest…if 
they weren’t already on it, that's a different situation obviously because that can form 
part my assessment and recommendation. If they're already on it I wouldn’t.” (CHS 
pharmacist 5) 
 
The CHS pharmacists shared many examples of experiences with MCAs, and it was these 
incidents that help shape their approach to assessing patients and deciding on MCA initiation: 
 
“I had one patient who…was popping out the night-time ones and then putting them 
back in.…I think her blister pack got delivered with all the temazepam in it at night…she 
would pop them all out to take the temazepam out. But then, of course, everything else 
got scattered across the carpet.” (CHS pharmacist 6) 
  
“…patients can use blister packs even if they don't know the day of the week, as long as 
they're fairly consecutive…I went to see a patient yesterday who had started Monday's 
drugs because Monday is at the top of the pack. Well, that makes sense to me. You 
start at the top and you just work down, even though it was Tuesday. I can understand 
that.” (CHS pharmacist 6) 
 
CHS pharmacists described the false sense of security that HCPs had when an MCA was in 
place; some had stopped MCAs despite fears expressed by other HCPs: 
 
“Nurses do seem to worry a lot that they don't know what the patient is doing with 
their medicines…district nurses will say, "We don't know if they're actually taking 
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it"…There is a bit of a fear I think, if a blister pack is stopped or if a blister pack isn't 
started....” (CHS pharmacist 5) 
 
“GP's seem to make changes to medication based on the fact that they think somebody 
has taken it and yet it's that communication thing again. Unless they said to the 
pharmacy and spoke to the pharmacy and said, "When is this going in the blister 
pack?" Pharmacy may not even look at the prescription and the change until three 
weeks down the line.” (CHS pharmacist 5) 
 
The stability of medicines in the MCA was a concern of the CHS pharmacists, and there were 
some issues around different brands, with patients using some brands incorrectly in some 
cases and even the pharmacists having difficulty assuring themselves of correct use: 
 
“Also as well a patient's medicines are never going to be as great as they are in the 
manufacturer's own packaging. That's been tested and pharmaceutically-regulated.” 
(CHS pharmacist 1) 
  
“People that have to turn it over to open it and then they're taking the evening ones in 
the morning because it's been flipped over. One of our pharmacists, he had a patient 
that took it….horizontally instead of vertically.” (CHS pharmacist 5) 
 
“I wish there could be a standard blister pack because there are two very different sorts 
of blister pack. There's one that's almost landscape rather than portrait...sometimes, 
I'm bewildered by them. And I think I got 20 years experience….” (CHS pharmacist 6) 
 
The CHS pharmacists had seen duplication errors, where the community pharmacist had 
dispensed more than one pack for a large regimen where the MCA was too small to 
accommodate it, and post-discharge from hospital where MCAs continued to be delivered 
during admission and were taken alongside discharge MCAs. Duplication errors were also 
possible where more than one week of MCAs were delivered together: 
 
“When they go home, they might have-- I don't know, Parkinson's tablets in the blister 
pack and dispensed outside because maybe the discharging pharmacist wasn’t sure 
whether it was in the blister pack…they just thought, “Let me just give it.”.…whoever's 
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doing medicines doesn't necessarily read it all to make sure that it's not a duplication.” 
(CHS pharmacist 1) 
 
“…they weren't really labelled very well. So you had blister pack one and blister pack 
two, but they were delivered for the whole four weeks. So, you have eight blister packs, 
you can see the error that's going to happen here. Instead of blister pack A and B being 
given, blister pack A and A were given…so basically, they received a double dose of A 
and nothing B.” (CHS pharmacist 6) 
 
“If a patient gets delivered it all four weekly packs once a month, they might dip in and 
out of all of them. They might start half of one and then go on to the next one…” (CHS 
pharmacist 5) 
 
Another problem with MCAs was a lack of flexibility - when changes had to be made to the 
regimen with immediate effect, the MCA slowed down this process and led to waste of 
dispensed MCAs; some CHS pharmacists took to amending the MCA themselves (discussed in 
Section 6.3.1.1 above). 
 
Sometimes medicines that should have gone into the pack were left outside due to delays in 
the dispensing pharmacist incorporating them. The inflexibility of MCAs with regard to 
medicine changes, and other disadvantages observed, meant that the CHS pharmacists would 
try to avoid them if possible, or delay them being started to make time to explore other 
solutions: 
 
“I'm more suspicious that they're not appropriate, and I resist them as much as I can.” 
(CHS pharmacist 3) 
 
“There are plenty of patients on our service that are medically unstable. They've got 
postural drops, they're U&Es are deranged and it's the wrong time to initiate putting in 
a blister pack…you don't want to put something in place that is rigid and you can't 
change.” (CHS pharmacist 6) 
 
The CHS pharmacists thought that MCAs were a last resort, with little chance of reversal once 
started: 
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“…patients who say they don't want blister packs and who you can see that if they start 
with blister packs now, they might only be 40 or 50. They're going to end up with blister 
packs for the rest of their lives and it's not fair.…people need to understand that it's 
really, really not appropriate for everyone and it should be more of a last resort…..” 
(CHS pharmacist 3) 
 
“When a patient goes from not having carers and they're already on a blister pack it 
would never get changed. I don't think I've ever seen it got changed to individual boxes. 
You never go back once you've got a blister pack it seems to be you’re on it for life.” 
(CHS pharmacist 5) 
 
Though there were advantages in patients with dexterity problems, MCAs did not always fully 
resolve the difficulties patients had with taking their own medicines and patients sometimes 
risked injury in removing tablets from the packs: 
 
“I think sometimes even with the dexterity problems you may be minimizing, it still can 
be quite hard for them to get them out of the blister packs and people quite creative 
with pens and cups and things to catch…so they don't always solve that problem.” (CHS 
pharmacist 4) 
 
“I don't think the blister pack is particularly helpful for the very elderly person because 
of dexterity required also to remove the things. So you see people with pens and knives 
to try and pierce the thing to take it out and cause injuries doing that.” (CHS 
pharmacist 6) 
 
The CHS pharmacists thought that MCAs had the potential to remove control from the patient, 
manifested by the patient being unable to identify their medicines and access the PILs; CHS 
pharmacists had experienced that for some patients it was important that they saw the 
original pack: 
 
“I think personally that they take away the ability to know what you're taking. They've 
taken a bit of power way. And I think that's a disadvantage.” (CHS pharmacist 1) 
 
198 
 
 “…there are lots of patients that despite acknowledging that this is making life easier 
for them…They don't know now what they're taking. Their cognition is still at that 
stage where it’s still quite good and they realize that they can't recognize what’s in 
there.” (CHS pharmacist 2) 
 
“There's some difficulty sometimes with identifying their tablets….It's just one step 
removing them from control of what they want to do…I don't think they quite always 
understand that by handing over the responsibility for that, they've actually lost control 
over that area of their lives.” (CHS pharmacist 3) 
 
6.3.2 Fragmented health and social care 
 
This theme explains the difficulty experienced or observed by the CHS pharmacists with 
communication across different care interfaces. Examples included communication at hospital 
discharge, lack of communication to care stakeholders about medication changes and delayed 
escalation of issues to GPs and community pharmacists. Variations in services provided by 
different contractors of the same type were also described under this theme; this un-
coordinated approach meant different care pathways for individual patients. Community 
pharmacists are discussed separately with respect to the part they played in the fragmented 
system, communication issues and variation in pharmacy services. 
 
The sub-themes are described below in Sections 6.3.2.1 to 6.3.2.3. 
 
6.3.2.1 Community pharmacy role 
 
The main interaction that CHS pharmacists had, and so their experiences with the community 
pharmacist role, was in the ordering, supply and delivery of medicines. Some CHS pharmacists 
also mentioned the role of the delivery driver: 
 
“...the delivery driver may refer them on to the pharmacist, that they’re to call the 
pharmacist if they were questioning what was in the package...” (CHS pharmacist 2) 
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“The drivers have noticed and will report back to the pharmacist issues. Often, a few of 
the referrals I've got have been “the drivers noticed this that and the other.” (CHS 
pharmacist 5) 
 
CHS pharmacists had seen some delivery errors, including patients being given the wrong 
packs. There were concerns about dispensing errors, though concerns were more theoretical 
than actual as the rate of error observed was very low: 
 
“The more steps you introduce into something, the more likely that you’ll introduce an 
error…There are a certain number of errors when you’re dispensing normal medicines, 
how can you possibly not have any errors when you’re dispensing blister packs?.” (CHS 
pharmacist 2) 
 
“I think it's very hard to make sure a blister pack's perfect when it's got huge amounts 
in…had one two or three weeks ago, where the clopidogrel was in the blister pack…the 
label had been missed off. I was like, "…I can see it, it's there."…I haven’t had any awful 
ones, but I do know that they happen.” (CHS pharmacist 3) 
 
The CHS pharmacists gave some examples of where they enlisted the support of community 
pharmacists in the ongoing management of patients, with continuing monitoring of adherence 
by looking at packs or creating reminder charts. Community pharmacists also created MAR 
charts, which theoretically was the responsibility of the care agency, but was something that 
neither the carers nor the CHS pharmacists had capacity to do. The CHS pharmacists found the 
increased proximity afforded for their housebound patients very valuable, though frustrations 
remained regarding over-ordering of non-MCA medicines, FP10 frequency and waste: 
 
“I think it's generally the rule that if it's prescribed monthly, they get it monthly, if it's 
prescribed weekly, they get it weekly…what I do find is massive amounts of surplus 
medicines, because the pharmacy will reorder all the PRNs at the same time…going to 
someone's house, and there's 1,000 paracetamol, or six Spirivas…they'll order a 
Ventolin a month and so you'll see them all piled up.” (CHS pharmacist 3) 
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Community pharmacists, it was reported, would sometimes flout concerns about stability in 
order to ensure patients had their medicines by putting certain unsuitable medicines in the 
MCA and sometimes at the request of the carers, presenting a paradoxical situation: 
 
“….sometimes the carers ask them to. You've got people that don't know about 
medication instructing people that do know about medication or how to dispense 
it…they know that if it's not in a blister pack, it doesn't get taken…aspirin especially… 
they know they're not going to get it otherwise.” (CHS pharmacist 1) 
 
There was some opinion that more could be done to incorporate the community pharmacist 
into ongoing compliance checks by reviewing returned MCAs or reviewing housebound 
patients after MCAs are started: 
 
“There's been plenty of times where I've been to see a patient and the pharmacy has no 
idea they're not managing their medicines. Because they're just sending the blister 
packs out. Again, there's not the contact because they're housebound or whatever” 
(CHS pharmacist 5) 
 
“wouldn't it be great if they were going back to community pharmacy for a level of 
monitoring? They don't, so once they’re delivered, that's it, you have no way of 
knowing what was going on within that house.” (CHS pharmacist 4) 
 
6.3.2.2 Communication across organisations 
 
The CHS pharmacists all mentioned the lack of communication at discharge as being an 
important problem encountered. The lack of communication to parties including the 
community pharmacist and the care agency led to delays in care, increased work for 
community pharmacies and safety breeches: 
 
“There have been numerous occasions I've had to e-mail [the community pharmacy] a 
discharge summary and write a quick summary of what they need to do in addition to 
what they were doing before. Because on discharge the hospitals don't communicate 
with them.” (CHS pharmacist 1) 
 
201 
 
“Often, the care agency don’t seem to know until the patient comes home with the bag 
and then they're expected to suddenly write it all up.” (CHS pharmacist 5) 
 
The CHS pharmacists cited the lack of awareness that the patient had been admitted to 
hospital (inpatient or A&E) as another issue, often causing waste as MCAs were dispensed and 
delivered unnecessarily, and contained incorrect regimens as changes from the hospital were 
not incorporated: 
 
 “They'd fallen and the A&E had stopped the Amlodipine and I think it was Furosemide, 
but he fell again two days later because it was in his blister pack. No one had thought 
that his blister pack needs are changing because he'd flipped in and out of A&E, so he 
hadn't been admitted, so he hadn't seen a pharmacist.” (CHS pharmacist 3) 
 
“So the patient's discharged from hospital with a new pack kindly provided by the 
hospital. They go back home. All their blister packs are stacked up there for the next 
four weeks…The carers once they finish that blister pack just carry on using the old 
blister packs…I think it's compounded with blister packs because carers will often think, 
"It's there, it's all been done." It looks official.” (CHS pharmacist 6) 
 
There were concerns about MCAs being used as a method of determining a patient’s drug 
history, when the MCA could not be relied upon to reflect how adherent a patient was with 
their medicines and rarely contained an entire regimen once short courses, PRN medicines and 
other non-MCA medicines were taken into consideration: 
 
“The problem that you have the things outside of the blister pack. You take your blister 
pack into hospital, you don't take everything perhaps…people assume that’s all your 
medicines.” (CHS pharmacist 6) 
 
6.3.2.3 Inconsistency in services 
 
The CHS pharmacists described scenarios where they had encountered variation in the services 
provided by different community pharmacists, the services provided by different care agencies 
and different approaches of GPs, hospitals and other HCPs. Having to navigate the uncertain 
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quality or consistency of patient care in individual patients was part of their role in tailoring 
recommendations to the individual patients they saw: 
 
I know acute trusts are quite good at…making sure pharmacist is made aware of any 
changes but that doesn’t always happen. That just happens on the basis of the 
pharmacists in the acute trust picking up on and doing something probably outside 
what they would normally do, so that’s an issue around that in terms of safety.” (CHS 
pharmacist 2) 
 
“GPs prefer four-weekly because obviously, that's a four-weekly script rather than a 
weekly one. Some chemists will only do weekly ones because of, obviously, money… 
there is a variation in that but it's not all patient-centred.” (CHS pharmacist 6) 
 
CHS pharmacists had also observed variation in the quality and motivation of carers: 
 
“…there just are occasions where I think that's not quite going as I thought, But then 
there’s other times when the carers have flagged up problems really well…They've got 
concerns because there is a big stockpile or something untoward is happening and it’s 
come back to the GP to us…there do seem to be excellent carers.” (CHS pharmacist 4) 
 
“Some care agencies really do try hard to give people the same faces and others not so 
much. Just like everything, good carers, bad…What they’re actually being asked to do, 
is task. The carer who really, really wants to do their job doesn’t just do that task, do 
they?” (CHS pharmacist 3) 
 
There were cases described where the workforce in community from both health and social 
care had to work in a very task-based, focussed way where the patient was not viewed 
holistically. This was because each service was under so much pressure and just had time to do 
the bare minimum that was within their remit: 
 
“Because you've got people…for years. Just having insulin. And actually they might 
have another two tablets, but the DNs won't do it. Because they're there just to do 
insulin. I've seen this…where people just want to stay in their own lane. They don't look 
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at – ‘Actually…I could do X, Y and Z. -- I could just do the tablets while I'm here’.” (CHS 
pharmacist 1) 
 
“Unfortunately, it's because of the workload I think -- the community nurses, they're 
given a list of patients and they've got to get around them. So they're not going to 
spend longer. When healthcare professionals go in to see a patient, they're not looking 
at the whole patient. The thing that they need to do... "I've got to just give a fragmin  
injection," they're just doing that.” (CHS pharmacist 6) 
 
There were examples of where the current workforce was misused, and some descriptions 
were linked to the changes that could possibly be put in place to make better use of the time 
HCPs had: 
 
”…often…they just want you to make the environment safe. I don’t think that’s 
necessarily the best use of an 8a’s time but, but safety wise, actually I do want to take 
that stuff away. I know this lady I’m seeing at lunchtime, will take that clopidogrel 
that's also now in the blister pack, given half the chance. And actually I want to make 
sure that's done safely.” (CHS pharmacist 4) 
 
6.3.3 Carers using blister packs is not right 
 
This theme explains the awareness that CHS pharmacists had of problems with carers using 
MCAs. The theme also describes that, even though the CHS pharmacists were aware carers 
using MCAs was not right, there were occasions where it was an unavoidable step; the 
alternative of carers administering from original labelled manufacturers’ packs had 
disadvantages from a patient safety or visit quality perspective. Lots of patients seen by the 
CHS pharmacists had MCAs and also had a carer, and it was difficult to pick apart which came 
first - the MCA or the carer - rendering reversal of initiated MCAs near impossible. The CHS 
pharmacists discussed how carer MCA use was beneficial exclusively within the context of the 
fragmented care system, being sometimes necessary in the non-ideal care provision scenarios 
they were familiar with. In this way, this theme is linked to the “fragmented health and social 
care” theme described above in Section 6.3.2. 
 
The sub-themes are described below in Sections 6.3.3.1 and 6.3.3.2. 
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6.3.3.1 The problems with carers using blister packs 
 
MCA use by carers was well established, usually in place before the CHS pharmacist was 
involved though sometimes requested prospectively by carers and agencies. The CHS 
pharmacists were aware that MCAs were not intended for use by carers but by patients; some 
felt this was how it should have stayed: 
 
“They're there to empower people; I don't think they empower carers in the same 
way.” (CHS pharmacist 1) 
 
“Do get asked quite a lot by care agencies….- We've had a patient come on to our 
books, they need a blister pack because we're giving them the medicines, so that's not 
necessarily appropriate because obviously that's been a blister pack for the carer and 
not necessarily for the patient.” (CHS pharmacist 5) 
 
“A lot of our carers will come up to us and say, "This patient needs a blister pack." 
What they really mean is, "This would be much easier for us to give if their medicines 
were in a blister pack.” I don't think it's just the agency. I think it's the carers, (CHS 
pharmacist 6) 
 
For some CHS pharmacists, being asked to organise MCAs was a standard part of setting up a 
POC, and there were no strong feelings about carers using MCAs: 
 
“Personally, I think that it's not necessarily a problem if we're doing it for the carer if 
that then helps the patient.” (CHS pharmacist 5) 
 
There were some frustrations around care agencies being paid to administer medicines, but 
that in reality, this did not happen and costs were picked up by the NHS: 
 
“They'll be going in to do everything that's in the blister pack, but they won't do the 
Buprenorphine patch, they won't do the eye drops. We'll simply have patients on our 
books that we're going in once or every day…even though the carer is going in. That 
causes quite a lot of unnecessary work.” (CHS pharmacist 2) 
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“Some of them are willing to listen to your suggestions but at the end of the day they 
don't have to do anything about it and if they decide they're not going to give the 
medicine unless it’s in a blister pack that's what they've decided.” (CHS pharmacist 5) 
 
“…I think if agencies are going to take on medication and get paid for it, they need to 
do it properly. And they're not doing it properly.” (CHS pharmacist 1) 
 
The CHS pharmacists did not see the problems with administration as being the fault of 
individual carers, rather a system problem: 
 
“…with the low money they get paid. I don't even know if it's ethical or fair to make 
them more responsible than they already are for medicines. It's a tough one.” (CHS 
pharmacist 1) 
 
There were examples described where carers using MCAs had led to medication errors and 
other incidents where medicines outside of the MCA were omitted. Missed non-oral 
medicines, PRN medicines and short courses outside of the MCA were a safety concern, and it 
was difficult to see what had been administered when an MCA was used by the carer: 
 
“Whenever I know that carers are involved…with the short courses of steroids or 
antibiotics, I will always ring up and just make sure they are actually going to give it. 
And that they're aware that they're supposed to do it.” (CHS pharmacist 1) 
 
“…you found that patient, on occasion, is having diarrhoea. You speak to the 
pharmacist and say “look this patient doesn’t actually need it in a blister pack, can you 
just leave it out as a PRN” but the flipside of that is then, you go back in…you find that 
actually patient’s constipated because the carers are not actually even asking.” (CHS 
pharmacist 2) 
 
CHS pharmacists reported false information was communicated within community nursing 
teams about the extent of what carers could administer, with a belief that non-MCA medicines 
had to be given by nurses. CHS pharmacists described their efforts to push that work back to 
the carers or care agency for the good of their NHS colleagues: 
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“For me it's about educating the district nurses and saying, “If you've got someone on 
eye drops, you don't need to see them if they've got carers that are going in. Actually 
the carers could do that.” But some people don't know what the carers can or can't 
do.” (CHS pharmacist 1) 
 
“Sometimes I'll be in the district nurses office and they'll talk about how they're going 
to see this patient to put their patch on it. You start exploring it and they'll say, "Well, 
the care agency said they won't do it." You speak to the care agency and say, ‘Why 
aren't you able to do it?’.” (CHS pharmacist 5) 
 
Care agency refusal to administer non-MCA medicines had an impact on the CHS nursing 
workload; One CHS pharmacist tried to quantify the scope of this impact: 
 
“I think I can remember…off the top of my head…one of the teams, had about 90 
something patients on that team's case load. 42 of them I think were medicines related 
patients…insulin, lidocaine [patches] or the rest of it. Out of these 40 odd just under 30, 
so 28, 29, we were going in for non insulin so either tablets, patches or eye 
drops…where they also had a carer going in at least twice a day. It's quite a significant 
bunch of people.” (CHS pharmacist 2) 
 
Sometimes carer insistence on MCAs was due to care agency policy; sometimes the policy was 
questioned and found they did not mention MCAs: 
 
“The staff and the care managers always think it has to be in a blister pack…it's only 
when you challenge it and then they go back to their policies, that they realise it 
doesn't...I've had many conversations with care agencies and I've said, “If everything 
has to be in a blister pack, where does that leave inhalers…patches…sachets?”” (CHS 
pharmacist 1) 
 
“…quite often it's written into their policies, and so if you want care, you've got no 
choice but to put a blister pack in.” (CHS pharmacist 3) 
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Insistence on MCAs stemmed from belief amongst the carers that the MCAs removed liability 
in cases of error; a false sense of reassurance was therefore found with their use: 
 
“There's lots of misconceptions. “If it's wrong, it's not down to me.”…“I can't give it 
unless it's in a blister pack. I'm not allowed.”…they think that once it's in there, they're 
allowed…that's just not the case.” (CHS pharmacist 1) 
 
“They don’t like the responsibility. They think they can’t get it wrong.” (CHS pharmacist 
3) 
 
Some CHS pharmacists mentioned the difference between “prompting” and “administering” – 
old fashioned descriptors of the level of intervention made by a carer in the medication taking 
process – and that the MCA may be masking what was “administering”, so that it looked like 
“prompting”. When assistance with non-oral medicines were called for, this was felt to be 
administering medicine; one further reason why carers may have been refusing to help with 
those. There is no doubting that putting a patch on a patient is proper administration, for 
example: 
 
“…if it is in a blister pack, they tend to think that they can get away with saying that we 
are just prompting the patient…their staff don't necessarily have to be trained to 
administer medicines…particularly around things like patches and eye-drops; they see 
that more as administering….then you are not providing the appropriately trained 
member of staff for that patient’s needs.” (CHS pharmacist 2) 
 
“There's an unwritten rule that if the patient's just got a blister pack, then you can say 
that you're prompting them, and that absolves all responsibility. I don't really buy it, 
because I said, “If there's a piece of plastic in the blister, would you give it to the 
patient? “ “(CHS pharmacist 3) 
 
Another disadvantage of carers using MCAs for proxy-administration was they became 
deskilled with regard to administering medicines, including identifying potentially harmful side 
effects, and this had negative consequences for the patient: 
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“…because it just means that the carers don't have to think about what they're doing. 
And I don't think that that's right. I would never give a medication to a child or 
someone who was in my care, without knowing what I was doing. But with carers, I 
think they think, “The pharmacy's done it, it must be correct.” And then they stop 
thinking about it” (CHS pharmacist 1) 
 
“I think it probably deskills a carer to use a blister pack. If actually it stops them 
thinking about…the medicines this patient is receiving” (CHS pharmacist 6) 
 
Education of carers was cited as the answer in resolving medication administration issues, 
whether from an MCA or otherwise: 
 
“It seems like the root of that would be better medicines training for carers. In terms of 
giving medicines, better systems of creating MAR charts…often it's the care manager 
that comes in and just picks up medicines and says, "Right that's what they're on," and 
nobody knows if that's actually what the GP has prescribed…I can't see that even now 
10 years down the line from when I started, that's any different.” (CHS pharmacist 5) 
 
6.3.3.2 Carers using blister packs is better than the alternative in the current situation 
 
CHS pharmacists appreciated that carers were working in a pressured system and that in some 
circumstances it may be appropriate for them to use the MCAs, even though it was not what 
they were designed for. There were limited resources, and the reality of situations rather than 
ideal situations called for the MCAs to be misused for patient benefit: 
 
“I'm sure most carers could cope [without MCAs] but they'd need to have an 
alternative really, MAR charts.” (CHS pharmacist 3) 
 
“….It’s more money obviously to put these blister packs in place, but it’s obviously 
cheaper for care calls and I think putting them in blister packs isn't a bad solution to 
enable the carers to safely administer…to make that budget stretch.” (CHS pharmacist 
4) 
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Because carers and agencies refused to administer non-MCA medicines, or sometimes because 
of visit timing or uncertain carer competency, the CHS pharmacists would go to great lengths 
to get certain items into the MCA that they knew would otherwise be missed, including 
ignoring stability issues or altering regimen frequencies: 
 
“It's common to come across where the blister pack is being given beautifully, but 
anything outside the blister pack isn't…even if something's not stable, then if that 
happens…it needs to still go in the blister pack.” (CHS pharmacist 3) 
 
“…social work, they quite often refer to us because they want to get the care calls 
down…getting the medicines down to clear times of day, so that they don't get twice a 
day schedules.” (CHS pharmacist 3) 
 
Sometimes it was not possible or safe to arrange for everything to go into the MCA at a 
suitable time: 
 
“I had this lady who…we tried to set up painkillers for…she did have carers four times a 
day and a blister pack but they weren't coming 4-hourly. We couldn’t put the 
paracetamol in the blister pack because the calls were so varied, despite then agreeing 
to come 4-hourly sometimes it became 2-hourly.” (CHS pharmacist 4) 
 
Care staff were not trained adequately, at all, or to known national standards according to the 
CHS pharmacists. There was some sympathy with the carers and agencies as the expectation 
that others had about their ability to complete the complex task of administering medicines 
was sometimes unreasonable: 
 
“It's different to a nurse administering, having seen even nurses administer in a 
hospital setting you know the best will in the world is not always straightforward, is 
it?” (CHS pharmacist 4) 
 
“But now carers are not trained as a nurse is. To expect them to be able to follow MAR 
charts well and administer everything not to leave things out…It's difficult for them to 
do.” (CHS pharmacist 6) 
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The CHS pharmacists doubted the quality of carer training so much that they thought it was 
sometimes better to allow MCA use as this would at least make sure it was given safely and 
reduce carer anxiety; the ideal situation of carers using original packs was unrealistic, 
unattainable and MCA use was likely to lead to fewer administration errors than administering 
from original boxes: 
 
“The community pharmacy will at least take that level of care to make sure that the 
right things are in the right holes…you just see big messes made when carers are giving 
medicines from boxes with no instructions…Carers giving blister packs is a necessary 
evil, I think, in the current situation.” (CHS pharmacist 3) 
 
“Seeing what carers have to do with limited amount of time…how easy it is to get 
things wrong…It gets lost in translation completely; sometimes I think it's safer really.” 
(CHS pharmacist 4) 
 
Sometimes it was appropriate to prevent carers becoming involved in the administration 
process; all CHS pharmacists mentioned experiences they had with proxy-administration of 
warfarin and the problems that the variable dosage presented. There were differing 
approaches to dealing with this complicated administration, with one pharmacist proposing a 
therapeutic change to an novel oral anticoagulant agent or NOAC (CHS pharmacist 4) and 
another expressing discomfort at an approach such as this (CHS pharmacist 2): 
 
“And what I really wanted was to put a NOAC in a blister pack with the carer, 
monitoring that…then I think the argument is that we can get a carer to support him 
with a NOAC in a blister pack.” (CHS pharmacist 4) 
 
“Warfarin is another classic example which is not in the blister pack…district nursing 
have been pushing to change a lot of patients from warfarin onto the NOACs simply 
because they could be put into a blister pack…it feels a bit strange to change them to a 
tablet just so this one could go into the blister pack.” (CHS pharmacist 2) 
 
There was the unanimous view that carers, agencies and social services preferred MCAs 
because they were quicker and easier to use. There was an assumption that the quicker 
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medicine administration process, the more time the carer spent with the patient, which was 
beneficial: 
 
“I've never really understood the concept of carers till I sit in the MDTs and we're 
talking about will care course they're got on, 15 minutes in the morning, what would 
we do in that time? They wash and breakfast and then do the meds in 15 minutes…I 
couldn't physically have my own breakfast in 15 minutes.” (CHS pharmacist 4) 
 
“…Your 15 minutes-- if they were on nine or ten-- we've got a lot of patients from ten 
medicines or more, aren't they? If you have ten medicines it's going to take you some 
time to do that call if they're not in a blister pack…you could say, well that's a good 
thing because then that’s time spent with the patient.” (CHS pharmacist 6) 
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6.4 Discussion and suggestions for future work 
 
6.4.1 The CHS pharmacist role in complex patients and situations 
 
The types of patients that the CHS pharmacist saw were complex, with established medicines 
management needs. The patient cohort was slightly different to the general cohort of patients 
seen by CHS nurses; not all of the nurses’ patients had issues with their medicines. The CHS 
pharmacists saw patients who required clinical review of their regimens, patients who were 
stockpiling and non-adherent, as identified by referring HCPs and sometimes social care 
professionals. Many of the patients they saw did not have a high level of cognitive function, 
believed by the interviewees to be a requirement for successful MCA use. By the time the 
patient had been referred to the CHS pharmacist, a MCA had usually already been started by 
somebody else, and probably without suitability assessment. 
 
Lots of the activities carried out by the CHS pharmacists were clinical, but retrospective. The 
CHS pharmacists described instances and experiences with medicines management that were 
problem-solving; for example editing MCAs that had already been dispensed or making the 
best of the fact that a MCA had been started by somebody else and was difficult to retract. 
This retrospective position was unavoidable, as the CHS pharmacist was not present at the 
point of prescribing. Though “de-prescribing” was viewed positively, instances described 
involved only stopping items that were obviously no longer required. “De-prescribing” is not 
the only approach to polypharmacy, and methods of preventing the prescription of so many 
medicines in multi-morbid patients are not part of the CHS pharmacist role. There is scope for 
a more proactive approach in future models of pharmacist working practices, where clinical 
pharmacists will work in GP practices to help with medicines optimisation and long term 
conditions management in a collaborative way
84
.  
 
Future research could focus on the role of clinical pharmacy technicians in CHS pharmacy 
practice; much of the work of the CHS pharmacists could have been carried out by a technician 
instead – e.g. checking whether a patient was using an MCA correctly, removing stockpiled 
medicines and arranging synchronised scripts with the community pharmacy. There could be a 
place for the technician in MCA prevention. It would be interesting to study quantitatively the 
time each CHS pharmacist spent on tasks that only they could perform versus those that either 
a pharmacist or technician could do; time that the CHS pharmacist spends on generic tasks 
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could then be redirected towards more therapeutic needs of the patient, drug monitoring and 
“de-prescribing” for example.  
 
6.4.2 Fragmentation and communication problems 
 
The CHS pharmacist role exists, by its nature, in a fragmented system. There are no national 
standards specifically for CHS pharmacy practice, and national commissioning of CHS pharmacy 
is not consistent, with some CCG areas having extensive CHS pharmacist roles and some having 
none.  
 
In both CHS teams studied, involvement in the MDT and therefore referral of patients to them 
was dependent on the subjective opinion of the referring HCP. This blunderbuss approach may 
suggest, though cannot be stated conclusively from the findings here, that there are patients 
who are being seen and do not need to be, plus patients being missed who would find the CHS 
pharmacist input most valuable. Further research into the scope of CHS pharmacist practice 
could use content analysis of the service specifications of different teams and the referral 
criteria, if there are any, to assess the level of consistency across CHS pharmacy teams and 
develop national frameworks or models of practice. 
 
The communication failures about medicines and changes in regimen were frustrating for the 
CHS pharmacists and potentially dangerous for patients. Lapses and lags in communication at 
discharge were discussed with concern, but there were also problems with communication 
downstream from this. The fragile one-way flow of information is depicted in Figure 6.2(a) 
below. 
 
There is scope for further studies, quantitative in nature, to assess how much time is spent by 
various NHS organisations in obtaining information about medicines from each other. It would 
be interesting to know, for example, how often discharge summaries do not reach the GP or 
arrive late, delaying the FP10 generation. The CHS pharmacists reported that the hospital 
pharmacists would send the discharge summary to the community pharmacist, and tell them 
when the patient had been admitted – but how often does this happen and can it be relied 
upon? The delays between FP10 generation and dispensing could be discovered by finding out 
the scale of electronic versus paper collection service use between GPs and community 
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pharmacists in localities, and what the barriers were in this information transfer, based on the 
understanding that electronic generation is quicker and more efficient. 
 
Figure 6.2(b) shows how, if there was a centralised approach and willingness to share 
information, many of the communication problems highlighted in this study could be avoided. 
The care agency would be party to the same information as the NHS providers, rather than 
having to wait for the dispensing process to be completed, overcoming the problem of not 
knowing what should and should not be given to the patient until the carer arrives on the 
premises. 
 
 
Figure 6.2 – Communication post-discharge from hospital (a) current and (b) proposed 
 
There was variation in the nature and quality of services provided by community pharmacies, 
care agencies, hospitals and other care provider organisations. Community pharmacists would 
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do all of the ordering of FP10s for patients, or none, or just the MCA medicines. Some 
community pharmacists would request weekly prescriptions, some would not; some would 
deliver weekly, some would not. Some would become involved in whether the patient was 
taking their medicines or not and help with plans to improve adherence, most would not 
become involved. Care agencies varied in terms of their training of carers, which may have 
been because some were private and some owned by social services. Individual carer 
motivation and quality of care was also diverse. 
 
The community pharmacy national contract does not standardise nor propose any 
remuneration for those areas of variation in contractors raised in this study, and there is no 
standard approach to MCAs within the agreement, e.g. with respect to FP10 frequency and 
delivery requirements. Including a model of future dispensing practice around MCAs and 
inclusion in the national contract, with remuneration, would encourage a standardised 
approach. 
 
6.4.3 Carers and MCAs 
 
Carers using MCAs was considered to be the wrong approach, and the CHS pharmacists were 
not happy about it having to be the case; yet some thought it was better than the alternative 
of carers administering from original packs. Both GSTT pharmacists were unsympathetic with 
regards to carers using MCAs, but most (not all) of the SCT pharmacists could see that they 
were sometimes safer in the current situation. There was not the infrastructure that would 
promote safe or ideal administration. Ideal situations included: proper medication training and 
competency checks for carers, sufficient visit length and frequency being negotiated at the 
care package design stage and a standard approach to MCA generation with ownership by one 
organisation or body. It is possible that the different views expressed by the CHS pharmacists 
from different organisations reflected different working situations. 
 
CHS pharmacists were despondent about MCA use generally; even for self-administration, they 
saw many disadvantages that other HCPs did not and thought they were difficult to reverse, 
rarely of use and ultimately a last resort. Because they saw such complex patients, patients 
who made best use of MCAs (those with cognition) were generally not the type of patient the 
CHS pharmacists would ever see. It is possible that the complex nature of their caseloads 
skewed their view of the usefulness of MCAs; the complexity of those caseloads did not, 
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however, mean they saw few patients with MCAs. It is not possible to say in this study how 
many patients on the caseloads of the CHS pharmacists had MCAs started when they were 
cognitively able to use them i.e. under appropriate assessment of their circumstances, versus 
how many were started as a knee-jerk reaction to perceived adherence issues; it would be 
interesting to quantify this. 
 
The lack of training for carers, the shortness of visits, the business models of private 
companies and unwillingness to become more involved in medication meant that it was 
sometimes viewed as being safer to use MCAs for carers to administer medicines. Even though 
the CHS pharmacists knew it was not right that medication administration should happen in 
this circumstance, they found it easier to engineer the situation around the presence of the 
MCA than to remove the MCA entirely, e.g. by putting PRN medicines in the MCA or paring 
down regimens to once or twice daily to fit in with carer capacity. The CHS pharmacists 
comforted themselves with the belief that quicker medicines administration meant more time 
spent with the patient; there is no evidence for this. If the carer finishes early, they might leave 
early to get to their next client rather than wait the full allocated time. If medication and other 
tasks (ADLs) cannot be completed in the short timeframe afforded by the care package, 
perhaps the package should be amended rather than an MCA introduced; this possibility was 
not explored with the CHS pharmacists. 
 
The CHS pharmacists knew that carers would not always administer the non-MCA medicines 
for various reasons; they did not always challenge this. There is no legal reason why carers 
should not be able to administer medicines like patches or eye drops. There was no standard 
approach to this refusal from the CHS pharmacists, but approaches ranged from arguing with 
the care staff over policy contents to allowing an MCA to be put in place. There is the 
possibility that challenging all inappropriate MCAs would lead to improved practice eventually, 
but would be exhausting from the CHS pharmacist perspective: they were often a lone voice. 
 
Some of the CHS pharmacists were more accepting of carers using MCAs than others, with the 
GSTT pharmacists being the least accepting and the newest pharmacist in post (from SCT) 
being the most accepting. It is not possible to say from this study what the reasons were 
behind the differing opinions here. 
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From the results, it is not possible to say that MCAs are always useful in self-administration or 
that they are never useful in proxy-administration of medicines. MCAs should be started only 
after careful assessment of the benefits and risks to individual patients, carried out in context 
by a CHS pharmacist who has considered the clinical need of each medicine, patient choice and 
the nature of the non-adherence. Starting an MCA to enable the carer to give medicines does 
not represent an ideal or desirable situation and should be avoided, if only to prevent the 
perpetuation of misleading information about medicines administration by care agency staff 
and, over time, to drive up the quality of their care provision.  
 
6.5 Conclusion 
 
The CHS pharmacists saw very complex patients and had many positive examples of their 
contributions to patient care; however they worked in a retrospective way and carried out 
some tasks that could have been performed by pharmacy technicians. There is scope for future 
research into the use of technicians and the impact that GP practice pharmacists will have on 
this same complex patient cohort. 
 
Communication difficulties at discharge had a negative impact on the patient and future 
research should aim to understand how much time is wasted by professionals involved in the 
care pathway due to these difficulties. It appears that there was no co-ordination with regard 
to the services offered by community pharmacists, CHS pharmacists or hospital pharmacists in 
terms of provision of MCAs or other adherence support, resulting in uncertainty within the 
profession. 
 
CHS pharmacists felt uncomfortable overall with the reliance that care staff had on MCAs; but 
it was sometimes the best option for the patient in that moment, as there was no capacity to 
address the real issues of poor carer training and time pressures in the social care system. 
Knowing that carers could legally give medicines outside of the MCA did not necessarily mean 
that the CHS pharmacists found it a valuable use of their own time to convince the carers of 
this; sometimes it was easier to condone inappropriate MCA use. 
 
There are many disadvantages to MCA use, and very few people for whom they are suitable, 
but when they are suitable they can have a very positive impact on patient independence. The 
way forward is individual assessment of all patients before an MCA is started, to include 
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addressing polypharmacy, so that only the minimum medicines required to maintain health 
are prescribed. Determining the patient’s adherence when taking each prescribed medicine 
and incorporating individual patient choice are essential components of patient assessment. 
Follow-up and feedback to professionals in the care pathway should also be enabled. 
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Chapter 7 Reflection 
 
7.1 Choosing to embark on a Doctorate in Pharmacy Practice  
 
As a pharmacist working closely with patients in receipt of care spanning more than one role, I 
had experienced problems with the use of MCAs. These included medication errors, omissions, 
confusion leading to double-dosing and unresolved adherence problems. As a trainer for social 
carers, I had become aware of a strong reliance on using MCAs for proxy-administration of 
medicines. I had also, as an HCP advising incremental increases in doses of ACE inhibitor and 
beta-blockers for heart failure patients, experienced difficulty and protracted dose 
optimisation in patients with MCAs.  
 
After reflecting on individual patients with MCAs I was often unsure why these patients had 
them. Many reported not knowing why they were using one or were unhappy about their 
medicines being packaged this way, without their agreement in some cases. There were 
instances where I had experienced patients being started on a MCA, and this had brought a 
sense of relief to them or their family members, but had occurred without any patient 
assessment of suitability, and so it seemed to happen by chance. Overall, I became interested 
in the patient perspective, the decision to start a MCA and whether predicting which patients 
would benefit from a MCA was as random as it appeared. 
 
My desire to find out more about the rationale for MCA use had yielded only anecdotal 
evidence from my own reading. I felt the use of MCAs, for administering medicines to others in 
particular, was a big under-researched part of my practice and in my profession. These 
incidents and experiences I had with MCA use in primary care settings also made me want to 
find out more about the experiences and opinions that other HCPs had with MCAs. 
 
7.2 Reflection on Part One of this professional doctorate 
 
In this section I will discuss how part one of the DPharm programme filled in gaps in my 
knowledge and education that existed, despite my professional pharmacy practice and 
previous academic endeavour. In Part One, I had the opportunity to undertake taught units in 
Professional Review and Development, Advanced Research Techniques and Publication and 
Dissemination. 
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My experience of research in my practice as a pharmacist before starting the DPharm 
programme was focussed on audits and critical appraisal of quantitative research conducted 
and published by medical professionals. I had heard that obtaining ethical approval to conduct 
primary research was a difficult and protracted process and seen occasions where colleagues 
had altered their research methodology in order to avoid it; for example by conducting an 
audit or service evaluation which was less thorough. I was concerned about the integrity of my 
project as I planned to recruit vulnerable patients. In Part One, I started to understand the 
importance of the ethical process, why it was so detailed and so necessary. Ultimately, 
knowing that the benefit of any research must outweigh the risk and the role of ethics was to 
validate this, dispelled many myths and fears in terms of my confidence in conducting 
research. I regained clarity in determining my participant groups.  
 
Learning about qualitative research techniques and their correct application was fascinating. I 
learned a great deal about the limitations of quantitative research when trying to ascertain 
meaning. I had never studied qualitative research methods before as an undergraduate or a 
postgraduate student, or considered conducting qualitative research. I used the learning sets 
and assignments to practice working with qualitative data and find out as much as I could 
about the correct application of qualitative methodology, which was essential in answering my 
research question. 
 
7.3 Part Two – the project 
 
At the end of Part One, I was committed to incorporating qualitative enquiry into my project in 
order to answer my “how” question. I was still daunted by my lack of experience in conducting 
research, especially qualitative analysis; I found the quantitative questionnaire part of my 
intended project not just a necessary scoping exercise but also a comforting starting point in 
order to launch the rest of the project. It made sense that my first experience of data 
collection and analysis was quantitative, therefore familiar territory. I wanted to avoid 
choosing more familiar, easier forms of enquiry and stay true to the research question I had 
devised and felt was a true reflection of the phenomenon I wanted to explore. 
 
The research proposal I submitted for approval to progress to Part Two was referred; this was 
particularly difficult timing as I had just given birth to my second son, who had jaundice and 
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was still an inpatient in the neonatal unit at East Surrey Hospital. With the support and advice 
of my academic supervisors in terms of what changes I could make to the proposal in order to 
secure a pass, I quickly produced a revised version. 
 
Progressing to Part Two coincided with a six-month period of maternity leave from my 
workplace. I had established links at my then workplace and felt confident of recruiting 
patients from within my trust using the methods laid out in my proposal document. I was 
aware of the research and development department in my trust and what I had to do to 
commence the research on my return to the workplace. I had frequent patient contact in this 
heart failure role and felt confident that, though not experienced in conducting interviews in a 
research context, my consultation skills were transferable to the research processes planned. 
My supervisor checked interview technique during transcription checks for the first few 
patient interviews, giving valuable advice that was applied thereafter.  
 
During my maternity leave throughout Part Two, I took frequent advantage of the post-
graduate development programme study events to supplement my taught learning from Part 
One and keep the momentum going with my project. I attended training days about qualitative 
research, NVIVO, researching the workplace, academic writing and questionnaire design. Each 
time I attended an event I applied the knowledge and skills acquired to my research project, 
using Skills Forge and the Annual Review process to document progress and shape ongoing 
learning needs with the support of assessors and supervisors. 
 
After gaining ethics approval and completing the first part of my study, the community 
pharmacist survey, as an employee of GSTT, I left that trust and started a new role as Associate 
Head of Pharmacy at Western Sussex NHS Foundation Trust. I was concerned that I would no 
longer have patient contact in this senior management role. Recruitment of suitable patients 
was facilitated by negotiating an honorary contract with GSTT, and by maintaining links with 
previous colleagues. The CHS pharmacy team at GSTT referred all of the patients to me, liaised 
with the CHS nurses on my behalf to arrange interviews and were supportive of the project. In 
my new role, I was able to rely on my professional relationships with the CHS pharmacists at 
SCT, who were supportive of the project and participated in interviews. 
 
As a practising clinical pharmacist with patient facing care responsibilities for over 12 years, I 
have an in-depth knowledge of the dispensing and use of MCAs and their use in various patient 
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groups, particularly elderly care. I was aware of the potential of my experience unduly 
influencing the study results and conclusions drawn from them throughout the study, and had 
to balance my need to be objective with my need to utilise my experience to shape pragmatic 
recommendations for future practice. Steps were taken to ensure a degree of detachment 
from the subject by: piloting the community pharmacy questionnaire, producing topic guides 
based on the community pharmacy questionnaire findings instead of my own opinions, third 
party assistance with recruitment, third party assistance with interview transcription and 
overall monitoring by supervisors (including listening to interview samples and checking a 
sample of open coding before analysis). My professional experiences, therefore, did not 
pollute the data gathering process, yet have helped me make an informed assessment. 
 
Once all of the data were collated and analysed I felt reassured about the direction of my 
progress and started my writing up. I took advantage of the “Thesis boot camp”, run by the 
Graduate Development Programme at Portsmouth University, and gained some valuable tips 
to pull the thesis together and made some determined headway with the first draft. 
 
7.4 Career development and future practice 
 
In conducting this study I have seen there are advantages and disadvantages of quantitative 
and qualitative research; using the right methodology to answer a research question is the key 
to success, and reliance on quantitative data to explain meaning is an invalid exercise. This 
discovery has shaped my approach, not just this study but my whole career. 
 
I plan to use what I have learned as a researcher to inspire the next generation of pharmacists 
to become active researchers, able to see how research may be incorporated into existing 
roles and helping to embed research into the fabric or pharmacy practice. I plan to always have 
research as part of my own practice. 
 
In terms of the results of the project, my vision is that no patient should be started on an MCA 
without full understanding of the implications and a booked follow-up assessment of how they 
are managing with the MCA, retaining the option to reverse the decision and use another 
compliance aid. The aim of this research had always been to produce recommendations for 
the appropriate use of MCAs. Though there are guidelines that make recommendations about 
MCAs, none are based on primary research where user experience or long-term implications 
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were explored fully. In order to be successful, guidelines should be in a format that is 
immediately useable, memorable and practicable so that the busy health and social care 
professionals who influence MCA initiation can use them in day to day practice for the benefit 
of patients. I plan to publish the results of this study in one or more peer-reviewed journals 
that are accessible by relevant health and social care professionals. 
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Chapter 8 Overall discussion and conclusions 
 
8.1 Overall study findings and common themes 
 
8.1.1 Variation 
 
There was variation experienced across all patient cases and reported by recruited 
professionals in terms of the MCA prescription duration (weekly or four-weekly) and delivery 
schedule, the depth of the community pharmacist assessment for a MCA, community 
pharmacy capacity to supply MCAs and responsibility they felt towards ensuring use was 
appropriate. Brands of MCAs supplied were found to be dependent on community pharmacy 
preference rather than patient preference. In the community pharmacy setting also, variation 
between contractors with regard to PIL supply, tablet descriptions and which oral medicines 
were enclosed and excluded from the MCA left patients and HCPs uncertain about the value 
that the MCA added. In a truly patient-centred service, the specifics around MCA provision 
would be determined by national standards, based on evidence, and individual contractors 
measured against those standards. 
 
CHS staff reported variation in services that they had encountered, with consequent variety in 
service coverage and quality. There were differences between carers and how involved they 
were prepared to become in medicines administration and the community pharmacists varied 
in their prescription ordering approaches for MCA patients. Hospital pharmacists faxing the 
discharge summary to community pharmacist or to them as CHS staff, was seen as very helpful 
but was a goodwill gesture rather than an enforceable standard. 
 
8.1.2 Communication 
 
Communication between HCPs and across interfaces of care was tenuous and sometimes 
strained. It seemed to be accepted that social care could refuse to accept a patient from the 
NHS, but it was not possible for CHS staff to refuse to accept a patient being discharged back 
to their own homes from hospital. The NHS was frequently called upon to fill the gaps in 
service provision; it cannot be shown that social care did the same from this study. 
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This study showed that housebound patients were frequently visited by health and social care 
professionals, who did not communicate with each other in a particularly effective way. 
Patients had to keep a plethora of documentation safe in their own homes. It is not known 
how useful each HCP found the documentation kept by their fellow HCPs, nor how often they 
referred to other documentation in order to glean an holistic view of the patient. Some 
patients were very occupied by frequent visits from DNs, specialist nurses, carers and 
ambulances taking them to various hospital appointments and by waiting in for deliveries of 
medication; it was unclear how housebound the patients truly were as they may have had to 
stay indoors on purpose simply to manage these interactions, or their anxiety about missing 
them. 
 
Discharge from hospital was mentioned by all patients and HCPs as an area in great need of 
revision in terms of communicating information about new medicines and sharing that 
information appropriately between care interfaces. Ineffective communication had led to 
patient harms. The findings here back up the RPS guidelines about the risks of transferring 
information across care interfaces 
85
. 
 
8.1.3 Medication review 
 
The CHS pharmacists reviewed the patients holistically, taking many factors into account when 
they reviewed medication taking behaviour of their patients and working with other disciplines 
to get this right for each patient they saw; MCA assessment was not a standalone activity and 
formed part of this review. Patients and CHS HCPs were aware of the benefits of medication 
review and medicines use review as a way of assessing the need for the MCA originally and 
then again when checking that the MCA was appropriate once in place; despite the benefits of 
this iterative process around MCA initiation, it was rarely the case that review was enabled. 
CHS HCPs reported that it was rare to see an MCA stopped once initiated, and rushing towards 
such an irrevocable decision was undesirable for the patient and the HCPs charged with 
optimising their medication regimens. 
 
Community pharmacists had little involvement with pre- and post-MCA supply of MCAs, but 
there was not necessarily the appetite to change this. It is not possible to say if community 
pharmacists would have felt differently had they believed that the process of supply had been 
adequately resourced. 
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8.1.4 MCA initiation and supply 
 
Despite the resource and patient safety implications of MCA provision, the pharmacy national 
contract
86
 contains no specific reference to MCA provision or remuneration. Pharmacist 
medicines use reviews are not geared towards housebound patients, meaning that MCA 
provision and review of patient satisfaction with MCAs is limited to those patients who 
attended the community pharmacy and not those who had their medicine delivered, i.e. those 
who need such a review the least. 
 
MCAs were funded by the NHS, for use by carers or self-administration by patients, 
irrespective of requirements under the EA 2010
87
. Appendix 15 shows how a typical 
community pharmacy advertises the MCA service it provides, targeting patients who might 
want one for the purposes of convenience. In the author’s opinion, the advert may encourage 
people to think that the service will be paid for by the NHS because it is described as being 
“free”. When carers use MCAs for administering to patients, for the purposes of reducing visit 
time or as a requirement before accepting any patient into their service, the NHS was charged 
for this. As part of the new care models programme
88
, vanguards of care are being developed 
where care services are integrated and improved for patients, so this may not be a concern in 
the future as financial interest is aligned
89
. Considering that there may be occasions where 
agencies find it beneficial for carers to use MCAs in the current care landscape, it is time to 
review the infrastructure around remuneration for community pharmacists and devise a more 
formal, standardised approach to payment that eliminates the requests for weekly scripts. As 
long as MCAs are supplied without assessment for proxy-administration of medicines by 
carers, there is no drive to train carers or prioritise the medicines administration process for 
purposes of patient safety. 
 
Two tiers of payment to community pharmacists are proposed in this thesis; the first is in 
response to the patient having a medication review that is part of an MDT referral. The 
medication review should be documented and then sent electronically to the nominated 
community pharmacist with patient consent. The medication review would be part of a 
package of adherence support and the community pharmacist input would attract a fee for 
MCA supply and delivery, and a follow-up consultation. The second tier is for patients who do 
not need the MCA but want one for convenience; in this instance the fee paid to the 
227 
 
community pharmacist is lower and borne by the patient. In both scenarios, the use of weekly 
scripts would have to be abolished by GP refusal and professional bodies (GMC, GPhC) 
disapproving of this practice. If the way that community pharmacists were funded were 
addressed, a registry of supply could be established: quantitative data collected prospectively 
would show numbers (extent) and patterns of use, enabling comparison across contractors, as 
is the case now with other non-dispensing services provided as part of the national contract. 
Commissioner verification of the detail around MCA supply at contract monitoring visits would 
be enabled with these changes. 
 
8.2 Contribution to the evidence base and limitations of this study 
 
Before this study, a literature review (Chapter 2) revealed that there was a lack of clarity 
around criteria in medication reviews and that review was rarely carried out before MCA 
supply. What was known about MCA use in housebound patients was anecdotal and there was 
no research focusing on the role of social care in the drive for MCA supply. The future of both 
hospital and community pharmacy is destined to have a more clinical focus, with the patient 
placed at the heart of care 
90, 91
. It is important that medication review is prioritised and de-
mystified; producing review criteria is a positive way to guide all pharmacists towards a more 
patient focussed future. Guidelines in this area have been produced based on current evidence 
available, but as evidence at the time they were published was scarce, they are based largely 
on anecdote
83
. The scarcity of evidence on this subject remains. 
 
The issue of carers using MCAs to administer medicine is not clear cut; in theory, it is not 
permitted. In practice however, re-structuring the stretched and under-funded system in order 
to prevent it is complicated. However, patient benefits in terms of choice, safety and 
motivation would be improved if medicines administration was prioritised rather than sped-up 
with MCAs solely for the sake of efficiency. 
 
In the author’s experience and from the results of this study, patients who are motivated to 
take their medicines will do it even if it is inconvenient; those who are not motivated will not 
take them, even if the regimen looks more straightforward by dispensing in an MCA. Not 
everyone who has a MCA wants one, needs one or has had assessment demonstrating 
suitability. This is due to the reliance on MCA use in the community being non-patient 
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focussed. This study did not show that MCAs increased adherence in self-administering 
patients, but that there may be instances where adherence is reduced. 
 
In order for MCA use to be of optimal benefit to a patient, he or she has to be motivated to 
take their medicines; the patients in this study were more likely to be motivated to take their 
medicines when they felt they were able to make decisions about their medicines at initiation 
and on an ongoing basis. Patients must also be physically and cognitively able to use the MCA 
and prescribed a regimen that they would find cumbersome (e.g. multiple daily frequencies) if 
the MCA were not there. Figure 8.1 shows the three conditions that must be in place before 
successful MCA use is enabled; even when satisfied, these criteria do not guarantee that MCA 
use in a particular patient will be a success or that the patient would want to use an MCA. 
Without satisfaction of all of these three criteria, MCA use will not succeed. 
 
Figure 8.1 – Conditions for appropriate MCA use in self-administration of medicines. 
 
Individual assessment of patients is essential before an MCA is supplied, and review once in 
use is necessary to enable reversal, MCA brand change or further problem solving if the MCA is 
unsuccessful; all measures should be carried out with full involvement and engagement of the 
patient. Pharmacists who are part of an MDT would be best placed to conduct these reviews in 
the author’s opinion. 
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8.3 Opportunities for future research 
 
Sections 3.3, 4.5, 5.5 and 6.4 discuss the areas of future research identified by the community 
pharmacist questionnaire, the patient case study, the CHS nurse interviews and policy analysis 
and the CHS pharmacist interviews respectively; limitations of each part of the study are 
discussed in the individual chapters under these sections and proposals for research methods 
to address new questions raised by the results are made. The rest of this section will discuss 
completely novel areas for future research that are not addressed in previous sections of this 
thesis. 
 
It is not known how other countries with very different health and social care infrastructures 
deal with their ageing populations, and one proposal is to investigate this further with 
research. There is a drive for patients to remain in their own homes as far as are possible in 
this country, but it is unclear what the tangible benefit of this approach is for the patient. It 
may well be that it benefits the frail elderly population to remain in their own home for as long 
as possible, even if the medication administration process is not perfect or even worsened 
with the addition of an MCA for either self- or proxy-administration by the carer. 
 
Waste from untaken medicines was mentioned by CHS nurses and pharmacists, but this study 
did not look at waste or make any attempt at quantifying or estimating costs associated with 
it. There is scope for future research into causes for this waste (potentially non-adherence, 
community pharmacist automatic re-ordering schemes or both) and the extent of medicines 
waste, and this information could be of use to those commissioning and providing CHSs. 
Employing nurses and pharmacists or pharmacy technicians on an “invest to save” basis of 
salaried versus recurrent costs of waste saved could be a possibility depending on results of 
such research. This approach is reliant on aligned priorities and finances of different 
organisations in health and social care. 
 
The licensed status of medicines once dispensed into a MCA was not considered as part of this 
study. Some of the CHS pharmacists mentioned the integrity of original packaging when 
discussing the problems with dispensing into MCAs, but the licensing status of the medicines 
and the impact that this had on responsibilities of the MCA requestor, prescriber and 
dispensing pharmacist are as yet unexplored. 
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There were very few instances experienced throughout the study of MCAs being successfully 
stopped, and it was noted that this was difficult and avoided by HCPs as far as possible. Further 
qualitative study using a design more focussed towards reversal, e.g. a collective case study, or 
an instrumental case, of where this has been successfully enabled, could lead to development 
of a standard process of reversing inappropriate MCAs. It cannot be shown from this study 
whether MCA reversal was avoided in cases where it would have benefited the patient in the 
long term. 
 
The assumption made by HCPs in this study that by using MCAs, better and more patient 
focussed use of the carers’ time is enabled, should be researched further; it is not known how 
time spent administering medicines would be spent otherwise, nor whether it is beneficial to 
the patient to save time from the medicines administration process. One way of finding out 
would be to design and conduct a randomised controlled trial of housebound patients, where 
two patient groups matched for demographic data and medication regimen particulars are 
administered their medicines by carers from either a MCA or not. Time spent could be 
recorded using a time and motion-type study on the workload of carers, with follow up surveys 
of patients to see if there was a difference in the satisfaction with the visit length and care 
they received between the groups. 
 
8.4 Final conclusions and recommendations 
 
 The variation in services experienced by patients in this study meant that they 
encountered inconsistent care quality. Health and social care organisations, and 
contracted third party providers, need to work together to put the patient at the 
centre of decisions made about their care. In particular, assessing medication 
adherence, MCA initiation and communication processes around discharge require 
standardisation and agreement across multiple organisations. 
 An MCA should only ever be started in patients who are motivated to take their 
medicine, demonstrably able to use the device and remain on a complex regimen 
despite clinical medication review aimed at reduction of their medicine burden - in this 
scenario, other adherence aids should be considered, patient consent gained and 
reliable continued monitoring of success with the aid organised prior to 
commencement. 
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 Community pharmacists should receive direct payment for supplying MCAs and for 
performing follow up reviews of their usefulness in individual patients, including those 
who are housebound. 
 The payment for community pharmacists to supply MCAs should recognise that there 
is a difference between those patients who really need MCAs and those who want 
them for convenience. Standards should be incorporated into the national contract 
around assessment parameters, gaining consent for MCA supply and abolishing weekly 
script requests. 
 The community pharmacy national contract should be amended to include medicines 
use review for all new patients started on an MCA one to two months post-initiation, 
with the option to go back to original packs under community pharmacist supervision 
(i.e. MCA “trials”). 
 Delivery drivers should be trained to understand what to do if a delivery cannot be 
made and when to escalate concerns they observe to the community pharmacist. 
 The reliance on the NHS to “pick up the slack” when social care refuse to accept 
medically fit patients has to end. One way of reversing this phenomenon is by 
adequately training the social care workforce to deal with medication effectively. Carer 
medication training and care agency acceptance of standardised medication 
administration policy should be agreed across organisational boundaries. 
 A national brokering template (or medication policy checklist for brokering teams) and 
standard medication policy should be developed and used by social care for use when 
care agencies are commissioned for populations. This policy template would be agreed 
at a strategic level between the NHS, social care, and in line with RPS, NICE and CQC 
standards. The policy template would be developed alongside, and therefore aligned 
with, the community pharmacist national contracting framework requirements above. 
 CHS pharmacists should be a part of the brokering process when care agencies are 
commissioned by social care, ensuring medication policy across providers is consistent 
and in line with national standards. Systems should be put in place to monitor 
medication policy implementation and decommission agencies who do not comply. 
 Evidence about MCA use collated using research methods described in this thesis 
should be used to develop national standards, presented in end user / clinician-
focused media (e.g. an app) that is low cost or free and easily accessible. Housebound, 
frail elderly patients would then be assessed and reviewed in a standard way. 
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Adherence - untaken BPs and other meds
GPs don't do proper MR freq enough
Carer general medication management
Unsafe to remove a BP once started
Safety disadvantages of BP incl carer admin
ID of tablets - hampered
Monitoring adherence
Patient suitability
SC insisting on BPs
Meds outside BP
Carers and others think BPs are safer
Unused meds
NHS funds
Lack of gaining consent when BP started
Lack of assessment or MR when BP started
Carer or agency insistence on BP
Interaction between nurses and carers
Adherence - Following up and monitoring
Delays in discharge from NHS to SC as BP …
Delivery
BP advantages to patient
Unecessary meds and polypharmacy
The CP inl variation
Discharge from hospital and med rec
Examples of good practice and services
Patient consenting to BP
NHS admin is different
Carers find BPs quicker
Disadvantages of carer proxy admin
Independence
Missing meds and disorganisation in the home
Advantages of carer proxy BP admin
Assessing pt for BP
Variation in carer quality
BP advantages to carer
BP disadvantages
Poor communication in care agency
Nurse admin is different
Support for carers
Communication problems
Fragmented system
Care agency management and policy
Documentation of meds given
Carer training
Carers use of BPs
Code frequency in CHS nurse interviews (x axis shows percentage 
coverage)
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Appendix 12 - Sussex Community Trust Letter of Access for 
community health services pharmacist interviews 
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Appendix 13 - Community health services pharmacist materials 
 
 Invite letter 
 Information sheet 
 Consent form 
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Appendix 14 - Topic guide for community health services pharmacist interviews 
  
336 
 
337 
 
 
 
Appendix 15 - A typical advertisement for multicompartment aid supply 
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